U.S. patent application number 11/464961 was filed with the patent office on 2006-12-07 for thiopyrimidine and isothiazolopyrimidine kinase inhibitors.
Invention is credited to Lee D. Arnold, Michael L. Curtin, Yujia Dai, Steven K. Davidsen, Robin R. Frey, Yan Guo, Zhiqin Ji, Michael R. Michaelides, Neil Wishart.
Application Number | 20060276490 11/464961 |
Document ID | / |
Family ID | 30448247 |
Filed Date | 2006-12-07 |
United States Patent
Application |
20060276490 |
Kind Code |
A1 |
Michaelides; Michael R. ; et
al. |
December 7, 2006 |
Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors
Abstract
Compounds having the formula ##STR1## are useful for inhibiting
protein tyrosine kinases. The present invention also discloses
methods of making the compounds, compositions containing the
compounds, and methods of treatment using the compounds.
Inventors: |
Michaelides; Michael R.;
(Libertyville, IL) ; Arnold; Lee D.; (Niantic,
CT) ; Curtin; Michael L.; (Pleasant Prairie, WI)
; Dai; Yujia; (Gurnee, IL) ; Davidsen; Steven
K.; (Libertyville, IL) ; Frey; Robin R.;
(Libertyville, IL) ; Guo; Yan; (Dallas, TX)
; Ji; Zhiqin; (Libertyville, IL) ; Wishart;
Neil; (Jefferson, MA) |
Correspondence
Address: |
ROBERT DEBERARDINE;ABBOTT LABORATORIES
100 ABBOTT PARK ROAD
DEPT. 377/AP6A
ABBOTT PARK
IL
60064-6008
US
|
Family ID: |
30448247 |
Appl. No.: |
11/464961 |
Filed: |
August 16, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10392951 |
Mar 20, 2003 |
|
|
|
11464961 |
Aug 16, 2006 |
|
|
|
60366708 |
Mar 21, 2002 |
|
|
|
Current U.S.
Class: |
514/260.1 ;
544/255; 544/278 |
Current CPC
Class: |
A61P 37/06 20180101;
A61P 35/04 20180101; C07D 513/04 20130101; C07D 495/04 20130101;
A61P 3/10 20180101; A61P 19/02 20180101 |
Class at
Publication: |
514/260.1 ;
544/255; 544/278 |
International
Class: |
A61K 31/519 20060101
A61K031/519; C07D 498/02 20060101 C07D498/02 |
Claims
1. A compound of formula (I) ##STR13## or a therapeutically
acceptable salt thereof, wherein X is selected from the group
consisting of --N-- and --CR.sup.3--; Z.sup.1 is selected from the
group consisting of --N-- and --CR.sup.4--; z.sup.2 is selected
from the group consisting of --N-- and --CR.sup.5--; Z.sup.3 is
selected from the group consisting of --N-- and --CR.sup.6--;
Z.sup.4 is selected from the group consisting of --N-- and
--CR.sup.7--; R.sup.1 is selected from the group consisting of
hydrogen and NH.sub.2; R.sup.2 is selected from the group
consisting of alkoxy, cyano, hydroxy, nitro, --NR.sup.aR.sup.b, and
-LR.sup.8; R.sup.3 is selected from the group consisting of
hydrogen, alkenyl, alkoxyalkyl, alkyl, arylalkyl, carboxyalkyl,
halo, haloalkyl, heteroarylalkyl, (heterocyclyl)alkyl,
hydroxyalkyl, (NR.sup.aR.sup.b)alkyl, and
(NR.sup.aR.sup.b)C(O)alkyl; R.sup.4, R.sup.5, R.sup.6, and R.sup.7
are independently selected from the group consisting of hydrogen,
alkoxy, alkyl, NR.sup.aR.sup.b, halo, and hydroxy; R.sup.8 is
selected from the group consisting of alkoxyalkyl, alkyl, aryl,
arylalkenyl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl,
heterocyclyl, and (heterocyclyl)alkyl; L is selected from the group
consisting of --O--, --(CH.sub.2).sub.nC(O)(CH.sub.2).sub.p--,
--CC--(CH.sub.2).sub.nO--, --C(O)NR.sup.9--, --NR.sup.9C(O)--,
--NR.sup.9--,
--(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--,
--NR.sup.9C(S)NR.sup.10--, --NR.sup.9C(.dbd.NCN)NR.sup.10--,
--NR.sup.9C(.dbd.NCN)O--, --OC(.dbd.NCN)NR.sup.9--,
--NR.sup.9SO.sub.2--, and --SO.sub.2NR.sup.9--, wherein each group
is drawn with its right side attached to R.sup.8, and wherein
R.sup.9 and R.sup.10 are independently selected from the group
consisting of hydrogen, and alkyl; m, n, and p are independently
0-2; provided that at least one of Z.sup.1, Z.sup.2, Z.sup.3, and
Z.sup.4 is other than --N--.
2. The compound of claim 1 wherein Z.sup.1 is --CR.sup.4--; Z.sup.3
is --CR.sup.6--; and Z.sup.4 is --CR.sup.7--.
3. The compound of claim 2 wherein Z.sup.2 is --CR.sup.5--; R.sup.1
is hydrogen; R.sup.2 is -LR.sup.8; and m is 0.
4. The compound of claim 3 wherein X is --N--.
5. The compound of claim 3 wherein X is --CR.sup.3--.
6. The compound of claim 5 wherein L is selected from the group
consisting of --(CH.sub.2).sub.nC(O)(CH.sub.2).sub.p--,
--CC--(CH.sub.2).sub.nO--, --C(O)NR.sup.9--, --NR.sup.9C(O)--,
--NR.sup.9--, --NR.sup.9C(S)NR.sup.10--,
--NR.sup.9C(.dbd.NCN)NR.sup.10--, --NR.sup.9C(.dbd.NCN)O, and
NR.sup.9SO.sub.2--.
7. The compound of claim 5 wherein L is
--(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--.
8. The compound of claim 7 wherein n and p are 0.
9. The compound of claim 8 wherein R.sup.8 is aryl.
10. The compound of claim 9 wherein R.sup.3 is selected from the
group consisting of alkenyl, alkoxyalkyl, arylalkyl, halo,
heteroarylalkyl, heterocyclylalkyl, hydroxyalkyl, and
(NR.sup.aR.sup.b)alkyl.
11. The compound of claim 9 wherein R.sup.3 is
(NR.sup.aR.sup.b)C(O)alkyl.
12. The compound of claim 9 wherein R.sup.3 is hydrogen.
13. The compound of claim 9 wherein R.sup.3 is alkyl.
14. The compound of claim 13 wherein the alkyl is selected from the
group consisting of ethyl, isopropyl, and propyl.
15. The compound of claim 13 wherein the alkyl is methyl.
16. A compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[2-fluoro-5-(trifluor-
omethyl)phenyl]urea.
17. A compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphenyl)urea.
18. A compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chlorophenyl)urea.
19. A compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-[3-(trifluor-
omethyl)phenyl]urea.
20. A compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-N'-[3-(trifluor-
omethyl)phenyl]urea.
21. A pharmaceutical composition comprising a compound of claim 1
or a therapeutically acceptable salt thereof, in combination with a
therapeutically acceptable carrier.
22. A method for inhibiting a protein kinase in a patient in
recognized need of such treatment comprising administering to the
patient a therapeutically acceptable amount of a compound of claim
1, or a therapeutically acceptable salt thereof.
23. A method for inhibiting KDR in a patient in recognized need of
such treatment comprising administering to the patient a
therapeutically acceptable amount of a compound of claim 1, or a
therapeutically acceptable salt thereof.
24. A method for inhibiting Tie-2 in a patient in recognized need
of such treatment comprising administering to the patient a
therapeutically acceptable amount of a compound of claim 1, or a
therapeutically acceptable salt thereof.
25. A method for treating cancer in a patient in recognized need of
such treatment comprising administering to the patient a
therapeutically acceptable amount of a compound of claim 1, or a
therapeutically acceptable salt thereof.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 10/392,951, filed Mar. 20, 2003, which claims priority to
U.S. Provisional Patent Application Ser. No. 60/366,708, filed on
Mar. 21, 2002.
TECHNICAL FIELD
[0002] The present invention relates to compounds which are useful
for inhibiting protein tyrosine kinases, methods of making the
compounds, compositions containing the compounds, and methods of
treatment using the compounds.
BACKGROUND OF THE INVENTION
[0003] Protein tyrosine kinases (PTKs) are enzymes which catalyse
the phosphorylation of specific tyrosine residues in cellular
proteins. This post-translational modification of these substrate
proteins, often enzymes themselves, acts as a molecular switch
regulating cell proliferation, activation, or differentiation.
Aberrant or excessive PTK activity has been observed in many
disease states including benign and malignant proliferative
disorders as well as diseases resulting from inappropriate
activation of the immune system (e.g., autoimmune disorders),
allograft rejection, and graft vs. host disease. In addition,
endothelial-cell specific receptor PTKs such as KDR and Tie-2
mediate the angiogenic process, and are thus involved in supporting
the progression of cancers and other diseases involving
inappropriate vascularization (e.g., diabetic retinopathy,
choroidal neovascularization due to age-related macular
degeneration, psoriasis, arthritis, retinopathy of prematurity, and
infantile hemangiomas).
[0004] The identification of effective small compounds which
specifically inhibit signal transduction and cellular proliferation
by modulating the activity of tyrosine kinases to regulate and
modulate abnormal or inappropriate cell proliferation,
differentiation, or metabolism is therefore desirable. In
particular, the identification of methods and compounds that
specifically inhibit the function of a tyrosine kinase which is
essential for angiogenic processes or the formation of vascular
hyperpermeability leading to edema, ascites, effusions, exudates,
and macromolecular extravasation and matrix deposition as well as
associated disorders would be beneficial.
SUMMARY OF THE INVENTION
[0005] In its principle embodiment the present invention discloses
a compound of formula (I) ##STR2## or a therapeutically acceptable
salt thereof, wherein
[0006] X is selected from the group consisting of --N-- and
--CR.sup.3--;
[0007] Z.sup.1 is selected from the group consisting of --N-- and
--CR.sup.4--;
[0008] z.sup.2 is selected from the group consisting of --N-- and
--CR.sup.5--;
[0009] Z.sup.3 is selected from the group consisting of --N-- and
--CR.sup.6--;
[0010] Z.sup.4 is selected from the group consisting of --N-- and
--CR.sup.7--;
[0011] R.sup.1 is selected from the group consisting of hydrogen
and NH.sub.2;
[0012] R.sup.2 is selected from the group consisting of alkoxy,
cyano, hydroxy, nitro, --NR.sup.aR.sup.b, and -LR.sup.8;
[0013] R.sup.3 is selected from the group consisting of hydrogen,
alkenyl, alkoxyalkyl, alkyl, arylalkyl, carboxyalkyl, halo,
haloalkyl, heteroarylalkyl, (heterocyclyl)alkyl, hydroxyalkyl,
(NR.sup.aR.sup.b)alkyl, and (NR.sup.aR.sup.b)C(O)alkyl;
[0014] R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are independently
selected from the group consisting of hydrogen, alkoxy, alkyl,
NR.sup.aR.sup.b, halo, and hydroxy;
[0015] R.sup.8 is selected from the group consisting of
alkoxyalkyl, alkyl, aryl, arylalkenyl, arylalkyl, cycloalkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, and
(heterocyclyl)alkyl;
[0016] L is selected from the group consisting of --O--,
--(CH.sub.2).sub.nC(O)(CH.sub.2).sub.p--,
--CC--(CH.sub.2).sub.nO--, --C(O)NR.sup.9--, --NR.sup.9C(O)--,
--NR.sup.9--,
--(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--,
--NR.sup.9C(S)NR.sup.10--, --NR.sup.9C(.dbd.NCN)NR.sup.10--,
--NR.sup.9C(.dbd.NCN)O--, --OC(.dbd.NCN)NR.sup.9--,
--NR.sup.9SO.sub.2--, and --SO.sub.2NR.sup.9--, wherein each group
is drawn with its right side attached to R.sup.8, and wherein
R.sup.9 and R.sup.10 are independently selected from the group
consisting of hydrogen, and alkyl;
[0017] m, n, and p are independently 0-2;
[0018] provided that at least one of Z.sup.1, Z.sup.2, Z.sup.3, and
Z.sup.4 is other than --N--.
[0019] In another embodiment the present invention provides a
compound of formula (I) wherein Z.sup.1 is --CR.sup.4--; Z.sup.3 is
--CR.sup.6--; and Z.sup.4 is --CR.sup.7
[0020] In another embodiment the present invention provides a
compound of formula (I) wherein X is --N--; Z.sup.1 is
--CR.sup.4--; Z.sup.2 is --CR.sup.5--; Z.sup.3 is --CR.sup.6--;
Z.sup.4 is --CR.sup.7--; R.sup.1 is hydrogen; R.sup.2 is -LR.sup.8;
and m is 0.
[0021] In another embodiment the present invention provides a
compound of formula (I) wherein X is --CR.sup.3--; Z.sup.1 is
--CR.sup.4--; Z.sup.2 is --CR.sup.5--; Z.sup.3 is --CR.sup.6--;
Z.sup.4 is --CR.sup.7--; R.sup.1 is hydrogen; R.sup.2 is -LR.sup.8;
and m is 0.
[0022] In another embodiment the present invention provides a
compound of formula (I) wherein X is --CR.sup.3--; Z.sup.1 is
--CR.sup.4--; Z.sup.2 is --CR.sup.5--; Z.sup.3 is --CR.sup.6--;
Z.sup.4 is --CR.sup.7--; R.sup.1 is hydrogen; R.sup.2 is -LR.sup.8;
L is selected from the group consisting of
--(CH.sub.2).sub.nC(O)(CH.sub.2).sub.p--,
--CC--(CH.sub.2).sub.nO--, --C(O)NR.sup.9--, --NR.sup.9C(O)--,
--NR.sup.9--, --NR.sup.9C(S)NR.sup.10--,
--NR.sup.9C(.dbd.NCN)NR.sup.10--, --NR.sup.9C(.dbd.NCN)O, and
NR.sup.9SO.sub.2--; and m is 0.
[0023] In another embodiment the present invention provides a
compound of formula (I) wherein X is --CR.sup.3--; Z.sup.1 is
--CR.sup.4--; Z.sup.2 is --CR.sup.5--; Z.sup.3 is --CR.sup.6--;
Z.sup.4 is --CR.sup.7--; R.sup.1 is hydrogen; R.sup.2 is -LR.sup.8;
L is --(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--; and
m is 0.
[0024] In another embodiment the present invention provides a
compound of formula (I) wherein X is --CR.sup.3--; Z.sup.1 is
--CR.sup.4--; Z.sup.2 is --CR.sup.5--; Z.sup.3 is --CR.sup.6--;
Z.sup.4 is --CR.sup.7--; R.sup.1 is hydrogen; R.sup.2 is -LR.sup.8;
L is --(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--; and
m, n, and p are 0.
[0025] In another embodiment the present invention provides a
compound of formula (I) wherein X is --CR.sup.3--; Z.sup.1 is
--CR.sup.4--; Z.sup.2 is --CR.sup.5--; Z.sup.3 is --CR.sup.6--;
Z.sup.4 is --CR.sup.7--; R.sup.1 is hydrogen; R.sup.2 is -LR.sup.8;
R.sup.3 is aryl; L is
--(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--; and m,
n, and p are 0.
[0026] In another embodiment the present invention provides a
compound of formula (I) wherein X is --CR.sup.3--; Z.sup.1 is
--CR.sup.4--; Z.sup.2 is --CR.sup.5--; Z.sup.3 is --CR.sup.6--;
Z.sup.4 is --CR.sup.7--; R.sup.1 is hydrogen; R.sup.2 is -LR.sup.8;
R.sup.3 is selected from the group consisting of alkenyl,
alkoxyalkyl, arylalkyl, halo, heteroarylalkyl, heterocyclylalkyl,
hydroxyalkyl, and (NR.sup.aR.sup.b)alkyl; R.sup.8 is aryl; L is
--(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--; and m,
n, and p are 0.
[0027] In another embodiment the present invention provides a
compound of formula (I) wherein X is --CR.sup.3--; Z.sup.1 is
--CR.sup.4--; Z.sup.2 is --CR.sup.5--; Z.sup.3 is --CR.sup.6--;
Z.sup.4 is --CR.sup.7--; R.sup.1 is hydrogen; R.sup.2 is -LR.sup.8;
R.sup.3 is (NR.sup.aR.sup.b)C(O)alkyl; R.sup.8 is aryl; L is
--(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--; and m,
n, and p are 0.
[0028] In another embodiment the present invention provides a
compound of formula (I) wherein X is --CR.sup.3--; Z.sup.1 is
--CR.sup.4--; Z.sup.2 is --CR.sup.5--; Z.sup.3 is --CR.sup.6--;
Z.sup.4 is --CR.sup.7--; R.sup.1 is hydrogen; R.sup.2 is -LR.sup.8;
R.sup.3 is hydrogen; R.sup.8 is aryl; L is
--(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--; and m,
n, and p are 0.
[0029] In another embodiment the present invention provides a
compound of formula (I) wherein X is --CR.sup.3--; Z.sup.1 is
--CR.sup.4--; Z.sup.2 is --CR.sup.5--; Z.sup.3 is --CR.sup.6--;
Z.sup.4 is --CR.sup.7--; R.sup.1 is hydrogen; R.sup.2 is -LR.sup.8;
R.sup.3 is alkyl; R.sup.8 is aryl; L is
--(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--; and m,
n, and p are 0.
[0030] In another embodiment the present invention provides a
compound of formula (I) wherein X is --CR.sup.3--; Z.sup.1 is
--CR.sup.4--; Z.sup.2 is --CR.sup.5--; Z.sup.3 is --CR.sup.6--;
Z.sup.4 is --CR.sup.7--; R.sup.1 is hydrogen; R.sup.2 is -LR.sup.8;
R.sup.3 is alkyl, wherein the alkyl is selected from the group
consisting of ethyl, isopropyl, and propyl; R.sup.8 is aryl; L is
--(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--; and m,
n, and p are 0.
[0031] In another embodiment the present invention provides a
compound of formula (I) wherein X is --CR.sup.3--; Z.sup.1 is
--CR.sup.4--; Z.sup.2 is --CR.sup.5--; Z.sup.3 is --CR.sup.6--;
Z.sup.4 is --CR.sup.7--; R.sup.1 is hydrogen; R.sup.2 is -LR.sup.8;
R.sup.3 is alkyl, wherein the alkyl is methyl; R.sup.8 is aryl; L
is --(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--; and
m, n, and p are 0.
[0032] In another embodiment the present invention provides a
compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[2-fluoro-5--
(trifluoromethyl)phenyl]urea.
[0033] In another embodiment the present invention provides a
compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphe-
nyl)urea.
[0034] In another embodiment the present invention provides a
compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chlorophe-
nyl)urea.
[0035] In another embodiment the present invention provides a
compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-[3--
(trifluoromethyl)phenyl]urea.
[0036] In another embodiment the present invention provides a
compound which is
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-N'-[3--
(trifluoromethyl)phenyl]urea.
[0037] In another embodiment the present invention provides a
pharmaceutical composition comprising a compound of formula (I) or
a therapeutically acceptable salt thereof, in combination with a
therapeutically acceptable carrier.
[0038] In another embodiment the present invention provides a
method for inhibiting protein kinase in a patient in recognized
need of such treatment comprising administering to the patient a
therapeutically acceptable amount of a compound of formula (I), or
a therapeutically acceptable salt thereof.
[0039] In another embodiment the present invention provides a
method for inhibiting KDR in a patient in recognized need of such
treatment comprising administering to the patient a therapeutically
acceptable amount of a compound of formula (I), or a
therapeutically acceptable salt thereof.
[0040] In another embodiment the present invention provides a
method for inhibiting Tie-2 in a patient in recognized need of such
treatment comprising administering to the patient a therapeutically
acceptable amount of a compound of formula (I), or a
therapeutically acceptable salt thereof.
[0041] In another embodiment the present invention provides a
method for treating cancer in a patient in recognized need of such
treatment comprising administering to the patient a therapeutically
acceptable amount of a compound of formula (I), or a
therapeutically acceptable salt thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0042] As used herein, the singular forms "a", "an", and "the"
include plural reference unless the context clearly dictates
otherwise.
[0043] As used in the present specification the following terms
have the meanings indicated:
[0044] The term "alkenyl," as used herein, refers to a straight or
branched chain group of one to six carbon atoms containing at least
one carbon-carbon double bond. Examples of alkenyl groups include,
but are not limited to, ethenyl, 2-methyl-1-propenyl, and
1-butenyl.
[0045] The term "alkoxy," as used herein, refers to an alkyl group
attached to the parent molecular moiety through an oxygen atom.
[0046] The term "alkoxyalkyl," as used herein, refers to an alkoxy
group attached to the parent molecular moiety through an alkyl
group.
[0047] The term "alkoxycarbonyl," as used herein, refers to an
alkoxy group attached to the parent molecular moiety through a
carbonyl group.
[0048] The term "alkoxycarbonylcarbonyl," as used herein, refers to
an alkoxycarbonyl group attached to the parent molecular moiety
through a carbonyl group.
[0049] The term "alkyl," as used herein, refers to a monovalent
group derived from a straight or branched chain saturated
hydrocarbon. Examples of alkyl groups include, but are not limited
to, methyl, ethyl, propyl, and isopropyl.
[0050] The term "alkylcarbonyl," as used herein, refers to an alkyl
group attached to the parent molecular moiety through a carbonyl
group.
[0051] The term "alkylsulfanyl," as used herein, refers to an alkyl
group attached to the parent molecular moiety through a sulfur
atom.
[0052] The term "alkylsulfonyl," as used herein, refers to an alkyl
group attached to the parent molecular moiety through a sulfonyl
group.
[0053] The term "aryl," as used herein, refers to a phenyl group,
or a bicyclic or tricyclic fused ring system wherein one or more of
the fused rings is a phenyl group. Bicyclic fused ring systems are
exemplified by a phenyl group fused to a cycloalkenyl group, a
cycloalkyl group, or another phenyl group. Tricyclic fused ring
systems are exemplified by a bicyclic fused ring system fused to a
cycloalkenyl group, a cycloalkyl group, or another phenyl group.
Examples of aryl groups include, but are not limited to,
anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, naphthyl,
phenyl, and tetrahydronaphthyl. The aryl groups of the present
invention can be optionally substituted with one, two, three, four,
or five substituents independently selected from the group
consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl,
alkylcarbonyl, alkylsulfanyl, alkylsulfonyl, a second aryl group,
arylalkoxy, arylalkyl, aryloxy, carboxy, cyano, halo, haloalkoxy,
haloalkyl, heteroaryl, heteroarylalkoxy, heteroarylalkyl,
heteroaryloxy, heterocyclyl, (heterocyclyl)alkyl, hydroxy,
hydroxyalkyl, nitro, NR.sup.aR.sup.b, (NR.sup.aR.sup.b)alkyl,
(NR.sup.aR.sup.b)C(O), (NR.sup.aR.sup.b)C(O)alkyl, and oxo; wherein
the second aryl group, the aryl part of the arylalkoxy, the
arylalkyl, and the aryloxy, the heteroaryl, the heteroaryl part of
the heteroarylalkoxy, the heteroarylalkyl, and the heteroaryloxy,
the heterocyclyl, and the heterocyclyl part of the
(heterocyclyl)alkyl can be further optionally substituted with one,
two, three, four, or five groups independently selected from the
group consisting of alkenyl, alkoxy, alkoxyalkyl, alkyl,
alkylsulfanyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy,
hydroxyalkyl, nitro, NR.sup.aR.sup.b, and oxo.
[0054] The term "arylalkoxy," as used herein, refers to an aryl
group attached to the parent molecular moiety through an alkoxy
group.
[0055] The term "arylalkyl," as used herein, refers to an alkyl
group substituted with at least one aryl group.
[0056] The term "arylcarbonyl," as used herein, refers to an aryl
group attached to the parent molecular moiety through a carbonyl
group.
[0057] The term "aryloxy," as used herein, refers to an aryl group
attached to the parent molecular moiety through an oxygen atom.
[0058] The term "carbonyl," as used herein, refers to --C(O)--.
[0059] The term "carboxy," as used herein, refers to
--CO.sub.2H.
[0060] The term "carboxyalkyl," as used herein, refers to an alkyl
group substituted with at least one carboxy group.
[0061] The term "cyano," as used herein, refers to --CN.
[0062] The term "cycloalkenyl," as used herein, refers to a
non-aromatic cyclic or bicyclic ring system having three to ten
carbon atoms and one to three rings, wherein each five-membered
ring has one double bond, each six-membered ring has one or two
double bonds, each seven- and eight-membered ring has one to three
double bonds, and each nine-to ten-membered ring has one to four
double bonds. Examples of cycloalkenyl groups include, but are not
limited to, cyclobutenyl, cyclohexenyl, octahydronaphthalenyl, and
norbornylenyl. The cycloalkenyl groups of the present invention can
be optionally substituted with one, two, or three substituents
independently selected from the group consisting of alkoxy, alkyl,
aryl, arylalkyl, cyano, halo, haloalkyl, heteroaryl,
heteroarylalkyl, heterocyclyl, heterocyclylalkyl, nitro,
--NR.sup.cR.sup.d, and oxo.
[0063] The term "cycloalkenylalkyl," as used herein, refers to an
alkyl group substituted with at least one cycloalkenyl group.
[0064] The term "cycloalkyl," as used herein, refers to a saturated
monocyclic, bicyclic, or tricyclic hydrocarbon ring system having
three to twelve carbon atoms. Examples of cycloalkyl groups
include, but are not limited to, cyclopropyl, cyclopentyl,
cyclohexyl, bicyclo[3.1.1]heptyl, and adamantyl. The cycloalkyl
groups of the present invention can be optionally substituted with
one, two, or three substituents independently selected from the
group consisting of alkoxy, alkyl, aryl, arylalkyl, cyano, halo,
haloalkyl, heteroaryl, heteroarylalkyl, heterocyclyl,
heterocyclylalkyl, nitro, --NR.sup.cR.sup.d, and oxo.
[0065] The term "(cycloalkyl)alkyl," as used herein, refers to a
cycloalkyl group attached to the parent molecular moiety through an
alkyl group.
[0066] The terms "halo" and "halogen," as used herein, refer to F,
Cl, Br, or I.
[0067] The term "haloalkoxy," as used herein, refers to a haloalkyl
group attached to the parent molecular moiety through an oxygen
atom.
[0068] The term "haloalkyl," as used herein, refers to an alkyl
group substituted by at least one halogen atom.
[0069] The term "heteroaryl," as used herein, refers to an aromatic
five- or six-membered ring where at least one atom is selected from
the group consisting of N, O, and S, and the remaining atoms are
carbon. The five-membered rings have two double bonds, and the
six-membered rings have three double bonds. The heteroaryl groups
are connected to the parent molecular group through a substitutable
carbon or nitrogen atom in the ring. The term "heteroaryl" also
includes systems where a heteroaryl ring is fused to an aryl group,
a cycloalkenyl group, a cycloalkyl group, a heterocyclyl group, or
another heteroaryl group. Examples of heteroaryl groups include,
but are not limited to, benzodioxolyl, benzothienyl,
benzoxadiazolyl, benzoxazolyl, cinnolinyl, furanyl, imidazolyl,
indazolyl, indolyl, isoxazolyl, isoquinolinyl, isothiazolyl,
naphthyridinyl, oxadiazolyl, oxadiazolyl, oxazolyl, thiazolyl,
thienopyridinyl, thienyl, triazolyl, thiadiazolyl, pyridinyl,
pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl,
quinolinyl, and triazinyl. The heteroaryl groups of the present
invention can be optionally substituted with one, two, three, four,
or five substituents independently selected from the group
consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl,
alkylcarbonyl, alkylsulfanyl, alkylsulfonyl, aryl, arylalkoxy,
arylalkyl, aryloxy, cyano, halo, haloalkoxy, haloalkyl, a second
heteroaryl group, heteroarylalkoxy, heteroarylalkyl, heteroaryloxy,
heterocyclyl, (heterocyclyl)alkyl, hydroxy, hydroxyalkyl, nitro,
NR.sup.aR.sup.b, (NR.sup.aR.sup.b)alkyl, (NR.sup.aR.sup.b)C(O),
(NR.sup.aR.sup.b)C(O)alkyl, and oxo; wherein the aryl, the aryl
part of the arylalkoxy, the arylalkyl, and the aryloxy, the second
heteroaryl group, the heteroaryl part of the hetoerarylalkoxy, the
heteroarylalkyl, and the heteroaryloxy, the heterocyclyl, and the
heterocyclyl part of the (heterocyclyl)alkyl can be further
optionally substituted with one, two, three, four, or five groups
independently selected from the group consisting of alkenyl,
alkoxy, alkoxyalkyl, alkyl, alkylsulfanyl, cyano, halo, haloalkoxy,
haloalkyl, hydroxy, hydroxyalkyl, nitro, NR.sup.aR.sup.b, and
oxo.
[0070] The term "heteroarylalkoxy," as used herein, refers to a
heteroaryl group attached to the parent molecular moiety through an
alkoxy group.
[0071] The term "heteroarylalkyl," as used herein, refers to an
alkyl group substituted by at least one heteroaryl group.
[0072] The term "heteroaryloxy," as used herein, refers to a
heteroaryl group attached to the parent molecular moiety through an
oxygen atom.
[0073] The term "heterocyclyl," as used herein, refers to cyclic,
non-aromatic, five-, six-, or seven-membered rings containing at
least one atom selected from the group consisting of oxygen,
nitrogen, and sulfur. The five-membered rings have zero or one
double bonds and the six- and seven-membered rings have zero, one,
or two double bonds. The heterocyclyl groups of the invention are
connected to the parent molecular group through a substitutable
carbon or nitrogen atom in the ring. The term "heterocyclyl" also
includes systems where a heterocyclyl ring is fused to an aryl
group, a cycloalkenyl group, a cycloalkyl group, or another
heterocyclyl group. Heterocyclyl groups include, but are not
limited to, benzothiazolyl, dihydroindolyl, dihydropyridinyl,
1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl,
morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl,
piperidinyl, and thiomorpholinyl. The heterocyclyl groups of the
present invention can be optionally substituted with one, two,
three, four, or five substituents independently selected from the
group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl,
alkyl, alkylcarbonyl, alkylsulfanyl, alkylsulfonyl, aminoalkyl,
aminocarbonyl, aryl, arylalkoxy, arylalkyl, aryloxy, cyano, halo,
haloalkoxy, haloalkyl, heteroaryl, heteroarylalkoxy,
heteroarylalkyl, heteroaryloxy, a second heterocyclyl group,
(heterocyclyl)alkyl, hydroxy, hydroxyalkyl, nitro, NR.sup.aR.sup.b,
(NR.sup.aR.sup.b)alkyl, (NR.sup.aR.sup.b)C(O),
(NR.sup.aR.sup.b)C(O)alkyl, and oxo; wherein the aryl, the aryl
part of the arylalkoxy, the arylalkyl, and the aryloxy, the
heteroaryl, the heteroaryl part of the heteroarylalkoxy, the
heteroarylalkyl, and the heteroaryloxy, the second heterocyclyl
group, and the heterocyclyl part of the (heterocyclyl)alkyl can be
further optionally substituted with one, two, three, four, or five
groups independently selected from the group consisting of alkenyl,
alkoxy, alkoxyalkyl, alkyl, alkylsulfanyl, cyano, halo, haloalkoxy,
haloalkyl, hydroxy, hydroxyalkyl, nitro, NR.sup.aR.sup.b, and
oxo.
[0074] The term "(heterocyclyl)alkyl," as used herein, refers to an
alkyl group substituted with at least one heterocyclyl group.
[0075] The term "hydroxy," as used herein, refers to --OH.
[0076] The term "hydroxyalkyl," as used herein, refers to an alkyl
group substituted with at least one hydroxy group.
[0077] The term "nitro," as used herein, refers to --NO.sub.2.
[0078] The term "NR.sup.aR.sup.b," as used herein, refers to two
groups, R.sup.a and R.sup.b, which are attached to the parent
molecular moiety through a nitrogen atom. R.sup.a and R.sup.b are
independently selected from the group consisting of hydrogen,
alkenyl, alkoxycarbonyl, alkyl, alkylcarbonyl,
alkoxycarbonylcarbonyl, aryl, arylalkyl, arylcarbonyl,
cycloalkenyl, (cycloalkenyl)alkyl, cycloalkyl, (cycloalkyl)alkyl,
heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl,
(NR.sup.cR.sup.d)alkyl, (NR.sup.cR.sup.d)C(O), and
(NR.sup.cR.sup.d)C(O)alkyl, wherein the aryl, the aryl part of the
arylalkyl, and the arylcarbonyl, the heteroaryl, the heteroaryl
part of the heteroarylalkyl and the heteroarylcarbonyl, the
heterocyclyl, and the heterocyclyl part of the heterocyclylalkyl
and the heterocyclylcarbonyl are further optionally substituted
with one, two, three, four, or five substituents independently
selected from the group consisting of alkoxy, alkyl, cyano, halo,
haloalkoxy, nitro, and oxo.
[0079] The term "(NR.sup.aR.sup.b)alkyl," as used herein, refers to
an alkyl group substituted with at least one NR.sup.aR.sup.b
group.
[0080] The term "(NR.sup.aR.sup.b)C(O)," as used herein, refers to
an NR.sup.aR.sup.b group attached to the parent molecular moiety
through a carbonyl group.
[0081] The term "(NR.sup.aR.sup.b)C(O)alkyl," as used herein,
refers to an alkyl group substituted with at least one
(NR.sup.aR.sup.b)C(O) group.
[0082] The term "NR.sup.cR.sup.d," as used herein, refers to two
groups, R.sup.c and R.sup.d, which are attached to the parent
molecular moiety through a nitrogen atom. R.sup.c and R.sup.d are
independently selected from the group consisting of hydrogen,
alkenyl, alkoxycarbonyl, alkyl, alkylcarbonyl, aryl, and arylalkyl;
wherein the aryl and the aryl part of the arylalkyl can be further
optionally substituted with one, two, three, four, or five
substituents independently selected from the group consisting of
alkoxy, alkyl, cyano, halo, haloalkoxy, nitro, and oxo.
[0083] The term "(NR.sup.cR.sup.d)alkyl," as used herein, refers to
an alkyl group substituted with at least one NR.sup.cR.sup.d
group.
[0084] The term "(NR.sup.cR.sup.d)C(O)," as used herein, refers to
an NR.sup.cR.sup.d group attached to the parent molecular moiety
through a carbonyl group.
[0085] The term "(NR.sup.cR.sup.d)C(O)alkyl," as used herein,
refers to an alkyl group substituted with at least one
(NR.sup.cR.sup.d)C(O) group.
[0086] The term "oxo," as used herein, refers to .dbd.O.
[0087] The term "sulfonyl," as used herein, refers to
--SO.sub.2.
[0088] The compounds of the present invention can exist as
therapeutically acceptable salts. The term "therapeutically
acceptable salt," as used herein, represents salts or zwitterionic
forms of the compounds of the present invention which are water or
oil-soluble or dispersible, which are suitable for treatment of
diseases without undue toxicity, irritation, and allergic response;
which are commensurate with a reasonable benefit/risk ratio, and
which are effective for their intended use. The salts can be
prepared during the final isolation and purification of the
compounds or separately by reacting a suitable nitrogen atom with a
suitable acid. Representative acid addition salts include acetate,
adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate,
bisulfate, butyrate, camphorate, camphorsulfonate, digluconate,
glycerophosphate, hemisulfate, heptanoate, hexanoate, formate,
fumarate, hydrochloride, hydrobromide, hydroiodide,
2-hydroxyethansulfonate, lactate, maleate, mesitylenesulfonate,
methanesulfonate, naphthylenesulfonate, nicotinate,
2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate,
3-phenylproprionate, picrate, pivalate, propionate, succinate,
tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate,
bicarbonate, para-toluenesulfonate, and undecanoate. Also, suitable
nitrogen atoms in the compounds of the present invention can be
quaternized with methyl, ethyl, propyl, and butyl chlorides,
bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl
sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides,
and iodides; and benzyl and phenethyl bromides. Examples of acids
which can be employed to form therapeutically acceptable addition
salts include inorganic acids such as hydrochloric, hydrobromic,
sulfuric, and phosphoric, and organic acids such as oxalic, maleic,
succinic, and citric.
[0089] Basic addition salts can be prepared during the final
isolation and purification of the compounds by reacting a carboxy
group with a suitable base such as the hydroxide, carbonate, or
bicarbonate of a metal cation or with ammonia or an organic
primary, secondary, or tertiary amine. The cations of
therapeutically acceptable salts include lithium, sodium,
potassium, calcium, magnesium, and aluminum, as well as nontoxic
quaternary amine cations such as ammonium, tetramethylammonium,
tetraethylammonium, methylamine, dimethylamine, trimethylamine,
triethylamine, diethylamine, ethylamine, tributylamine, pyridine,
N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine,
dicyclohexylamine, procaine, dibenzylamine,
N,N-dibenzylphenethylamine, 1-ephenamine, and
N,N'-dibenzylethylenediamine. Other representative organic amines
useful for the formation of base addition salts include
ethylenediamine, ethanolamine, diethanolamine, piperidine, and
piperazine.
[0090] The present compounds can also exist as therapeutically
acceptable prodrugs. The term "therapeutically acceptable prodrug,"
refers to those prodrugs or zwitterions which are suitable for use
in contact with the tissues of patients without undue toxicity,
irritation, and allergic response, are commensurate with a
reasonable benefit/risk ratio, and are effective for their intended
use. The term "prodrug," refers to compounds which are rapidly
transformed in vivo to parent compounds of formula (I) for example,
by hydrolysis in blood.
[0091] In accordance with methods of treatment and pharmaceutical
compositions of the invention, the compounds can be administered
alone or in combination with other anticancer agents. When using
the compounds, the specific therapeutically effective dose level
for any particular patient will depend upon factors such as the
disorder being treated and the severity of the disorder; the
activity of the particular compound used; the specific composition
employed; the age, body weight, general health, sex, and diet of
the patient; the time of administration; the route of
administration; the rate of excretion of the compound employed; the
duration of treatment; and drugs used in combination with or
coincidently with the compound used. The compounds can be
administered orally, parenterally, osmotically (nasal sprays),
rectally, vaginally, or topically in unit dosage formulations
containing carriers, adjuvants, diluents, vehicles, or combinations
thereof. The term "parenteral" includes infusion as well as
subcutaneous, intravenous, intramuscular, and intrasternal
injection.
[0092] Parenterally administered aqueous or oleaginous suspensions
of the compounds can be formulated with dispersing, wetting, or
suspending agents. The injectable preparation can also be an
injectable solution or suspension in a diluent or solvent. Among
the acceptable diluents or solvents employed are water, saline,
Ringer's solution, buffers, monoglycerides, diglycerides, fatty
acids such as oleic acid, and fixed oils such as monoglycerides or
diglycerides.
[0093] The inhibitory effect of parenterally administered compounds
can be prolonged by slowing their absorption. One way to slow the
absorption of a particular compound is administering injectable
depot forms comprising suspensions of crystalline, amorphous, or
otherwise water-insoluble forms of the compound. The rate of
absorption of the compound is dependent on its rate of dissolution
which is, in turn, dependent on its physical state. Another way to
slow absorption of a particular compound is administering
injectable depot forms comprising the compound as an oleaginous
solution or suspension. Yet another way to slow absorption of a
particular compound is administering injectable depot forms
comprising microcapsule matrices of the compound trapped within
liposomes, microemulsions, or biodegradable polymers such as
polylactide-polyglycolide, polyorthoesters or polyanhydrides.
Depending on the ratio of drug to polymer and the composition of
the polymer, the rate of drug release can be controlled.
[0094] Transdermal patches can also provide controlled delivery of
the compounds. The rate of absorption can be slowed by using rate
controlling membranes or by trapping the compound within a polymer
matrix or gel. Conversely, absorption enhancers can be used to
increase absorption.
[0095] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In these solid dosage forms,
the active compound can optionally comprise diluents such as
sucrose, lactose, starch, talc, silicic acid, aluminum hydroxide,
calcium silicates, polyamide powder, tableting lubricants, and
tableting aids such as magnesium stearate or microcrystalline
cellulose. Capsules, tablets and pills can also comprise buffering
agents, and tablets and pills can be prepared with enteric coatings
or other release-controlling coatings. Powders and sprays can also
contain excipients such as talc, silicic acid, aluminum hydroxide,
calcium silicate, polyamide powder, or mixtures thereof. Sprays can
additionally contain customary propellants such as
chlorofluorohydrocarbons or substitutes therefore.
[0096] Liquid dosage forms for oral administration include
emulsions, microemulsions, solutions, suspensions, syrups, and
elixirs comprising inert diluents such as water. These compositions
can also comprise adjuvants such as wetting, emulsifying,
suspending, sweetening, flavoring, and perfuming agents.
[0097] Topical dosage forms include ointments, pastes, creams,
lotions, gels, powders, solutions, sprays, inhalants, and
transdermal patches. The compound is mixed under sterile conditions
with a carrier and any needed preservatives or buffers. These
dosage forms can also include excipients such as animal and
vegetable fats, oils, waxes, paraffins, starch, tragacanth,
cellulose derivatives, polyethylene glycols, silicones, bentonites,
silicic acid, talc and zinc oxide, or mixtures thereof.
Suppositories for rectal or vaginal administration can be prepared
by mixing the compounds with a suitable non-irritating excipient
such as cocoa butter or polyethylene glycol, each of which is solid
at ordinary temperature but fluid in the rectum or vagina.
Ophthalmic formulations comprising eye drops, eye ointments,
powders, and solutions are also contemplated as being within the
scope of this invention.
[0098] The total daily dose of the compounds administered to a host
in single or divided doses can be in amounts from about 0.1 to
about 200 mg/kg body weight or preferably from about 0.25 to about
100 mg/kg body weight. Single dose compositions can contain these
amounts or submultiples thereof to make up the daily dose.
[0099] Preferred compounds of the present invention are compounds
of formula (I) where R.sup.2 is -LR.sup.8; L is
--(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--; R.sup.9
and R.sup.10 are hydrogen; and m is 0.
Determination of Biological Activity
[0100] The in vitro potency of compounds in inhibiting these
protein kinases may be determined by the procedures detailed
below.
[0101] The potency of compounds can be determined by the amount of
inhibition of the phosphorylation of an exogenous substrate (e.g.,
synthetic peptide (Z. Songyang et al., Nature. 373:536-539) by a
test compound relative to control.
KDR Tyrosine Kinase Production Using Baculovirus System:
[0102] The coding sequence for the human KDR intra-cellular domain
(aa789-1354) was generated through PCR using cDNAs isolated from
HUVEC cells. A poly-His6 sequence was introduced at the N-terminus
of this protein as well. This fragment was cloned into transfection
vector pVL1393 at the Xba 1 and Not 1 site. Recombinant baculovirus
(BV) was generated through co-transfection using the BaculoGold
Transfection reagent (PharMingen). Recombinant BV was plaque
purified and verified through Western analysis. For protein
production, SF-9 cells were grown in SF-900-II medium at
2.times.106/mL, and were infected at 0.5 plaque forming units per
cell (MOI). Cells were harvested at 48 hours post infection.
Purification of KDR
[0103] SF-9 cells expressing (His).sub.6 KDR(aa789-1354) were lysed
by adding 50 mL of Triton X-100 lysis buffer (20 mM Tris, pH 8.0,
137 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 10 .mu.g/mL
aprotinin, 1 .mu.g/mL leupeptin) to the cell pellet from 1 L of
cell culture. The lysate was centrifuged at 19,000 rpm in a Sorval
SS-34 rotor for 30 minutes at 4.degree. C. The cell lysate was
applied to a 5 mL NiCl.sub.2 chelating sepharose column,
equilibrated with 50 mM HEPES, pH7.5, 0.3M NaCl. KDR was eluted
using the same buffer containing 0.25M imidazole. Column fractions
were analyzed using SDS-PAGE and an ELISA assay (below) which
measures kinase activity. The purified KDR was exchanged into 25 mM
HEPES, pH7.5, 25 mM NaCl, 5 mM DTT buffer and stored at -80.degree.
C.
[0104] Compounds of the present invention inhibited KDR at IC50's
between about 0.003 .mu.M and >50 .mu.M. Preferred compounds
inhibited KDR at IC50's between about 0.003 .mu.M and about 0.5
.mu.M.
Human Tie-2 Kinase Production and Purification
[0105] The coding sequence for the human Tie-2 intra-cellular
domain (aa775-1124) was generated through PCR using cDNAs isolated
from human placenta as a template. A poly-His.sub.6 sequence was
introduced at the N-terminus and this construct was cloned into
transfection vector pVL 1939 at the Xba 1 and Not 1 site.
Recombinant BV was generated through co-transfection using the
BaculoGold Transfection reagent (PharMingen). Recombinant BV was
plaque purified and verified through Western analysis. For protein
production, SF-9 insect cells were grown in SF-900-II medium at
2.times.106/mL, and were infected at MOI of 0.5. Purification of
the His-tagged kinase used in screening was analogous to that
described for KDR.
[0106] Compounds of the present invention inhibited Tie-2 at IC50's
between about 0.01 .mu.M and >50 .mu.M. Preferred compounds
inhibited Tie-2 at IC50's between about 0.01 .mu.M and 0.5
.mu.M.
Human Flt-1 Tyrosine Kinase Production and Purification
[0107] The baculoviral expression vector pVL1393 (Phar Mingen, Los
Angeles, Calif.) was used. A nucleotide sequence encoding poly-His6
was placed 5' to the nucleotide region encoding the entire
intracellular kinase domain of human Flt-1 (amino acids 786-1338).
The nucleotide sequence encoding the kinase domain was generated
through PCR using cDNA libraries isolated from HUVEC cells. The
histidine residues enabled affinity purification of the protein as
a manner analogous to that for KDR and ZAP70. SF-9 insect cells
were infected at a 0.5 multiplicity and harvested 48 hours post
infection.
EGFR Tyrosine Kinase Source
[0108] EGFR was purchased from Sigma (Cat # E-3641; 500 units/50
.mu.l) and the EGF ligand was acquired from Oncogene Research
Products/Calbiochem (Cat # PF011-100).
Expression of ZAP70
[0109] The baculoviral expression vector used was pVL1393.
(Pharmingen, Los Angeles, Calif.) The nucleotide sequence encoding
amino acids M(H)6 LVPR.sub.9S was placed 5' to the region encoding
the entirety of ZAP70 (amino acids 1-619). The nucleotide sequence
encoding the ZAP70 coding region was generated through PCR using
cDNA libraries isolated from Jurkat immortalized T-cells. The
histidine residues enabled affinity purification of the protein
(vide infra). The LVPR.sub.9S bridge constitutes a recognition
sequence for proteolytic cleavage by thrombin, enabling removal of
the affinity tag from the enzyme. SF-9 insect cells were infected
at a multiplicity of infection of 0.5 and harvested 48 hours post
infection.
Extraction and Purification of ZAP70
[0110] SF-9 cells were lysed in a buffer consisting of 20 mM Tris,
pH 8.0, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 1
.mu.g/mL leupeptin, 10 .mu.g/mL aprotinin and 1 mM sodium
orthovanadate. The soluble lysate was applied to a chelating
sepharose HiTrap column (Pharmacia) equilibrated in 50 mM HEPES, pH
7.5, 0.3M NaCl. Fusion protein was eluted with 250 mM imidazole.
The enzyme was stored in buffer containing 50 mM HEPES, pH 7.5, 50
mM NaCl and 5 mM DTT.
Protein Kinase Source
[0111] Lck, Fyn, Src, Blk, Csk, and Lyn, and truncated forms
thereof may be commercially obtained (e.g., from Upstate
Biotechnology Inc. (Saranac Lake, N.Y.) and Santa Cruz
Biotechnology Inc. (Santa Cruz, Ca.)) or purified from known
natural or recombinant sources using conventional methods.
Enzyme Linked Immunosorbent Assay (ELISA) for PTKs
[0112] Enzyme linked immunosorbent assays (ELISA) were used to
detect and measure the presence of tyrosine kinase activity. The
ELISA were conducted according to known protocols which are
described in, for example, Voller, et al., 1980, "Enzyme-Linked
Immunosorbent Assay," In: Manual of Clinical Immunology, 2d ed.,
edited by Rose and Friedman, pp 359-371 Am. Soc. of Microbiology,
Washington, D.C.
[0113] The disclosed protocol was adapted for determining activity
with respect to a specific PTK. For example, preferred protocols
for conducting the ELISA experiments is provided below. Adaptation
of these protocols for determining a compound's activity for other
members of the receptor PTK family, as well as non-receptor
tyrosine kinases, are well within the abilities of those in the
art. For purposes of determining inhibitor selectivity, a universal
PTK substrate (e.g., random copolymer of poly(Glu.sub.4 Tyr),
20,000-50,000 MW) was employed together with ATP (typically 5
.mu.M) at concentrations approximately twice the apparent Km in the
assay.
[0114] The following procedure was used to assay the inhibitory
effect of compounds of this invention on KDR, Flt-1, Flt-4, Tie-1,
Tie-2, EGFR, FGFR, PDGFR, IGF-1-R, c-Met, Lck, hck, Blk, Csk, Src,
Lyn, fgr, Fyn and ZAP70 tyrosine kinase activity:
Buffers and Solutions:
PGTPoly (Glu, Tyr) 4:1
Store powder at -20.degree. C. Dissolve powder in phosphate
buffered saline (PBS) for 50 mg/mL solution. Store 1 mL aliquots at
-20.degree. C. When making plates dilute to 250 .mu.g/mL in Gibco
PBS.
Reaction Buffer: 100 mM Hepes, 20 mM MgCl.sub.2, 4 mM MnCl.sub.2, 5
mM DTT, 0.02% BSA, 200 .mu.M NaVO.sub.4, pH 7.10
ATP: Store aliquots of 100 mM at -20.degree. C. Dilute to 20 .mu.M
in water
Washing Buffer: PBS with 0.1% Tween 20
Antibody Diluting Buffer: 0.1% bovine serum albumin (BSA) in
PBS
TMB Substrate: mix TMB substrate and Peroxide solutions 9:1 just
before use or use K-Blue Substrate from Neogen
Stop Solution: 1M Phosphoric Acid
Procedure
1. Plate Preparation:
[0115] Dilute PGT stock (50 mg/mL, frozen) in PBS to a 250
.mu.g/mL. Add 125 .mu.L per well of Corning modified flat bottom
high affinity ELISA plates (Corning #25805-96). Add 125 .mu.L PBS
to blank wells. Cover with sealing tape and incubate overnight
37.degree. C. Wash 1.times. with 250 .mu.L washing buffer and dry
for about 2 hours in 37.degree. C. dry incubator.
Store coated plates in sealed bag at 4.degree. C. until used.
2. Tyrosine Kinase Reaction:
[0116] Prepare inhibitor solutions at a 4.times. concentration in
20% DMSO in water. [0117] Prepare reaction buffer [0118] Prepare
enzyme solution so that desired units are in 50 .mu.L, e.g. for KDR
make to 1 ng/.mu.L for a total of 50 ng per well in the reactions.
Store on ice [0119] Make 4.times.ATP solution to 2 .mu.M from 100
mM stock in water. Store on ice [0120] Add 50 .mu.L of the enzyme
solution per well (typically 5-50 ng enzyme/well depending on the
specific activity of the kinase) [0121] Add 25 .mu.L 4.times.
inhibitor [0122] Add 25 .mu.L 4.times.ATP for inhibitor assay
[0123] Incubate for 10 minutes at room temperature [0124] Stop
reaction by adding 50 .mu.L 0.05N HCl per well [0125] Wash plate
**Final Concentrations for Reaction: 5 .mu.M ATP, 5% DMSO 3.
Antibody Binding [0126] Dilute 1 mg/mL aliquot of PY20-HRP (Pierce)
antibody (a phosphotyrosine antibody) to 50 ng/mL in 0.1% BSA in
PBS by a 2 step dilution (100.times., then 200.times.) [0127] Add
100 .mu.L Ab per well. Incubate 1 hour at room temperature.
Incubate 1 hour at 4.degree. C. [0128] Wash 4.times. plate 4. Color
reaction [0129] Prepare TMB substrate and add 100 .mu.L per well
[0130] Monitor OD at 650 nm until 0.6 is reached [0131] Stop with
1M phosphoric acid. Shake on plate reader. [0132] Read OD
immediately at 450 nm
[0133] Optimal incubation times and enzyme reaction conditions vary
slightly with enzyme preparations and are determined empirically
for each lot.
[0134] For Lck, the Reaction Buffer utilized was 100 mM MOPSO, pH
6.5, 4 mM MnCl.sub.2, 20 mM MgCl.sub.2, 5 mM DTT, 0.2% BSA, 200 mM
NaVO.sub.4 under the analogous assay conditions.
Cdc2 Source
[0135] The human recombinant enzyme and assay buffer may be
obtained commercially (New England Biolabs, Beverly, Mass. USA) or
purified from known natural or recombinant sources using
conventional methods.
Cdc2 Assay
[0136] A protocol that can be used is that provided with the
purchased reagents with minor modifications. In brief, the reaction
is carried out in a buffer consisting of 50 mM Tris pH 7.5, 100 mM
NaCl, 1 mM EGTA, 2 mM DTT, 0.01% Brij, 5% DMSO and 10 mM MgCl.sub.2
(commercial buffer) supplemented with fresh 300 .mu.M ATP (31
.mu.Ci/mL) and 30 .mu.g/mL histone type IIIss final concentrations.
A reaction volume of 80 .mu.L, containing units of enzyme, is run
for 20 minutes at 25 degrees C. in the presence or absence of
inhibitor. The reaction is terminated by the addition of 120 .mu.L
of 10% acetic acid. The substrate is separated from unincorporated
label by spotting the mixture on phosphocellulose paper, followed
by 3 washes of 5 minutes each with 75 mM phosphoric acid. Counts
are measured by a betacounter in the presence of liquid
scintillant.
PKC Kinase Source
[0137] The catalytic subunit of PKC may be obtained commercially
(Calbiochem).
PKC Kinase Assay
[0138] A radioactive kinase assay is employed following a published
procedure (Yasuda, I., Kirshimoto, A., Tanaka, S., Tominaga, M.,
Sakurai, A., Nishizuka, Y. Biochemical and Biophysical Research
Communication 3:166, 1220-1227 (1990)). Briefly, all reactions are
performed in a kinase buffer consisting of 50 mM Tris-HCl pH7.5, 10
mM MgCl.sub.2, 2 mM DTT, 1 mM EGTA, 100 .mu.M ATP, 8 .mu.M peptide,
5% DMSO and .sup.33P ATP (8 Ci/mM). Compound and enzyme are mixed
in the reaction vessel and the reaction is initiated by addition of
the ATP and substrate mixture. Following termination of the
reaction by the addition of 10 .mu.L stop buffer (5 mM ATP in 75 mM
phosphoric acid), a portion of the mixture is spotted on
phosphocellulose filters. The spotted samples are washed 3 times in
75 mM phosphoric acid at room temperature for 5 to 15 minutes.
Incorporation of radiolabel is quantified by liquid scintillation
counting.
Erk2 Enzyme Source
[0139] The recombinant murine enzyme and assay buffer may be
obtained commercially (New England Biolabs, Beverly Mass. USA) or
purified from known natural or recombinant sources using
conventional methods.
Erk2 Enzyme Assay
[0140] In brief, the reaction is carried out in a buffer consisting
of 50 mM Tris pH 7.5, 1 mM EGTA, 2 mM DTT, 0.01% Brij, 5% DMSO and
10 mM MgCl.sub.2 (commercial buffer) supplemented with fresh 100
.mu.M ATP (31 .mu.Ci/mL) and 30 .mu.M myelin basic protein under
conditions recommended by the supplier. Reaction volumes and method
of assaying incorporated radioactivity are as described for the PKC
assay (vide supra).
Cellular Receptor PTK Assays
[0141] The following cellular assay was used to determine the level
of activity and effect of the different compounds of the present
invention on KDR/VEGFR2. Similar receptor PTK assays employing a
specific ligand stimulus can be designed along the same lines for
other tyrosine kinases using techniques well known in the art.
[0142] VEGF-Induced KDR Phosphorylation in Human Umbilical Vein
Endothelial Cells (HUVEC) as Measured by Western Blots:
[0143] 1. HUVEC cells (from pooled donors) can be purchased from
Clonetics (San Diego, Calif.) and cultured according to the
manufacturer directions. Only early passages (3-8) are used for
this assay. Cells are cultured in 100 mm dishes (Falcon for tissue
culture; Becton Dickinson; Plymouth, England) using complete EBM
media (Clonetics).
[0144] 2. For evaluating a compound's inhibitory activity, cells
are trypsinized and seeded at 0.5-1.0.times.10.sup.5 cells/well in
each well of 6-well cluster plates (Costar; Cambridge, Mass.).
[0145] 3. 3-4 days after seeding, plates are typically 90-100%
confluent. Medium is removed from all the wells, cells are rinsed
with 5-10 mL of PBS and incubated 18-24 h with 5 mL of EBM base
media with no supplements added (i.e., serum starvation).
[0146] 4. Serial dilutions of inhibitors are added in 1 mL of EBM
media (25 .mu.M, 5 .mu.M, or 1 .mu.M final concentration to cells
and incubated for one hour at 37.degree. C. Human recombinant
VEGF.sub.165 (R & D Systems) is then added to all the wells in
2 mL of EBM medium at a final concentration of 50 ng/mL and
incubated at 37.degree. C. for 10 minutes. Control cells untreated
or treated with VEGF only are used to assess background
phosphorylation and phosphorylation induction by VEGF.
[0147] All wells are then rinsed with 5-10 mL of cold PBS
containing 1 mM Sodium Orthovanadate (Sigma) and cells are lysed
and scraped in 200 .mu.L of RIPA buffer (50 mM Tris-HCl) pH 7, 150
mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA) containing
protease inhibitors (PMSF 1 mM, aprotinin 1 .mu.g/mL, pepstatin 1
.mu.g/mL, leupeptin 1 .mu.g/mL, Na vanadate 1 mM, Na fluoride 1 mM)
and 1 .mu.g/mL of Dnase (all chemicals from Sigma Chemical Company,
St Louis, Mo.). The lysate is spun at 14,000 rpm for 30 minutes, to
eliminate nuclei.
[0148] Equal amounts of proteins are then precipitated by addition
of cold (-20.degree. C.) ethanol (2 volumes) for a minimum of 1
hour or a maximum of overnight. Pellets are reconstituted in LaemLi
sample buffer containing 5%-mercaptoethanol (BioRad; Hercules,
Calif.) and boiled for 5 minutes. The proteins are resolved by
polyacrylamide gel electrophoresis (6%, 1.5 mm Novex, San Deigo,
Calif.) and transferred onto a nitrocellulose membrane using the
Novex system. After blocking with bovine serum albumin (3%), the
proteins are probed overnight with anti-KDR polyclonal antibody
(C20, Santa Cruz Biotechnology; Santa Cruz, Calif.) or with
anti-phosphotyrosine monoclonal antibody (4G10, Upstate
Biotechnology, Lake Placid, N.Y.) at 4.degree. C. After washing and
incubating for 1 hour with HRP-conjugated F(ab).sub.2 of goat
anti-rabbit or goat-anti-mouse IgG the bands are visualized using
the emission chemiluminescience (ECL) system (Amersham Life
Sciences, Arlington Heights, Ill.).
In Vivo Uterine Edema Model
[0149] This assay measures the capacity of compounds to inhibit the
acute increase in uterine weight in mice which occurs in the first
few hours following estrogen stimulation. This early onset of
uterine weight increase is known to be due to edema caused by
increased permeability of uterine vasculature. Cullinan-Bove and
Koss (Endocrinology (1993), 133:829-837) demonstrated a close
temporal relationship of estrogen-stimulated uterine edema with
increased expression of VEGF mRNA in the uterus. These results have
been confirmed by the use of neutralizing monoclonal antibody to
VEGF which significantly reduced the acute increase in uterine
weight following estrogen stimulation (WO 97/42187). Hence, this
system can serve as a model for in vivo inhibition of VEGF
signalling and the associated hyperpermeability and edema.
[0150] Materials: All hormones can be purchased from Sigma (St.
Louis, Mo.) or Cal Biochem (La Jolla, Calif.) as lyophilized
powders and prepared according to supplier instructions. Vehicle
components (DMSO, Cremaphor EL) can be purchased from Sigma (St.
Louis, Mo.). Mice (Balb/c, 8-12 weeks old) can be purchased from
Taconic (Germantown, N.Y.) and housed in a pathogen-free animal
facility in accordance with institutional Animal Care and Use
Committee Guidelines.
Method:
[0151] Day 1: Balb/c mice are given an intraperitoneal (i.p.)
injection of 12.5 units of pregnant mare's serum gonadotropin
(PMSG).
[0152] Day 3: Mice receive 15 units of human chorionic gonadotropin
(hCG) i.p.
[0153] Day 4: Mice are randomized and divided into groups of 5-10.
Test compounds are administered by i.p., i.v. or p.o. routes
depending on solubility and vehicle at doses ranging from 1-100
mg/kg. Vehicle control group receive vehicle only and two groups
are left untreated.
[0154] Thirty minutes later, experimental, vehicle and 1 of the
untreated groups are given an i.p. injection of 17-estradiol (500
mg/kg). After 2-3 hours, the animals are sacrificed by CO.sub.2
inhalation. Following a midline incision, each uterus was isolated
and removed by cutting just below the cervix and at the junctions
of the uterus and oviducts. Fat and connective tissue were removed
with care not to disturb the integrity of the uterus prior to
weighing (wet weight). Uteri are blotted to remove fluid by
pressing between two sheets of filter paper with a one liter glass
bottle filled with water. Uteri are weighed following blotting
(blotted weight). The difference between wet and blotted weights is
taken as the fluid content of the uterus. Mean fluid content of
treated groups is compared to untreated or vehicle treated groups.
Significance is determined by Student's test. Non-stimulated
control group is used to monitor estradiol response.
[0155] Certain compounds of this invention which are inhibitors of
angiogenic receptor tyrosine kinases can also be shown active in a
Matrigel implant model of neovascularization. The Matrigel
neovascularization model involves the formation of new blood
vessels within a clear marble of extracellular matrix implanted
subcutaneously which is induced by the presence of proangiogenic
factor producing tumor cells (for examples see: Passaniti, A., et
al., Lab. Investig. (1992), 67(4), 519-528; Anat. Rec. (1997),
249(1), 63-73; Int. J. Cancer (1995), 63(5), 694-701; Vasc. Biol.
(1995), 15(11), 1857-6). The model preferably runs over 3-4 days
and endpoints include macroscopic visual/image scoring of
neovascularization, microscopic microvessel density determinations,
and hemoglobin quantitation (Drabkin method) following removal of
the implant versus controls from animals untreated with inhibitors.
The model may alternatively employ bFGF or HGF as the stimulus.
[0156] The compounds of the present invention may be used in the
treatment of protein kinase-mediated conditions, such as benign and
neoplastic proliferative diseases and disorders of the immune
system. Such diseases include autoimmune diseases, such as
rheumatoid arthritis, thyroiditis, type 1 diabetes, multiple
sclerosis, sarcoidosis, inflammatory bowel disease, Crohn's
disease, myasthenia gravis and systemic lupus erythematosus;
psoriasis, organ transplant rejection (e.g., kidney rejection,
graft versus host disease), benign and neoplastic proliferative
diseases, human cancers such as lung, breast, stomach, bladder,
colon, pancreatic, ovarian, prostate and rectal cancer and
hematopoietic malignancies (leukemia and lymphoma), glioblastoma,
infantile hemangioma, and diseases involving inappropriate
vascularization (for example diabetic retinopathy, retinopathy of
prematurity, choroidal neovascularization due to age-related
macular degeneration, and infantile hemangiomas in human beings).
Such inhibitors may be useful in the treatment of disorders
involving VEGF mediated edema, ascites, effusions, and exudates,
including for example macular edema, cerebral edema, acute lung
injury and adult respiratory distress syndrome (ARDS). In addition,
the compounds of the invention may be useful in the treatment of
pulmonary hypertension, particularly in patients with
thromboembolic disease (J. Thorac. Cardiovasc. Surg. 2001, 122 (1),
65-73).
[0157] Compounds of the invention may have therapeutic utility in
the treatment of diseases involving both identified, including
those not mentioned herein, and as yet unidentified protein
tyrosine kinases. Preferred compounds of the invention are
compounds which have shown the ability to inhibit multiple kinases
and may not necessarily be the most potent inhibitors of any one
particular kinase.
Synthetic Methods
[0158] Abbreviations which have been used in the descriptions of
the scheme and the examples that follow are: THF for
tetrahydrofuran; NBS for N-bromosuccinimide; AIBN for
2,2'-azobisisobutyronitrile; DMF for N,N-dimethylformamide; NMP for
1-methyl-2-pyrrolidinone; EDC for
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; DCC
for 1,3-dicyclohexylcarbodiimide; HOBT for 1-hydroxybenzotriazole;
PPh.sub.3 for triphenylphosphine; DMSO for dimethylsulfoxide; NMM
for N-methylmorpholine; and TBAF for tetrabutylammonium
fluoride.
[0159] The compounds and processes of the present invention will be
better understood in connection with the following synthetic
schemes which illustrate the methods by which the compounds of the
invention may be prepared. Starting materials can be obtained from
commercial sources or prepared by well-established literature
methods known to those of ordinary skill in the art. The groups
R.sup.3, R.sup.8, R.sup.9, R.sup.10, X, Z.sup.1, Z.sup.2, Z.sup.3,
Z.sup.4, and m are as defined above unless otherwise noted
below.
[0160] This invention is intended to encompass compounds having
formula (I) when prepared by synthetic processes or by metabolic
processes. Preparation of the compounds of the invention by
metabolic processes include those occurring in the human or animal
body (in vivo) or processes occurring in vitro. ##STR3##
[0161] Scheme 1 shows the synthesis of compounds of formula (6).
Compounds of formula (2) can be converted to compounds of formula
(3) by treatment with malonitrile, ammonium acetate, and acetic
acid. The reaction is typically conducted in benzene under
azeotropic conditions at temperatures of about 80.degree. C. to
about 90.degree. C. Reactions times are about 12 to about 96
hours.
[0162] Compounds of formula (4) can be formed from compounds of
formula (3) by treatment with a base such as triethylamine,
diethylamine, or diisopropylethylamine and sulfur. Examples of
solvents used in these reactions include ethanol, methanol, and
isopropanol. The reaction is typically conducted at about
25.degree. C. to about 80.degree. C. for about 1 to about 6
hours.
[0163] Conversion of compounds of formula (4) to compounds of
formula (5) can be accomplished by treatment with formamide. The
reaction is typically run neat at temperatures of about 150.degree.
C. to about 160.degree. C. for about 8 to about 24 hours or in a
microwave oven at temperatures of about 180.degree. C. to about
250.degree. C. for about 5 minutes to about 90 minutes.
[0164] Compounds of formula (4) can also be converted to compounds
of formula (5) by treatment with ammonium sulfate in
triethylorthoformate followed by treatment with ammonia. The
reaction is typically conducted at temperatures between about
20.degree. C. and about 180.degree. C. for about 4 to about 12
hours.
[0165] Compounds of formula (5) can be converted to compounds of
formula (6) by treatment with a reducing agent. Representative
reducing agents include iron powder and ammonium chloride, iron
powder and HCl, tin and HCl, and zinc and HCl. Examples of solvents
used in these reactions include ethanol, THF, water, methanol, and
mixtures thereof. The reaction is typically conducted at about
60.degree. C. to about 85.degree. C. and reaction times are about 1
to about 4 hours. ##STR4##
[0166] An alternative synthesis of compounds of formula (6) is
shown in Scheme 2. Compounds of formula (7) (prepared according to
the procedures described in Scheme 1), can be converted to
compounds of formula (8) by radical bromination with NBS and AIBN.
Representative solvents used in these reactions include benzene and
THF. The reaction is typically conducted at about 70.degree. C. to
about 80.degree. C. for about 2 to about 6 hours.
[0167] Compounds of formula (8) can be treated with a nucleophile
such as a heterocyclyl group, an amine, or an alkoxy group to
provide compounds of formula (5) where R.sup.3 is alkoxyalkyl,
(NR.sup.aR.sup.b)alkyl, or (heterocyclyl)alkyl. Representative
solvents used in these reactions include DMF, NMP, and dioxane. The
reaction is typically conducted at about 20.degree. C. to about
35.degree. C. for about 12 to about 24 hours.
[0168] Conversion of compounds of formula (5) to compounds of
formula (6) can be accomplished by treatment with a reducing agent
as described in Scheme 1. ##STR5##
[0169] The synthesis of compounds of formula (9) (compounds of
formula (I) where R.sup.2 is -LR.sup.8 and L is
--(CH.sub.2).sub.nNR.sup.9C(O)NR.sup.10(CH.sub.2).sub.p--) is shown
in Scheme 3. Compounds of formula (6) can be converted to compounds
of formula (9) by treatment with an appropriately substituted
isocyanate (R.sup.10N(R.sup.8)C(O)). Examples of solvents used in
these reactions include dichloromethane, chloroform, and carbon
tetrachloride, and DMF. The reaction is typically conducted at
about -10.degree. C. to about 25.degree. C. for about 12 to about
24 hours.
[0170] Alternatively, compounds of formula (6) can be reacted with
an acylating agent such as p-nitrophenyl chloroformate then treated
with an appropriately substituted amine (HNR.sup.10R.sup.8) in the
presence of a base such as triethylamine, diisopropylethylamine, or
pyridine to provide compounds of formula (9). The reaction is
typically conducted in a solvent such as THF, methyl tert-butyl
ether, or diethyl ether. The reaction is commonly run at
temperatures between -5.degree. C. and 35.degree. C. for between
about 1 hour and 24 hours. ##STR6##
[0171] Scheme 4 shows the synthesis of compounds of formula (10)
(compounds of formula (I) where R.sup.2 is -LR.sup.8 and L is
--NR.sup.9SO.sub.2--). Compounds of formula (6) can be treated with
an appropriately substituted sulfonyl chloride (R.sup.8SO.sub.2Cl)
and a base such as pyridine or triethylamine. Representative
solvents used in these reactions include dichloromethane, carbon
tetrachloride, and chloroform. The reaction is typically conducted
at about -10.degree. C. to about 20.degree. C. for about 12 to
about 24 hours. ##STR7##
[0172] As shown in Scheme 5, compounds of formula (6) can be
converted to compounds of formula (11) (R.sup.5 is selected from
the group of substituents listed in the definition of heteroaryl; a
is 0, 1, 2, 3, or 4; these are compounds of formula (I) where
R.sup.2 is -LR.sup.8; L is --NR.sup.9--; and R.sup.8 is heteroaryl)
by treatment with 1,1-thiocarbonyldiimidazole in the presence of
pyridine and an optionally substituted 2-aminophenol; followed by
treatment with a coupling agent such as EDC or DCC. The reaction is
typically conducted at about -5.degree. C. to about 65.degree. C.
for about 32 to about 48 hours. ##STR8##
[0173] As shown in Scheme 6, compounds of formula (6) can be
converted to compounds of formula (12) (compounds of formula (I)
where R.sup.2 is -LR.sup.8; L is --NR.sup.c--; and R.sup.8 is
heteroaryl) by treatment with a heteroaryl group substituted by a
leaving group such as a chloride or a fluoride. Typically the
reaction is run neat at temperatures of about 150.degree. C. to
about 210.degree. C. Reaction times are about 10 minutes to about
24 hours. ##STR9##
[0174] Scheme 7 shows the synthesis of compounds of formula (13)
(compounds of formula (I) where R.sup.2 is -LR.sup.8 and L is
--NR.sup.cC(O)--). Compounds of formula (6) can be treated with an
appropriately substituted acid chloride (R.sup.8C(O)Cl) and a base
such as pyridine, triethylamine, or diisopropylethylamine.
Representative solvents used in these reactions include
dichloromethane, chloroform, and diethyl ether. The reaction is
typically conducted at about -5.degree. C. to about 30.degree. C.
for about 2 to about 24 hours. ##STR10##
[0175] Compounds of formula (16) (compounds of formula (I) where
R.sup.2 is -LR.sup.8 and L is --C(O)NR.sup.9--) can be prepared as
described in Scheme 8. Compounds of formula (14) (which can be
prepared by substituting the corresponding 4-bromophenyl ketone for
the compound of formula (2) in the synthesis of compounds of
formula (5) described in Scheme 1) can be treated with an
alkyllithium such as n-butyllithium or t-butyllithium and dry ice
to provide compounds of formula (15). Representative solvents used
in these reactions include hexanes, THF and heptane. The reaction
is typically conducted at about -80.degree. C. to about 0.degree.
C. for about 30 minutes to about 2 hours.
[0176] Conversion of compounds of formula (15) to compounds of
formula (16) can be accomplished by treatment with an appropriately
substituted amine (HNR.sup.9R.sup.8) in the presence of agents such
as HOBT and EDC or DCC or 1,1'-carbonyldiimidazole in the presence
of a base such as N-methylmorpholine. Examples of solvents used in
these reactions include DMF and NMP. The reaction is typically
conducted at about 20.degree. C. to about 35.degree. C. for about
12 to about 24 hours. ##STR11##
[0177] Scheme 9 shows the synthesis of compounds of formula (22)
(compounds of formula (I) where X is N and R.sup.2 is NO.sub.2).
Compounds of formula (17) can be treated with PCl.sub.5 to provide
compounds of formula (18). Representative solvents include
dichloromethane, chloroform, and carbon tetrachloride. The reaction
is typically run at about 25.degree. C. to about 40.degree. C. for
about 10 to about 30 hours.
[0178] Conversion of compounds of formula (18) to compounds of
formula (19) can be accomplished by treatment with ammonium
hydroxide to provide compounds of formula (19). Examples of
solvents include ethanol and methanol. The reaction is typically
conducted at about 20.degree. C. to about 30.degree. C. for about 2
to about 6 hours.
[0179] Compounds of formula (19) can be converted to compounds of
formula (20) by treatment with diethyl dithiophosphate.
Representative solvents include ethanol and methanol. The reaction
is typically conducted at about 70.degree. C. to about 80.degree.
C. for about 12 to about 36 hours.
[0180] Conversion of compounds of formula (20) to compounds of
formula (21) can be accomplished by treatment with hydrogen
peroxide. Representative solvents used in these reactions include
ethanol and methanol. The reaction is typically conducted at about
20.degree. C. to about 30.degree. C. for about 12 to about 24
hours.
[0181] Compounds of formula (21) can be converted to compounds of
formula (22) following the procedures described in Scheme 1. Upon
reducing the nitro group to an amine following the procedures in
Scheme 1, these compounds can be further modified to provide
compounds similar in structure to those shown in Schemes 3 through
8. ##STR12##
[0182] Scheme 10 shows the synthesis of compounds of formula (25)
(compounds of formula (I) where R.sup.1 is NH.sub.2). Compounds of
formula (23) (prepared according to the methods described in
Schemes 1, 2, or 9) can be converted to compounds of formula (24)
by treatment with chloroformamidine in diglyme. The reaction is
typically conducted at temperatures of between about 120 and
140.degree. C. for about 12 to about 18 hours.
[0183] Compounds of formula (24) can be converted to compounds of
formula (25) using the procedures described in the previous
schemes.
[0184] The present invention will now be described in connection
with certain preferred embodiments which are not intended to limit
its scope. On the contrary, the present invention covers all
alternatives, modifications, and equivalents as can be included
within the scope of the claims. Thus, the following examples, which
include preferred embodiments, will illustrate the preferred
practice of the present invention, it being understood that the
examples are for the purposes of illustration of certain preferred
embodiments and are presented to provide what is believed to be the
most useful and readily understood description of its procedures
and conceptual aspects.
[0185] Compounds of the invention were named by ACD/ChemSketch
version 5.0 (developed by Advanced Chemistry Development, Inc.,
Toronto, ON, Canada) or were given names which appeared to be
consistent with ACD nomenclature.
EXAMPLE 1
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-phenylurea
EXAMPLE 1A
1-(4-nitrophenyl)propan-1-one
[0186] A solution of 0.5M ZnCl.sub.2 in THF (60 mL, 30 mmol) in THF
(20 mL) was treated with 2M ethyl magnesium chloride in THF (15 mL,
30 mmol) dropwise by syringe, cooled with an ice bath for about 10
minutes, stirred at room temperature for about 20 minutes, cooled
to 0.degree. C., and treated sequentially with Pd(PPh.sub.3).sub.4
(1.73 g, 1.5 mmol) and a solution of 4-nitrobenzoyl chloride (6.12
g, 33 mmol) in THF (20 mL). The mixture was stirred at 0.degree. C.
for 40 minutes, diluted with water, adjusted to pH 1 with 2N HCl
and extracted three times with ethyl acetate. The combined extracts
were washed sequentially with saturated Na.sub.2CO.sub.3, water,
and brine, dried (MgSO.sub.4), filtered, and concentrated. The
concentrate was purified by flash column chromatography on silica
gel with 6:1 hexanes/ethyl acetate to provide 2.17 g (40%) of the
desired product as a yellow solid. R.sub.f=0.6 (3:1 hexanes/ethyl
acetate).
EXAMPLE 1B
2-[1-(4-nitrophenyl)propylidene]malononitrile
[0187] A solution of Example 1A (3.4 g, 19 mmol), malononitrile
(1.25 g, 19 mmol) ammonium acetate (1.46 g) and acetic acid (2 mL)
in benzene (50 mL) was heated to reflux in a flask fitted with a
Dean-Stark trap for 14 hours. Additional ammonium acetate (1.46 g)
and acetic acid (2 mL) were added and the reaction was stirred at
reflux for 4 more hours. The mixture was cooled to room temperature
and partitioned between water and ethyl acetate. The aqueous layer
was extracted twice with ethyl acetate and the combined extracts
were washed with brine, dried (MgSO.sub.4), filtered, and
concentrated. The concentrate was purified by flash column
chromatography on silica gel with 3:1 hexanes/ethyl acetate to
provide 4.01 g (93%) of the desired product as a yellow solid.
R.sub.f=0.45 (3:1 hexanes/ethyl acetate).
EXAMPLE 1C
2-amino-5-methyl-4-(4-nitrophenyl)thiophene-3-carbonitrile
[0188] Diethylamine (1.57 mL) was added dropwise to a suspension of
Example 1B (4.0 g, 17.6 mmol) and sulfur (0.563 g, 17.6 mmol) in
ethanol (60 mL). The mixture was heated to 70.degree. C. for 2
hours, cooled to room temperature, and concentrated. The
concentrate was purified by flash column chromatography on silica
gel with 3:2 hexanes/ethyl acetate to provide 4.05 g (89%) of the
desired product. MS (CI) m/e 277 (M+NH.sub.4).sup.+.
EXAMPLE 1D
6-methyl-5-(4-nitrophenyl)thieno[2,3-d]pyrimidin-4-amine
[0189] A suspension of Example 1C (4.03 g, 15.5 mmol) in formamide
(60 mL) was stirred at 155.degree. C. for 17 hours, cooled to room
temperature, diluted with water, and filtered. The filter cake was
dried to provide 4.126 g (93%) of the desired product. MS (CI) m/e
287 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.36
(d, J=9.0 Hz, 2H); 8.30 (s, 1H); 7.68 (d, J=9.0 Hz, 2H); 2.32 (s,
3H); Anal. Calcd. for C.sub.13H.sub.10N.sub.4O.sub.2S: C, 54.53; H,
3.52; N, 19.57. Found: C, 54.75; H, 3.39; N, 19.17.
EXAMPLE 1E
5-(4-aminophenyl)-6-methylthieno[2,3-d]pyrimidin-4-amine
[0190] A suspension of Example 1D (1.01 g, 3.53 mmol) in ethanol
(60 mL), THF (20 mL), and water (10 mL) was treated with NH.sub.4Cl
(0.19 g, 3.53 mmol) and iron powder (1.18 g, 21.2 mmol), and
stirred at 70-80.degree. C. for 1 hour. The mixture was diluted
with ethanol (40 mL) and filtered through a pad of diatomaceous
earth (Celite.RTM.) while still hot. The pad was washed with
ethanol and the filtrate was concentrated. The concentrate was
diluted with water and extracted three times with ethyl acetate.
The combined extracts were washed with brine, dried (MgSO.sub.4),
filtered, and concentrated to provide 1 g of the desired product.
MS (CI) m/e 257 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.23 (s, 1H); 7.01 (d, J=8.4 Hz, 2H); 6.70 (d, J=8.4 Hz,
2H); 5.39 (s, 2H); 2.27 (s, 3H); Anal. Calcd. for
C.sub.13H.sub.12N.sub.4S.0.2C.sub.4H.sub.8O.sub.2.0.2H.sub.2O: C,
59.72; H, 5.08; N, 20.19. Found: 59.64; H, 4.99; N, 20.22.
EXAMPLE 1F
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-phenylurea
[0191] A 0.degree. C. solution of Example 1E (80 mg, 0.3 mmol) in
dichloromethane (4 mL) was treated with phenyl isocyanate (0.037
mL, 0.34 mmol), stirred overnight, and filtered. The filter cake
was dried to provide 0.103 g (87%) of the desired product. MS (CI)
m/e 376 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
8.89 (s, 1H); 8.75 (s, 1H); 8.26 (s, 1H); 7.63 (d, J=8.7 Hz, 2H);
7.47 (d, J=8.7 Hz, 2H); 7.33-7.26 (m, 4H); 6.99 (t, J=7.5 Hz, 1H);
2.30 (s, 3H); Anal. Calcd. for
C.sub.20H.sub.17N.sub.5OS.0.1CH.sub.2Cl.sub.2: C, 62.88; H, 4.52;
N, 18.24. Found: C, 62.85; H, 4.64; N, 18.15.
EXAMPLE 2
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfonamid-
e
[0192] A 0.degree. C. solution of Example 1E (0.1 g, 0.39 mmol) in
dichloromethane (4 mL) was treated with pyridine (0.038 mL, 0.47
mmol) and benzenesulfonyl chloride (0.05 mL, 0.4 mmol), stirred at
0.degree. C. for 1 hour, then stirred at room temperature
overnight. The reaction mixture was diluted with water and
extracted twice with dichloromethane. The combined extracts were
washed with brine, dried (MgSO.sub.4), filtered, and concentrated.
The concentrate was triturated from dichloromethane/hexanes to
provide 91 mg (59%) of the desired product. MS(ESI(+)) m/e 397
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.49 (s,
1H); 8.25 (s, 1H); 7.77 (m, 2H); 7.65-7.55 (m, 3H); 7.24 (m, 4H);
1.99 (s, 3H); Anal. Calcd. for
C.sub.19H.sub.16N.sub.4O.sub.2S.sub.20.3C.sub.2H.sub.4O.sub.2: C,
57.37; H, 4.39; N, 13.25. Found: C, 57.22; H, 4.48; N, 13.32.
EXAMPLE 3
5-[4-(1,3-benzoxazol-2-ylamino)phenyl]-6-methylthieno[2,3-d]pyrimidin-4-am-
ine
[0193] A solution of Example 1E (100 mg, 0.39 mmol) in pyridine (3
mL) was added dropwise over 5 minutes to a 0.degree. C. solution of
1,1-thiocarbonyldiimidazole (77 mg, 0.39 mmol) in pyridine (3 mL).
The reaction was stirred at 0.degree. C. for 1.5 hours, then
treated with 2-aminophenol (43 mg, 0.39 mmol), stirred overnight at
room temperature, treated with
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (90 mg,
0.47 mmol), and heated to 50.degree. C. for 20 hours. The mixture
was concentrated and the residue was partitioned between ethyl
acetate and water. The aqueous phase was extracted twice with ethyl
acetate and the combined extracts were washed with brine, dried
(MgSO.sub.4), filtered, and concentrated. The concentrate was
purified by flash column chromatography on silica gel with ethyl
acetate to provide 28 mg (20%) of the desired product. MS (CI) m/e
374 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.89
(s, 1H); 8.27 (s, 1H); 7.94 (d, J=8.4 Hz, 2H); 7.51 (m, 2H); 7.42
(d, J=8.4 Hz, 2H); 7.25 (td, J=7.5 Hz, 1.5 Hz, 1H); 7.16 (td, J=7.5
Hz, 1.5 Hz, 1H); 3.10 (s, 3H); Anal. Calcd. for
C.sub.20H.sub.15N.sub.5OS.0.2C.sub.4H.sub.8O.sub.2.0.2H.sub.2O: C,
63.30; H, 4.34; N, 17.75. Found: C, 63.52; H, 4.30; N, 17.33.
EXAMPLE 4
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]benzamide
[0194] A 0.degree. C. solution of Example 1E (80 mg, 0.31 mmol) in
dichloromethane (4 mL) was treated with pyridine (0.03 mL, 0.38
mmol) and benzoyl chloride (0.038 mL, 0.32 mmol), stirred at
0.degree. C. for 1 hour, then at room temperature overnight. The
reaction mixture was diluted with water and extracted twice with
dichloromethane. The combined extracts were washed with brine,
dried (MgSO.sub.4), filtered, and concentrated. The concentrate was
purified by flash column chromatography on silica gel with ethyl
acetate to provide 39 mg (35%) of the desired product. .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 10.46 (s, 1H); 8.28 (s, 1H); 7.98
(d, J=8.1 Hz, 4H); 7.63-7.54 (m, 3H); 7.40 (d, J=8.1 Hz, 2H); 2.31
(s, 3H); HRMS(ESI) Calcd. for C.sub.20H.sub.17N.sub.4O.sub.S:
361.1118. Found: 36.1122.
EXAMPLE 5
N-[4-(4-amino-6-isopropylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-methylp-
henyl)urea
EXAMPLE 5A
6-isopropyl-5-(4-nitrophenyl)thieno[2,3-d]pyrimidin-4-amine
[0195] The desired product was prepared by substituting isobutyl
magnesium bromide for ethyl magnesium bromide in Examples 1A-1D.
m.p. >260.degree. C.; MS(ESI(+)) m/e 315 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 1.20-1.22 (d, J=6.9 Hz, 6H);
2.94-3.03 (m, 1H); 7.68-7.70 (d, J=8.7 Hz, 2H); 8.29 (s, 1H);
8.35-8.38 (d, J=8.7 Hz, 2H); Anal. Calcd. for
C.sub.15H.sub.14N.sub.4O.sub.2S: C, 57.31; H, 4.49; N, 17.82.
Found: C, 57.42; H, 4.51; N, 17.89.
EXAMPLE 5B
5-(4-aminophenyl)-6-isopropylthieno[2,3-d]pyrimidin-4-amine
[0196] The desired product was prepared by substituting Example 5A
for Example 1D in Example 1E. m.p. 187-189.degree. C.; MS(ESI(+))
m/e 285 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
1.18-1.21 (d, J=6.9 Hz, 6H); 3.02-3.11 (m, 1H); 6.68-6.71 (d, J=8.4
Hz, 2H); 6.99-7.02 (d, J=8.4 Hz, 2H); 8.22 (s, 1H); Anal. Calcd.
for C.sub.15H.sub.16N.sub.4S.0.2C.sub.4H.sub.8O.sub.2: C, 62.84; H,
5.87; N, 18.55. Found: C, 62.90; H, 5.47; N, 18.35.
EXAMPLE 5C
N-[4-(4-amino-6-isopropylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-methylp-
henyl)urea
[0197] The desired product was prepared by substituting Example 5B
and 4-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+)) m/e 418 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.20-1.22 (d, J=6.9 Hz,
6H); 2.25 (s, 3H); 3.00-3.09 (m, 1H); 7.09-7.11 (d, J=8.1 Hz, 2H);
7.29-7.32 (d, J=8.7 Hz, 2H); 7.34-7.37 (d, J=8.7 Hz, 2H); 7.60-7.63
(d, J=8.7 Hz, 2H); 8.26 (s, 1H); 8.64 (s, 1H); 8.85 (s, 1H); Anal.
Calcd. for C.sub.23H.sub.23N.sub.5OS.0.3H.sub.2O: C, 65.32; H,
5.62; N, 16.56. Found: C, 65.24; H, 5.68; N, 16.40.
EXAMPLE 6
N-[4-(4-amino-6-isopropylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylp-
henyl)urea
[0198] The desired product was prepared by substituting Example 5B
and 3-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. m.p. 169-171.degree. C.; MS(ESI(+))
m/e 418 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
1.20-1.23 (d, J=6.9 Hz, 6H); 2.29 (s, 3H); 3.00-3.09 (m, 1H);
6.79-6.82 (d, 1H, J=7.8 Hz); 7.14-7.19 (t, J=7.5 Hz, 1H); 7.24-7.27
(d, 1H, 8.1 Hz); 7.30-7.33 (m, 3H); 7.61-7.64 (d, J=9 Hz, 2H); 8.26
(s, 1H); 8.67 (s, 1H); 8.88 (s, 1H); Anal. Calcd. for
C.sub.23H.sub.23N.sub.5OS: C, 66.16; H, 5.55; N, 16.77. Found: C,
65.95; H, 5.60; N, 16.53.
EXAMPLE 7
N-[4-(4-amino-6-isopropylthieno[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfona-
mide
[0199] The desired product was prepared by substituting Example 5B
for Example 1E in Example 2. MS(ESI(+)) m/e 425 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.14-1.16 (d, J=6.6 Hz,
6H); 2.84-2.93 (m, 1H); 7.19-7.22 (d, J=8.4 Hz, 2H); 7.27-7.29 (d,
J=8.4 Hz, 2H); 7.55-7.64 (m, 3H); 7.74-7.77 (d, 2H, J=6.6 Hz); 8.25
(s, 1H); 10.48 (s, 1H); Anal. Calcd. for
C.sub.21H.sub.20N.sub.4O.sub.2S.sub.2: C, 59.41; H, 4.75; N, 13.20.
Found: C, 59.22; H, 4.48; N, 13.10.
EXAMPLE 8
N-[4-(4-amino-6-isopropylthieno[2,3-d]pyrimidin-5-yl)phenyl]benzamide
[0200] The desired product was prepared by substituting Example 5B
for Example 1E in Example 4. m.p. >250.degree. C.; MS(ESI) m/e
389 (M+H).sup.+, 387 (M-H).sup.-; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 1.22-1.25 (d, J=6.6 Hz, 6H); 3.03-3.12 (m,
1H); 7.41-7.43 (d, J=8.7 Hz, 2H); 7.53-7.65 (m, 3H); 7.93-7.02 (m,
4H); 8.46 (s, 1H); 10.51 (s, 1H); HRMS (FAB) Calcd. for
C.sub.22H.sub.20N.sub.4OS: 389.1436. Found: 389.1451.
EXAMPLE 9
N-[4-(4-amino-6-benzylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-methylphen-
yl)urea
EXAMPLE 9A
6-benzyl-5-(4-nitrophenyl)thieno[2,3-d]pyrimidin-4-amine
[0201] The desired product was prepared by substituting
phenethylmagnesium bromide for ethyl magnesium bromide in Examples
1A-1D. m.p. 231-233.degree. C.; MS(ESI) m/e 363 (M+H).sup.+, 361
(M-H).sup.-; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 4.00 (s,
2H); 7.11-7.14 (d, 2H, J=6.9 Hz); 7.19-7.31 (m, 3H); 7.70-7.73 (d,
J=9 Hz, 2H); 8.29(s, 1H); 8.35-8.38 (d, J=9 Hz, 2H); Anal. Calcd.
for C.sub.19H.sub.14N.sub.4O.sub.2S: C, 62.97; H, 3.89; N, 15.46.
Found: C, 62.78; H, 3.99; N, 15.47.
EXAMPLE 9B
5-(4-aminophenyl)-6-benzylthieno[2,3-d]pyrimidin-4-amine
[0202] The desired product was prepared by substituting Example 9A
for Example 1D in Example 1E. m.p. 208-210.degree. C.; MS(ESI) m/e
333 (M+H).sup.+, 331 (M-H).sup.-; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 3.98 (s, 2H); 5.43 (s, 2H); 6.70-6.73 (d,
J=8.4 Hz, 2H); 7.05-7.08 (d, J=8.4 Hz, 2H); 7.13-7.15 (d, 2H, 6.9
Hz); 7.18-7.32 (m, 3H); 8.23 (s, 1H); Anal. Calcd. for
C.sub.19H.sub.16N.sub.4S.0.1CH.sub.2Cl.sub.2: C, 67.29; H, 4.79; N,
16.43. Found: C, 67.47; H, 4.78; N, 16.52.
EXAMPLE 9C
N-[4-(4-amino-6-benzylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-methylphen-
yl)urea
[0203] The desired product was prepared by substituting Example 9B
and 4-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. m.p. 169-173.degree. C. MS(ESI) m/e
466 (M+H).sup.+, 464 (M-H).sup.-, 500 (M+Cl).sup.-; .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 2.25 (s, 3H); 3.99 (s, 2H);
7.08-7.37 (11H); 7.63-7.65 (d, 2H, J=8.7 Hz); 8.26 (s, 1H); 8.64
(s, 1H); 8.86 (s, 1H); Anal. Calcd. for C.sub.27H.sub.23N.sub.5OS:
C, 69.66; H, 4.98; N, 15.04. Found: C, 69.49; H, 4.94; N,
14.79.
EXAMPLE 10
N-[4-(4-amino-6-benzylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphen-
yl)urea
[0204] The desired product was prepared by substituting Example 9B
and 3-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+)) m/e 466 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.29 (s, 3H); 3.99 (s,
2H); 6.79-6.82 (d, J=7.5 Hz, 1H); 7.14-7.32 (m, 8H); 7.35-7.38 (d,
J=8.7 Hz, 2H); 7.63-7.66 (d, J=8.4 Hz, 2H); 8.26 (s, 1H); 8.67(s,
1H); 8.89 (s, 1H); Anal. Calcd. for
C.sub.27H.sub.23N.sub.5OS.0.75H.sub.2O: C, 67.69; H, 5.15; N,
14.62. Found: C, 67.75; H, 5.01; N, 14.60.
EXAMPLE 11
N-[4-(4-amino-6-benzylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methylphen-
yl)urea
[0205] The desired product was prepared by substituting Example 9B
and 2-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. m.p. 245-248.degree. C.; MS(ESI) m/e
466 (M+H).sup.+, 464 (M-H).sup.-; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 2.26 (s, 3H); 3.99 (s, 2H); 6.94-6.99 (dt,
J=1.2, 7.5 Hz, 1H); 7.14-7.32 (m, 7H); 7.35-7.38 (d, J=8.4 Hz, 2H);
7.65-7.68 (d, J=8.4 Hz, 2H); 7.80-7.83 (d, J=8.1 Hz, 1H); 8.02 (s,
1H); 8.26 (s, 1H); 9.25 (s, 1H); Anal. Calcd. for
C.sub.27H.sub.23N.sub.5OS.0.1CH.sub.2Cl.sub.2: C, 68.66; H, 4.93;
N, 14.77. Found: C, 68.53; H, 4.74; N, 14.48.
EXAMPLE 12
N-[4-(4-amino-6-isopropylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methylp-
henyl)urea
[0206] The desired product was prepared by substituting Example 5B
and 2-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. m.p. 233-234.degree. C.; MS(ESI(+))
m/e 418 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
1.21-1.23 (d, J=6.6 Hz, 6H); 2.26 (s, 3H); 3.01-3.10 (m, 1H);
6.94-6.70 (dt, J=1.2 Hz, 7.5 Hz, 1H); 7.13-7.21 (m, 2H); 7.30-7.33
(d, J=8.7 Hz, 2H); 7.63-7.66 (d, J=8.4 Hz, 2H); 7.81-7.84 (d, J=8.1
Hz, 1H); 8.01(s, 1H); 8.26 (s, 1H); 9.24 (s, 1H); Anal. Calcd. for
C.sub.23H.sub.23N.sub.5OS: C, 66.16; H, 5.55; N, 16.77. Found: C,
66.20; H, 5.49; N, 16.82.
EXAMPLE 13
N-[4-(4-amino-6-benzylthieno[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfonamid-
e
[0207] The desired product was prepared by substituting Example 9B
for Example 1E in Example 2. m.p. 100-105.degree. C.; MS(ESI) m/e
437 (M+H).sup.+, 435 (M-H).sup.-; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 3.87 (s, 2H); 7.01-7.04 (d, 2H, J=8.1 Hz);
7.16-7.33 (m, 7H); 7.53-7.65 (m, 3H); 7.75-7.78 (d, 2H, J=8.1 Hz);
8.25 (s, 1H); 10.51 (s, 1H); Anal. Calcd. for
C.sub.25H.sub.20N.sub.4O.sub.2S.sub.2: C, 63.54; H, 4.27; N, 11.86.
Found: C, 63.27; H, 4.14; N, 11.82.
EXAMPLE 14
N-{4-[4-amino-6-(pyridin-4-ylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-
-(3-methylphenyl)urea
EXAMPLE 14A
(2E)-1-(4-nitrophenyl)-3-pyridin-4-ylprop-2-en-1-one
[0208] A suspension of 4'-nitroacetophenone (5 g, 30.3 mmol) and
4-pyridinecarboxaldehyde (2.89 mL, 30.3 mmol) in water (45 mL) at
room temperature was treated with 6% NaOH in H.sub.2O/ethanol
(2:1)(0.606 mL), stirred overnight, and filtered. The filter cake
was washed with water and small amount of ethanol then triturated
with dichloromethane to provide 1.95 g (25%) of the desired
product. MS(ESI(+)) m/e 255 (M+H).sup.+.
EXAMPLE 14B
1-(4-nitrophenyl)-3-pyridin-4-ylpropan-1-one
[0209] Trinbutyltin hydride (0.36 mL, 1.34 mmol) was added slowly
by syringe pump to a room temperature mixture of Example 14A (0.2
g, 0.78 mmol) and Pd(PPh.sub.3).sub.4 (27 mg, 0.023 mmol), stirred
overnight, diluted with water, and extracted three times with ethyl
acetate. The combined extracts were washed with brine, dried
(Na.sub.2SO.sub.4), filtered, and concentrated. The concentrate was
putrified by flash column chromatography on silica gel with 80%
ethyl acetate/hexanes to provide 227 mg (100%) of the desired
product. MS(ESI(-)) m/e 255 (M-H).sup.-.
EXAMPLE 14C
N-{4-[4-amino-6-(pyridin-4-ylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-
-(3-methylphenyl)urea
[0210] The desired product was prepared by substituting Example 14B
and 3-methylphenyl isocyanate for Example 1A and phenyl isocyanate,
respectively, in Examples 1B-1F. MS(ESI) m/e 467 (M+H).sup.+, 465
(M-H).sup.-; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.28 (s,
3H); 3.32 (s, 2H); 6.79-6.82 (d, J=7.5 Hz, 1H); 7.13-7.30 (m, 5H);
7.32-7.35 (d, J=8.4 Hz, 2H); 7.61-7.64 (d, J=8.4 Hz, 2H); 8.28 (s,
1H); 8.45-8.47 (dd, J=4.2, 1.5 Hz, 2H); 8.67 (s, 1H); 8.88 (s, 1H);
HRMS (FAB) Calcd. for C.sub.26H.sub.23N.sub.6OS: 467.1654. Found:
467.1649.
EXAMPLE 15
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-methylphen-
yl)urea
[0211] The desired product was prepared by substituting
4-methylphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 390 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.84 (s, 1H); 8.63 (s, 1H); 8.26 (s, 1H); 7.62 (d, J=8.4
Hz, 2H); 7.35 (d, J=8.4 Hz, 2H); 7.30 (d, J=8.4 Hz, 2H); 7.10 (d,
J=8.4 Hz, 2H); 2.29 (s, 3H); 2.25 (s, 3H); Anal. Calcd. for
C.sub.21H.sub.19N.sub.5OS.0.5H.sub.2O.0.1C.sub.8H.sub.18: C, 63.88;
H, 5.36; N, 17.09. Found: C, 63.98; H, 5.41; N, 16.90.
EXAMPLE 16
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphen-
yl)urea
[0212] The desired product was prepared by substituting
3-methylphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(-)) m/e 388 (M-H).sup.-; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.87 (s, 1H); 8.67 (s, 1H); 8.26 (s, 1H); 7.63 (d, J=8.1
Hz, 2H); 7.32-7.23 (m, 4H); 7.17 (t, J=7.8 Hz, 1H); 6.81 (d, J=7.8
Hz, 1H); 2.30 (s, 3H); 2.29 (s, 3H); Anal. Calcd. for
C.sub.21H.sub.19N.sub.5OS.0.5H.sub.2O: C, 63.30; H, 5.06; N, 17.58.
Found: C, 63.62; H, 5.20; N, 17.38.
EXAMPLE 17
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methylphen-
yl)urea
[0213] The desired product was prepared by substituting
2-methylphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 390 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.24 (s, 1H); 8.27 (s, 1H); 8.01 (s, 1H); 7.82 (d, J=7.5
Hz, 1H); 7.64 (d, J=8.1 Hz, 2H); 7.31 (d, J=8.1 Hz, 2H); 7.21-7.13
(m, 2H); 6.97 (t, J=7.5 Hz, 1H); 2.30 (s, 3H); 2.27 (s, 3H); Anal.
Calcd. for C.sub.21H.sub.19N.sub.5OS.0.7H.sub.2O: C, 62.73; H,
5.11; N, 17.42. Found: C, 62.91; H, 5.15; N, 17.10.
EXAMPLE 18
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,
5-dimethylphenyl)urea
[0214] The desired product was prepared by substituting
3,5-dimethylphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 404 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.85 (s, 1H); 8.59 (s, 1H); 8.26 (s, 1H); 7.62 (d, J=8.4
Hz, 2H); 7.30 (d, J=8.4 Hz, 2H); 7.09 (s, 2H); 6.63 (s, 1H); 2.30
(s, 3H); 2.24 (s, 6H); Anal. Calcd. for C.sub.22H.sub.21N.sub.5OS:
C, 65.49; H, 5.25; N, 17.36. Found: C, 65.19; H, 5.18; N,
17.24.
EXAMPLE 19
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methoxyphe-
nyl)urea
[0215] The desired product was prepared by substituting
3-methoxyphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 406 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.88 (s, 1H); 8.76 (s, 1H); 8.26 (s, 1H); 7.63 (d, J=8.7
Hz, 2H); 7.31 (d, J=8.7 Hz, 2H); 7.22-7.17 (m, 2H); 6.95 (m, 1H);
6.57 (m, 1H); 3.74 (s, 3H); 2.30 (s, 1H); Anal. Calcd. for
C.sub.21H.sub.19N.sub.5O.sub.2S.0.3H.sub.2O: C, 61.39; H, 4.81; N,
17.04. Found: C, 61.41; H, 4.65; N, 17.04.
EXAMPLE 20
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[3-(trifluoro-
methyl)phenyl]urea
[0216] The desired product was prepared by substituting
3-trifluoromethylphenyl isocyanate for phenyl isocyanate in Example
1F. MS(ESI(+)) m/e 444 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 9.12 (s, 1H); 9.01 (s, 1H); 8.27 (s, 1H);
8.03 (s, 1H); 7.67-7.59 (m, 3H); 7.53 (t, J=7.8 Hz, 1H); 7.33 (m,
3H); 2.30 (s, 1H); Anal. Calcd. for
C.sub.21H.sub.16F.sub.3N.sub.5OS: C, 56.88; H, 3.64; N, 15.79.
Found: C, 56.65; H, 3.51; N, 15.52.
EXAMPLE 21
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-bromopheny-
l)urea
[0217] The desired product was prepared by substituting
3-bromophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 454, 456 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.97 (s, 1H); 8.96 (s, 1H); 8.27 (s, 1H);
7.88 (t, J=1.8 Hz, 1H); 7.64 (d, J=9.0 Hz, 2H); 7.36-7.29 (m, 3H);
7.25 (t, J=7.8 Hz, 1H); 7.19-7.14 (m, 1H); 2.30 (s, 3H); Anal.
Calcd. for C.sub.20H.sub.16BrN.sub.5OS: C, 52.87; H, 3.55; N,
15.41. Found: C, 52.56; H, 3.46; N, 15.21.
EXAMPLE 22
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-bromopheny-
l)urea
[0218] The desired product was prepared by substituting
4-bromophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 454, 456 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.93 (s, 1H); 8.90 (s, 1H); 8.26 (s, 1H);
7.63 (d, J=8.7 Hz, 2H); 7.46 (s, 4H); 7.32 (d, J=8.7 Hz, 2H); 2.29
(s, 3H); Anal. Calcd. for
C.sub.20H.sub.16BrN.sub.5OS.0.4H.sub.2O-0.2C.sub.8H.sub.18: C,
53.56; H, 4.24; N, 14.46. Found: C, 53.32; H, 3.96; N, 14.24.
EXAMPLE 23
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-fluorophen-
yl)urea
[0219] The desired product was prepared by substituting
2-fluorophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 394 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.30 (s, 1H); 8.63 (d, J=2.4 Hz, 1H); 8.27 (s, 1H); 8.17
(td, J=8.1 Hz, 1.5 Hz, 1H); 7.64 (d, J=8.4 Hz, 2H); 7.33 (d, J=8.4
Hz, 2H); 7.26 (ddd, J=12.0 Hz, 8.1 Hz, 1.2 Hz, 1H); 7.16 (t, J=7.8
Hz, 1H); 7.05-6.99 (m, 1H); 2.30 (s, 3H); Anal. Calcd. for
C.sub.20H.sub.16FN.sub.5OS.0.2C.sub.8H.sub.18: C, 62.32; H, 4.10;
N, 16.82. Found: C, 62.05; H, 4.68; N, 16.87.
EXAMPLE 24
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chlorophen-
yl)urea
[0220] The desired product was prepared by substituting
3-chlorophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 410 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.97 (s, 2H); 8.27 (s, 1H); 7.73 (m, 1H); 7.64 (d, J=8.7
Hz, 2H); 7.34-7.29 (m, 4H); 7.06-7.02 (m, 1H); 2.30 (s, 1H); Anal.
Calcd. for C.sub.20H.sub.16ClN.sub.5OS.0.2H.sub.2O: C, 58.09; H,
4.00; N, 16.94. Found: C, 58.45; H, 3.99; N, 16.58.
EXAMPLE 25
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,
5-dimethoxyphenyl)urea
[0221] The desired product was prepared by substituting
3,5-dimethoxyphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 436 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.85 (s, 1H); 8.75 (s, 1H); 8.26 (s, 1H); 6.20 (d, J=8.4
Hz, 2H); 7.31(d, J=8.4 Hz, 2H); 6.70 (d, J=2.1 Hz, 2H); 6.16 (t,
J=2.1 Hz, 1H); 3.72 (s, 6H); 2.29 (s, 3H); Anal. Calcd. for
C.sub.22H.sub.21N.sub.5O.sub.3S: C, 60.67; H, 4.86; N, 16.08.
Found: C, 60.59; H, 4.89; N, 15.92.
EXAMPLE 26
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[3-fluoro-5-(-
trifluoromethyl)phenyl]urea
[0222] The desired product was prepared by substituting
3-fluoro-5-trifluoromethylphenyl isocyanate for phenyl isocyanate
in Example 1F. MS(ESI(+)) m/e 462 (M+H).sup.+; .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 9.33 (s, 1H); 9.13 (s, 1H); 8.27 (s,
1H); 7.73 (s, 1H); 7.67-7.62 (m, 3H); 7.33 (d, J=8.7 Hz, 2H); 7.25
(d, J=8.4 Hz, 1H); 2.30 (s, 3H); Anal. Calcd. for
C.sub.21H.sub.15F.sub.4N.sub.5OS: C, 54.66; H, 3.28; N, 15.18.
Found: 54.47; H, 3.06; N, 15.02.
EXAMPLE 27
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[4-fluoro-3-(-
trifluoromethyl)phenyl]urea
[0223] The desired product was prepared by substituting
4-fluoro-3-trifluoromethylphenyl isocyanate for phenyl isocyanate
in Example 1F. MS(ESI(+)) m/e 462 (M+H).sup.+; .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 9.12 (s, 1H); 9.02 (s, 1H); 8.27 (s,
1H); 8.02 (dd, J=6.6 Hz, 2.7 Hz, 1H); 7.70-7.62 (m, 3H); 7.45 (t,
J=9.6 Hz); 7.32 (d, J=8.4 Hz, 2H); 2.30 (s, 3H); Anal. Calcd. for
C.sub.21H.sub.15F.sub.4N.sub.5OS.0.2H.sub.2O: C, 54.24; H, 3.34; N,
15.06. Found: C, 54.13; H, 2.98; N, 14.85.
EXAMPLE 28
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-1,3-benzodiox-
ol-5-ylurea
[0224] The desired product was prepared by substituting
5-isocyanato-1,3-benzodioxole for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 420 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.82 (s, 1H); 8.63 (s, 1H); 8.26 (s, 1H); 7.61 (d, J=8.4
Hz, 2H); 7.30 (d, J=8.4 Hz, 2H); 7.22 (d, J=1.8 Hz, 1H); 6.86-6.76
(m, 2H); 5.98 (s, 2H); 2.29 (s, 3H); Anal. Calcd. for
C.sub.21H.sub.17N.sub.5O.sub.3S: C, 60.13; H, 4.09; N, 16.70.
Found: C, 57.91; H, 4.07; N, 15.65.
EXAMPLE 29
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-methoxyphe-
nyl)urea
[0225] The desired product was prepared by substituting
4-methoxyphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 406 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.81 (s, 1H); 8.56 (s, 1H); 8.27 (s, 1H); 7.62 (d, J=8.1
Hz, 2H); 7.38 (d, J=9.0 Hz, 2H); 7.30 (d, J=8.1 Hz, 2H); 6.89 (d,
J=9.0 Hz, 2H); 3.73 (s, 3H); 2.30 (s, 3H).
EXAMPLE 30
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-chlorophen-
yl)urea
[0226] The desired product was prepared by substituting
4-chlorophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 410 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.92 (s, 1H); 8.89 (s, 1H); 8.26 (s, 1H); 7.63 (d, J=8.7
Hz, 2H); 7.51 (s, J=9.0 Hz, 2H); 3.37-7.29 (m, 4H); 2.29 (s,
3H).
EXAMPLE 31
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[2-fluoro-5-(-
trifluoromethyl)phenyl]urea
[0227] The desired product was prepared by substituting
2-fluoro-5-trifluoromethylphenyl isocyanate for phenyl isocyanate
in Example 1F. MS(ESI(+)) m/e 462 (M+H).sup.+; .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 9.39 (s, 1H); 8.98 (d, J=2.7 Hz, 1H);
8.64 (dd, J=7.2 Hz, 1.8 Hz, 1H); 8.27 (s, 1H); 7.65 (d, J=8.4 Hz,
2H); 7.52 (t, J=9.0 Hz, 1H); 7.44-7.37 (m, 1H); 7.34 (d, J=8.4 Hz,
2H); 2.30 (s, 3H).
EXAMPLE 32
methyl
3-[({[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl}amino]c-
arbonyl)amino]benzoate
[0228] The desired product was prepared by substituting methyl
3-isocyanatobenzoate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 434 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.04 (s, 1H); 8.94 (s, 1H); 8.27 (s, 1H); 8.22 (t, 1H);
7.65 (d, 3H); 7.59 (dt, 1H); 7.44 (t, 1H); 7.32 (d, 2H); 3.86 (s,
3H); 2.30 (s, 3H).
EXAMPLE 33
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-phenoxyphe-
nyl)urea
[0229] The desired product was prepared by substituing
4-phenoxyphenyl isocyanate for phenyl isocyanate. MS(ESI) m/e 468
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.88 (s,
1H); 8.77 (s, 1H); 8.26 (s, 1H); 7.64 (d, J=8.4 Hz, 2H); 7.50 (d,
J=8.4 Hz, 2H); 7.40-7.28 (m, 4H); 7.11(t, J=7.1 Hz, 1H); 7.02-6.94
(m, 4H); 2.30 (s, 3H).
EXAMPLE 34
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[3-(methylsul-
fanyl)phenyl]urea
[0230] The desired product was prepared by substituting
1-isocyanato-3-(methylsulfanyl)benzene for phenyl isocyanate in
Example 1F. MS(ESI(+)) m/e 422 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.91 (s, 1H); 8.80 (s, 1H); 8.27 (s, 1H);
7.63 (d, J=8.4 Hz, 2H); 7.49 (t, J=1.5 Hz, 1H); 7.31 (d, J=8.4 Hz,
2H); 7.23 (t, J=7.5 Hz, 1H); 7.17 (dt, J=9.0 Hz, 1.5 Hz, 1H); 6.88
(dt, J=8.4 Hz, 1.5 Hz, 1H); 2.30 (s, 3H).
EXAMPLE 35
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2,5-dimethyl-
phenyl)urea
[0231] The desired product was prepared by substituting
2,5-dimethylphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 404 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.22 (s, 1H); 8.27 (s, 1H); 7.94 (s, 1H); 7.66 (s, 1H);
7.64 (d, J=9.0 Hz, 2H); 7.30 (d, J=9.0 Hz, 2H); 7.06 (d, J=7.2 Hz,
1H); 7.87 (d, J=7.4 Hz, 1H); 2.30 (s, 3H); 2.26 (s, 3H); 2.21 (s,
3H).
EXAMPLE 36
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-chlorophen-
yl)urea
[0232] The desired product was prepared by substituting
2-chlorophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 410, 412 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 9.64 (s, 1H); 8.40 (s, 1H); 8.27 (s, 1H);
8.17 (dd, J=8.4 Hz, 1.8 Hz, 1H); 7.65 (d, J=8.4 Hz, 2H); 7.48 (dd,
J=7.8 Hz, 1.8 Hz, 1H); 7.36-7.28 (m, 3H); 7.05 (td, J=8.4 Hz, 1.8
Hz, 1H); 2.30 (s, 1H).
EXAMPLE 37
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,5-dichloro-
phenyl)urea
[0233] The desired product was prepared by substituting
3,5-dichlorophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 444, 446 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 9.14 (s, 1H); 9.11 (s, 1H); 8.27 (s, 1H);
7.64 (d, J=8.4 Hz, 2H); 7.56 (d, J=1.8 Hz, 2H); 7.33 (d, J=8.4 Hz,
2H); 7.19 (t, J=1.8 Hz, 1H); 2.29(s, 3H).
EXAMPLE 38
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chloro-4-m-
ethylphenyl)urea
[0234] The desired product was prepared by substituting
3-chloro-4-methylphenyl isocyanate for phenyl isocyanate in Example
1F. MS(ESI(+)) m/e 424 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.93 (s, 1H); 8.85 (s, 1H); 8.27 (s, 1H);
7.71 (d, J=1.8 Hz, 1H); 7.63 (d, J=8.4 Hz, 2H); 7.31 (d, J=8.4 Hz,
2H); 7.26 (d, J=8.4 Hz, 1H); 7.21 (dd, J=8.4 Hz, 1.8 Hz, 1H); 2.29
(s, 3H); 2.27 (s, 3H).
EXAMPLE 39
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2,6-difluoro-
phenyl)urea
[0235] The desired product was prepared by substituting
2,6-difluorophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 412 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.18 (s, 1H); 8.26 (s, 1H); 8.20 (s, 1H); 7.63 (d, 1H);
7.36-7.27 (m, 3H); 7.22-7.10 (m, 2H); 2.29 (s, 1H).
EXAMPLE 40
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[2-chloro-5-(-
trifluoromethyl)phenyl]urea
[0236] The desired product was prepared by substituting
2-chloro-5-trifluoromethylphenyl isocyanate for phenyl isocyanate
in Example 1F. MS(ESI) m/e 478 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 9.78 (s, 1H); 8.70 (s, 1H); 8.65 (d, J=2.1
Hz, 1H); 8.27 (s, 1H); 7.74 (d, J=8.4 Hz, 1H); 7.66 (d, J=8.7 Hz,
2H); 4.41 (dd, J=8.4 Hz, 2.1 Hz, 1H); 7.35 (d, J=8.7 Hz, 2H); 2.30
(s, 3H).
EXAMPLE 41
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-ethylpheny-
l)urea
[0237] The desired product was prepared by substituting
3-ethylphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 404 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.86 (s, 1H); 8.68 (s, 1H); 8.27 (s, 1H); 7.63 (d, J=8.7
Hz, 2H); 7.31 (d, J=8.7 Hz, 2H); 7.35-7.25 (m, 2H); 7.20 (t, J=7.8
Hz, 1H); 6.84(d, J=7.2 Hz, 1H); 2.58 (q, J=7.5 Hz, 2H); 2.30 (s,
3H); 1.19 (t, J=7.5 Hz, 3H).
EXAMPLE 42
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-ethylpheny-
l)urea
[0238] The desired product was prepared by substituting
4-ethylphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 404 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.85 (s, 1H); 8.65 (s, 1H); 8.27 (s, 1H); 7.63 (d, J=8.4
Hz, 2H); 9.38 (d, J=8.4 Hz, 2H); 7.30 (d, J=8.4 Hz, 2H); 7.13 (d,
J=8.4 Hz, 2H); 2.51 (q, J=7.8 Hz, 2H); 2.29 (s, 3H); 1.16 (t, J=7.8
Hz, 3H).
EXAMPLE 43
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-bromo-2-fl-
uorophenyl)urea
[0239] The desired product was prepared by substituting
2-fluoro-4-bromophenyl isocyanate for phenyl isocyanate in Example
1F. MS(ESI(+)) m/e 474 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 9.31 (s, 1H); 8.73 (d, J=2.4 Hz, 1H); 8.27
(s, 1H); 8.15 (t, J=8.7 Hz, 1H); 7.63 (d, J=8.7 Hz, 2H); 7.59 (dd,
J=10.8 Hz, 2.1 Hz, 1H); 7.38 (m, 1H); 7.33 (d, J=8.7 Hz, 2H); 2.29
(s, 1H).
EXAMPLE 44
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-fluoro-5-m-
ethylphenyl)urea
[0240] The desired product was prepared by substituting
2-fluoro-5-methylphenyl isocyanate for phenyl isocyanate in Example
1F. MS(ESI) m/e 408 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 9.28 (s, 1H); 8.56 (d, J=2.7 Hz, 1H); 8.27
(s, 1H); 8.00 (dd, J=8.1 Hz, 2.1 Hz, 1H); 7.63 (d, J=9.0 Hz, 2H);
7.32 (d, J=9.0 Hz, 2H); 7.12 (dd, J=11.4 Hz, 8.1 Hz, 1H); 6.82 (m,
1H); 2.30 (s, 3H); 2.28 (s, 3H).
EXAMPLE 45
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-Ny-[4-chloro-3-(-
trifluoromethyl)phenyl]urea
[0241] The desired product was prepared by substituting
4-chloro-3-trifluoromethylphenyl isocyanate for phenyl isocyanate
in Example 1F. MS(ESI(+)) m/e 478 (M+H).sup.+; .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 9.25 (s, 1H); 9.07 (s, 1H); 8.27 (s,
1H); 8.13 (d, J=2.4 Hz, 1H); 7.70-7.60 (m, 4H); 7.33 (d, J=8.4 Hz,
2H); 2.30 (s, 3H).
EXAMPLE 46
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,4-dimethyl-
phenyl)urea
[0242] The desired product was prepared by substituting
3,4-dimethylphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 404 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.83 (s, 1H); 8.56 (s, 1H); 8.26 (s, 1H); 7.62 (d, J=8.4
Hz, 2H); 7.30 (d, J=8.4 Hz, 2H); 7.25 (s, 1H); 7.19 (d, J=8.1 Hz,
1H); 7.04 (d, J=8.1 Hz, 1H); 2.30 (s, 3H); 2.20 (s, 3H); 2.16 (s,
3H).
EXAMPLE 47
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-chloro-5-m-
ethylphenyl)urea
[0243] The desired product was prepared by substituting
2-chloro-5-methylphenyl isocyanate for phenyl isocyanate in Example
1F. MS(ESI(+)) m/e 424 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 9.61 (s, 1H); 8.32 (s, 1H); 8.27 (s, 1H);
8.02 (d, J=2.1 Hz, 1H); 7.65 (d, J=8.7 Hz, 2H); 7.36-7.31 (m, 3H);
6.87 (dd, J=8.7 Hz, 2.1 Hz, 1H); 2.30 (s, 6H).
EXAMPLE 48
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methoxyphe-
nyl)urea
[0244] The desired product was prepared by substituting
2-methoxyphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 406 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.55 (s, 1H); 8.31 (s, 1H); 8.27 (s, 1H); 8.15 (dd, J=7.8
Hz, 2.1 Hz, 1H); 7.63 (d, J=8.7 Hz, 2H); 7.31 (d, J=8.7 Hz, 2H);
7.04 (dd, J=8.1 Hz, 1.8 Hz, 1H); 6.70-6.87 (m, 2H); 3.90 (s, 3H);
2.30 (s, 3H).
EXAMPLE 49
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2,5-dichloro-
phenyl)urea
[0245] The desired product was prepared by substituting
2,5-dichlorophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 444 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.74 (s, 1H); 8.55 (s, 1H); 8.33 (d, J=2.4 Hz, 1H); 8.27
(s, 1H); 7.65 (d, J=8.7 Hz, 2H); 7.52 (d, J=8.4 Hz, 1H); 7.34 (d,
J=8.7 Hz, 2H); 7.12 (dd, J=8.4 Hz, 2.4 Hz, 1H); 2.20 (s, 3H).
EXAMPLE 50
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2,4-difluoro-
phenyl)urea
[0246] The desired product was prepared by substituting
2,4-difluorophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 412 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.24 (s, 1H); 8.59 (s, 1H); 8.27 (s, 1H); 8.09 (td, J=9.6
Hz, 6.0 Hz, 1H); 7.63 (d, J=8.4 Hz, 2H); 7.37-7.28 (m, 3H); 7.07
(m, 1H); 2.29 (s, 3H).
EXAMPLE 51
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,
4,5-trimethoxyphenyl)urea
[0247] The desired product was prepared by substituting
3,4,5-trimethoxyphenyl isocyanate for phenyl isocyanate in Example
1F. MS(ESI(+)) m/e 466 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.31 (s, 1H); 8.70 (s, 1H); 8.27 (s, 1H);
7.63 (d, J=8.4 Hz, 2H); 7.31 (d, J=8.4 Hz, 2H); 6.83 (s, 2H); 3.76
(s, 6H); 3.62 (s, 3H); 2.30 (s, 3H).
EXAMPLE 52
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2,5-dimethox-
yphenyl)urea
[0248] The desired product was prepared by substituting
2,5-dimethoxyphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 436 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.58 (s, 1H); 8.33 (s, 1H); 8.27 (s, 1H); 7.88 (d, J=3.0
Hz, 1H); 7.63 (d, J=8.7 Hz, 2H); 7.31 (d, J=8.7 Hz, 2H); 6.94 (d,
J=9.0 Hz, 1H); 6.51 (dd, J=9.0 Hz, 3.0 Hz, 1H); 3.84 (s, 3H); 3.70
(s, 3H); 2.30 (s, 3H).
EXAMPLE 53
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-2-naphthylure-
a
[0249] The desired product was prepared by substituting 2-naphthyl
isocyanate for phenyl isocyanate in Example 1F. MS(ESI) m/e 426
(M+H); .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.99 (s, 1H);
8.98 (s, 1H); 8.27 (s, 1H); 8.13 (d, J=2.1 Hz, 1H); 7.83 (m, 3H);
7.68 (d, J=8.4 Hz, 2H); 7.52 (dd, J=8.7 Hz, 2.1 Hz, 1H); 7.46 (t,
J=7.5 Hz, 1H); 7.40-7.31 (m, 3H).
EXAMPLE 54
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-benzylurea
[0250] The desired product was prepared by substituting benzyl
isocyanate for phenyl isocyanate in Example 1F. MS(ESI(+)) m/e 390
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.81(s,
1H); 8.26 (s, 1H); 7.59 (d, J=8.7 Hz, 2H); 8.38-7.28 (m, 4H);
7.27-7.22 (m, 3H); 6.71(t, J=6.0 Hz, 1H); 4.33 (d, J=6.0 Hz, 2H);
2.28 (s, 3H).
EXAMPLE 55
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-cyanopheny-
l)urea
[0251] The desired product was prepared by substituting
4-cyanophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 401 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.29 (s, 1H); 9.08 (s, 1H); 8.27 (s, 1H); 7.75 (d, J=9.0
Hz, 2H); 7.69-7.62 (m, 4H); 7.34 (d, J=8.4 Hz, 2H); 2.29 (s,
3H).
EXAMPLE 56
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[4-(dimethyla-
mino)phenyl]urea
[0252] The desired product was prepared by substituting
4-dimethylaminophenyl isocyanate for phenyl isocyanate in Example
1F. MS(ESI(+)) m/e 419 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.75 (s, 1H); 8.37 (s, 1H); 8.26 (s, 1H);
7.61 (d, J=8.4 Hz, 2H); 7.28 (m, 4H); 6.71 (d, J=9.0 Hz, 2H); 2.84
(s, 6H); 2.29 (s, 3H).
EXAMPLE 57
N-(4-{4-amino-6-[(4-methylpiperazin-1-yl)methyl]thieno[2,3-d]pyrimidin-5-y-
l}phenyl)-N'-(3-methylphenyl)urea
EXAMPLE 57A
6-(bromomethyl)-5-(4-nitrophenyl)thieno[2,3-d]pyrimidin-4-amine
[0253] A suspension of Example 1D (500 mg, 1.75 mmol) in benzene
(50 mL) was treated with NBS (340 mg, 1.91 mmol) and AIBN (50 mg),
stirred at reflux for 3.5 hours, and concentrated. The concentrate
was absorbed onto silica gel and purified by flash column
chromatography with ethyl acetate to provide 330 mg of a 1.7:1
mixture of the desired product and recovered starting material.
EXAMPLE 57B
6-[(4-methylpiperazin-1-yl)methyl]-5-(4-nitrophenyl)thieno[2,3-d]pyrimidin-
-4-amine
[0254] A mixture of Example 57A (330 mg) and N-methylpiperazine
(0.3 mL, 2.71 mmol) in DMF (6 mL) was stirred at room temperature
overnight and concentrated. The concentrate was absorbed on silica
gel and purified by flash column chromatography with ethyl acetate
fillowed by 12% methanol/dichloromethane to provide 115 mg the
desired product. R.sub.f=0.38 (12% methanol/dichloromethane).
EXAMPLE 57C
5-(4-aminophenyl)-6-[(4-methylpiperazin-1-yl)methyl]thieno[2,3-d]pyrimidin-
-4-amine
[0255] The desired product was prepared by substituting Example 57B
for Example 1D in Example 1E. MS(ESI(+)) m/e 355 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.24 (s, 1H); 6.98 (d,
J=8.4 Hz, 2H); 6.68 (d, J=8.4 Hz, 2H); 5.41 (br s, 2H); 3.50 (s,
2H); 2.48 (s, 3H); 2.45 (br s), 4H); 2.26 (br s, 4H).
EXAMPLE 57D
N-(4-{4-amino-6-[(4-methylpiperazin-1-yl)methyl]thieno[2,3-d]pyrimidin-5-y-
l}phenyl)-N'-(3-methylphenyl)urea
[0256] The desired product was prepared by substituting Example 57C
and 3-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.88 (s, 1H); 8.68 (s, 1H); 8.27 (s, 1H); 7.62 (d, J=9.0
Hz, 2H); 7.32-7.23 (m, 4H); 7.17 (t, J=7.5 Hz, 1H); 6.81 (d, J=7.5
Hz, 1H); 3.50 (s, 2H); 2.45-2.20 (br s), 8H); 2.29 (s, 3H); 2.14
(s, 3H).
EXAMPLE 58
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphenyl)urea
EXAMPLE 58A
2-[1-(4-nitrophenyl)ethylidene]malononitrile
[0257] A mixture of 1-(4-nitrophenyl)ethanone (15 g, 90.8 mmol),
malononitrile (6 g, 90.8 mmol), ammonium acetate (7 g, 90.8 mmol)
and acetic acid (10 mL) in benzene (200 mL) was stirred at reflux
overnight in a flask equipped with a Dean-Stark trap. The reaction
mixture was cooled to room temperature, poured into water, and
extracted three times with ethyl acetate. The combined organic
extracts were washed with water and brine, dried (MgSO.sub.4),
filtered, and concentrated. The residue was purified by silica gel
chromatography eluting with 25% ethyl acetate/hexanes to provide
9.42 g of the desired product. R.sub.f=0.33 (25% ethyl
acetate/hexanes).
EXAMPLE 58B
2-amino-4-(4-nitrophenyl)thiophene-3-carbonitrile
[0258] A solution of Example 58A (4.14 g, 19.6 mmol) in ethanol
(200 mL) and THF (80 mL) at room temperature was treated
sequentially with sulfur (621 mg, 19.4 mmol) and triethylamine
(1.82 mL, 19.4 mmol), stirred overnight, and filtered. The filter
cake was absorbed on silica and purified by flash column
chromatography with 3:2 hexanes/ethyl acetate to provide 2.51 g of
the desired product.
EXAMPLE 58C
5-(4-nitrophenyl)thieno[2,3-d]pyrimidin-4-amine
[0259] A suspension of Example 58B (1.23 g, 5.01 mmol) in formamide
(20 mL) was heated to between 150 and 160.degree. C. for 19 hours,
cooled to room temperature, and filtered. The filter cake was dried
to give 1.09 g of the desired product. MS (ESI(+)) m/e 273
(M+H).sup.+.
EXAMPLE 58D
5-(4-aminophenyl)thieno[2,3-d]pyrimidin-4-amine
[0260] A suspension of Example 58C (0.5 g, 1.83 mmol) in THF (30
mL), water (15 mL), and ethanol (40 mL) was heated to 50.degree.
C., treated with iron powder (0.616 g, 11.02 mmol), heated to
between 70 and 80.degree. C. for two hours, and filtered while hot
through diatomaceous earth (Celite.RTM.). The pad was washed with
THF (10 mL) and ethanol and the combined filtrates were
concentrated. The residue was partitioned between water and ethyl
acetate and the aqueous phase was extracted three times with ethyl
acetate. The combined extracts were washed with brine, dried
(MgSO.sub.4), filtered, and concentrated to give 0.432 g of the
desired product. MS (CI) m/e 243 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.30 (s, 1H); 7.28 (s, 1H); 7.11 (d, J=8.4
Hz, 2H); 6.68 (d, J=8.4 Hz, 2H); 5.39 (br s, 2H).
EXAMPLE 58E
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphenyl)urea
[0261] The desired product was prepared by substituting Example 58D
and 3-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+)) m/e 376 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.88 (s, 1H); 8.67 (s,
1H); 8.34 (s, 1H); 7.61 (d, J=8.7 Hz, 2H); 7.43(s, 1H); 7.39 (d,
J=8.7 Hz, 2H); 7.31 (s, 1H); 7.25 (d, J=7.5 Hz, 1H); 7.17 (t, J=7.5
Hz, 1H); 6.81 (d, J=7.5 Hz, 1H); Anal. Calcd. for
C.sub.20H.sub.17N.sub.5OS: C, 63.98; H, 4.56; N, 18.65. Found: C,
63.65; H, 4.56; N, 18.36.
EXAMPLE 59
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-phenylurea
[0262] The desired product was prepared by substituting Example 58D
for Example 1E in Example 1F. MS(ESI(+)) m/e 362 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.89 (s, 1H); 8.75 (s,
1H); 8.34 (s, 1H); 7.61 (d, J=8.4 Hz, 2H); 7.47 (d, J=7.5 Hz, 2H);
7.43 (s, 1H); 7.40 (d, J=8.4 Hz, 2H); 7.30 (t. J=7.5 Hz, 1H); 6.98
(t, J=7.5 Hz, 1H); Anal. Calcd. for
C.sub.19H.sub.15N.sub.5OS.0.2H.sub.2O: C, 62.52; H, 4.25; N, 19.19.
Found: C, 52.65; H, 4.13; N, 18.86.
EXAMPLE 60
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-ethylphenyl)urea
[0263] The desired product prepared by substituting Example 58D and
3-ethylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+)) m/e 390 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.86 (s, 1H); 8.68 (s,
1H); 8.33 (s, 1H); 7.61 (d, 2H); 7.43 (s, 1H); 7.39 (d, 2H); 7.34
(s, 1H); 7.27 (d, 1H); 7.19 (s, 1H); 6.83 (s, 1H); 2.58 (q, 2H);
1.18 (t, 3H); Anal. Calcd. for C.sub.21H.sub.19N.sub.5OS: C, 64.76;
H, 4.92; N, 17.98. Found: C, 64.38; H, 4.93; N, 17.68.
EXAMPLE 61
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylpheny-
l)urea
EXAMPLE 61A
6-bromo-5-(4-nitrophenyl)thieno[2,3-d]pyrimidin-4-amine
[0264] A suspension of Example 58C (50 mg, 0.18 mmol) in acetic
acid (1 mL) and DMF (3 mL) was heated with a heat gun to obtain a
clear solution, cooled to 0.degree. C., and treated with bromine
(0.02 mL). The reaction mixture was stirred at 0.degree. C. for 1
hour, diluted with saturated NaHCO.sub.3, and filtered. The filter
cake was dried to provide 56 mg of the desired product.
EXAMPLE 61B
5-(4-aminophenyl)-6-bromothieno[2,3-d]pyrimidin-4-amine
[0265] The desired product was prepared by substituting Example 61A
for Example 1D in Example 1E. MS(ESI(+)) m/e 321, 323 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.29 (s, 1H); 7.05 (d,
J=8.4 Hz, 2H); 6.70 (d, J=8.4 Hz, 2H); 5.50 (s, 2H).
EXAMPLE 61C
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylpheny-
l)urea
[0266] The desired product was prepared by Example 61B for and
3-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+)) m/e 454, 456 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.92 (s, 1H); 8.69 (s,
1H); 8.33 (s, 1H); 7.65 (d, J=8.4 Hz, 2H); 7.36(d, J=8.4 Hz, 2H);
7.32 (s, 1H); 7.26 (d, J=7.8 Hz, 1H); 7.17 (t, J=7.8 Hz, 1H); 6.81
(d, J=7.8 Hz, 1H); Anal. Calcd. for
C.sub.20H.sub.16BrN.sub.5OS.0.4H.sub.2O: C, 52.05; H, 3.67; N,
15.17. Found: C, 52.07; H, 3.36; N, 15.13.
EXAMPLE 62
4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-N-(3-chlorophenyl)benzamid-
e
[0267] The desired product was prepared by substituting
3-chloroaniline for aniline in Example 66. MS(ESI(-)) m/e 393
(M-H).sup.-; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.57 (s,
1H); 8.30 (s, 1H); 8.12 (d, J=8.4 Hz, 2H); 8.01 (t, J=1.8 Hz, 1H);
7.73 (m, 1H); 7.60 (d, J=8.4 Hz, 2H); 7.41 (t, J=7.2 Hz, 1H); 7.19
(m, 1H); 2.32 (s, 3H).
EXAMPLE 63
5-{4-[(5,
7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl}-6-methylthieno[2,3--
d]pyrimidin-4-amine
[0268] The desired product was prepared by substituting
2-amino-4,6-dimethylphenol for 2-aminophenol in Example 3.
MS(ESI(+)) m/e 402 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 10.89 (s, 1H); 8.27 (s, 1H); 7.93 (d, J=8.4 Hz, 2H); 7.41
(d, J=8.4 Hz, 2H); 7.11 (s, 1H); 6.80 (s, 1H); 2.41 (s, 3H); 2.34
(s, 3H); 2.31 (s, 3H); Anal. Calcd. for
C.sub.22H.sub.19N.sub.5OS.0.2H.sub.2O: C, 65.78; H, 5.08; N, 16.82.
Found: C, 65.41; H, 4.90; N, 17.15.
EXAMPLE 64
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-2-(3-methylpheny-
l)acetamide
[0269] The desired product was prepared by substituting
3-methylphenylacetyl chloride for benzoyl chloride in Example 4.
MS(ESI(+)) 389 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 10.37 (s, 1H); 8.26 (s, 1H); 7.78 (d, J=8.4 Hz, 2H); 7.32
(d, J=8.4 Hz, 2H); 7.26-7.13 (m, 3H); 7.07 (d, J=7.5 Hz, 1H); 3.64
(s, 2H); 2.31 (s, 3H); 2.27 (s, 3H); Anal. Calcd. for
C.sub.22H.sub.20N.sub.4OS: C, 68.02; H, 5.19; N, 14.42. Found: C,
67.76; H, 5.29; N, 14.31.
EXAMPLE 65
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-3-methylbenzamid-
e
[0270] The desired product was prepared by substituting
3-methylbenzoyl chloride for benzoyl chloride in Example 4. MS (CI)
m/e 375 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
10.42 (s, 1H); 8.28 (s, 1H); 7.98 (d, J=8.4 Hz, 2H); 7.80-7.75 (m,
2H); 7.45-7.36 (m, 4H); 2.42 (s, 3H); 2.31 (s, 3H); Anal. Calcd.
for C.sub.12H.sub.18N.sub.4OS.0.2C.sub.4H.sub.8O.sub.2: C, 66.78;
H, 5.04; N, 14.29. Found: H, 66.55; H, 6.29; N, 13.95.
EXAMPLE 66
4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-N-phenylbenzamide
EXAMPLE 66A
5-(4-bromophenyl)-6-methylthieno[2,3-d]pyrimidin-4-amine
[0271] The desired product was prepared by substituting
4-bromophenylethyl ketone for Example 1A in Examples 1B and 1C.
MS(ESI(+)) 320, 322 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.278 (s, 1H); 7.74 (d, J=8.1 Hz, 2H); 7.36
(d, J=8.1 Hz, 2H); 2.28 (s, 3H).
EXAMPLE 66B
4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)benzoic acid
[0272] A -78.degree. C. solution of Example 66A (1.5 g, 4.68 mmol)
in THF (50 mL) was treated dropwise with 2.5M n-butyllithium in
hexanes (4.7 mL, 11.71 mmol), stirred for 30 minutes at -78.degree.
C., then treated with excess dry ice. The reaction was stirred at
-78.degree. C. for 30 minutes, warmed to room temperature, diluted
with water, adjusted to pH 3 with 2N HCl, and filtered. The filter
cake was dried to provide 686 mg (51%) of the desired product. MS
(CI) m/e 285 (M.sup.+); .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
13.13 (br s, 1H); 8.29 (s, 1H); 8.09 (d, J=8.4 Hz, 2H); 7.53 (d,
J=8.4 Hz, 2H); 2.28 (s, 3H).
EXAMPLE 66C
4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-N-phenylbenzamide
[0273] A suspension of Example 66B (89 mg, 0.31 mmol) and HOBT (46
mg, 0.35 mmol) in DMF (4 mL) at room temperature was treated with
aniline (0.029 mL, 0.31 mmol), NMM (0.086 mL, 0.78 mmol) and
EDC.HCl (66 mg, 0.34 mmol), stirred overnight, and partitioned
between water and ethyl acetate. The aqueous phase was extracted
three times with ethyl acetate and the combined organic extracts
ware washed with water, and brine, dried (Na.sub.2SO.sub.4),
filtered, and concentrated to a volume of about 3 mL. The product
was treated with hexanes and the resulting precipitate was
collected by filtration to provide 84 mg (75%) of the desired
product. MS(ESI(+)) m/e 361 (M+H); .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 10.40 (s, 1H); 8.30 (s, 1H); 8.12 (d, J=8.4
Hz, 2H); 7.80 (d, J=7.5 Hz, 2H); 7.58 (d, J=8.4 Hz, 2H); 7.37 (t,
J=7.5 Hz, 2H); 7.12 (t, J=7.5 Hz, 1H); 2.32 (s, 3H); Anal. Calcd.
for C.sub.20H.sub.16N.sub.4OS.0.1C.sub.4H.sub.8O.sub.2: C, 66.36;
H, 4.59; N, 15.17. Found: 66.07; H, 4.76; N, 15.32.
EXAMPLE 67
4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-N-(3-methylphenyl)benzamid-
e
[0274] The desired product was prepared by substituting
3-methylaniline for aniline in Example 66C. MS(ESI(+)) 375
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 10.33 (s,
1H); 8.30 (s, 1H); 8.11 (d, J=8.1 Hz, 2H); 7.66 (s, 1H); 7.61-7.55
(m, 3H); 7.25 (t, J=7.5 Hz, 1H); 6.94 (d, J=7.5 Hz, 1H); 2.32 (s,
6H).
EXAMPLE 68
N-(4-{4-amino-6-[(dimethylamino)methyl]thieno[2,3-d]pyrimidin-5-yl}phenyl)-
-N'-(3-methylphenyl)urea
[0275] The desired product was prepared by substituting
dimethylamine for N-methylpiperazine in Examples 57B-D. MS(ESI(+))
m/e 433 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
8.92 (s, 1H); 8.71 (s, 1H); 8.28 (s, 1H); 7.32-7.22 (m, 4H); 7.17
(t, J=7.8 Hz, 1H); 6.81 (d, J=7.8 Hz, 1H); 3.45 (br s, 2H); 2.29
(s, 3H); 2.17 (s, 6H).
EXAMPLE 69
N-{4-[4-amino-6-(morpholin-4-ylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}--
N'-(3-methylphenyl)urea
[0276] The desired product was prepared by substituting morpholine
for N-methylpiperazine in Examples 57B-D. MS(ESI(+)) m/e 475
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.90 (s,
1H); 8.69 (s, 1H); 8.28 (s, 1H); 7.63 (d, J=8.7 Hz, 2H); 7.33-7.23
(m, 4H); 7.17 (t, J=7.5 Hz, 1H); 6.81 (d, J=7.5 Hz, 1H); 3.56 (br
s, 4H); 3.51 (s, 2H); 2.36 (br s, 4H); 2.29 (s, 3H); Anal. Calcd.
for C.sub.25H.sub.26N.sub.6O.sub.2S.0.5H.sub.2O: C, 62.09; H, 5.63;
N, 17.38. Found: C, 62.20; H, 5.46; N, 17.41.
EXAMPLE 70
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]benzene-
sulfonamide
EXAMPLE 70A
5-(4-amino-3-methoxyphenyl)-6-methylthieno[2,3-d]pyrimidin-4-amine
[0277] The desired product was prepared by substituting
3-methoxy-4-nitrobenzoyl chloride for 4-nitrobenzoyl chloride in
Examples 1A-1E.
EXAMPLE 70B
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]benzene-
sulfonamide
[0278] The desired product was prepared by substituting Example 70A
for Example 1E in Example 2. MS(ESI(+)) m/e 427 (M+H).sup.+;
.sup.1H NMR (DMSO-d.sub.6) .delta. 9.64 (s, 1H); 8.26 (s, 1H);
7.70-7.67 (m, 2H); 7.65-7.53 (m, 3H); 7.37 (d, 1H, J=7.8 Hz);
6.93-6.90 (m, 2H); 3.44 (s, 3H); 2.26 (s, 3H).
EXAMPLE 71
5-[4-(1,3-benzoxazol-2-ylamino)-3-methoxyphenyl]-6-methylthieno[2,3-d]pyri-
midin-4-amine
[0279] The desired product was prepared by substituting Example 70A
for Example 1E in Example 3. MS(ESI (+)) m/e 404 (M+H).sup.+;
.sup.1H NMR (DMSO-d.sub.6) .delta. 9.86 (s, 1H); 8.44 (d, 1H, J=8.1
Hz); 8.28 (s, 1H); 7.51-7.46 (m, 2H); 7.26-7.21 (m, 1H); 7.17-7.10
(m, 2H); 7.05 (dd, 1H, J=1.7, 8.1 Hz); 3.90 (s, 3H); 2.35 (s,
3H).
EXAMPLE 72
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-(3--
chlorophenyl)urea
[0280] The desired product was prepared by substituting Example 70A
and 3-chlorophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+)) m/e 440 (M+H).sup.+;
.sup.1H NMR (DMSO-d.sub.6) .delta. 9.60 (s, 1H); 8.45 (s, 1H); 8.29
(d, J=8.1 Hz, 1H); 8.27 (s, 1H); 7.76 (t, J=2.0 Hz, 1H); 7.32 (t,
J=8.1 Hz, 1H); 7.26-7.22 (m, 1H); 7.06-7.01 (m, 2H); 6.93 (dd,
J=1.7, 8.1 Hz, 1H); 3.92 (s, 3H); 2.33 (s, 3H).
EXAMPLE 73
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-(4--
methylphenyl)urea
[0281] The desired product was prepared by substituting Example 70A
and 4-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+)) m/e 420 (M+H).sup.+;
.sup.1H NMR (DMSO-d.sub.6) .delta. 9.29 (s, 1H); 8.37 (s, 1H); 8.31
(d, 1H, J=8.1 Hz); 8.26 (s, 1H); 7.35 (d, 2H, J=8.5 Hz); 7.10 (d,
2H, J=8.1 Hz); 7.03 (d, 1H, J=2.0 Hz); 6.93-6.89 (m, 1H); 3.91 (s,
3H); 2.32 (s, 3H); 2.25 (s, 3H).
EXAMPLE 74
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-(3--
methylphenyl)urea
[0282] The desired product was prepared by substituting Example 70A
and 3-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+)) m/e 420 (M+H).sup.+;
.sup.1H NMR (DMSO-d.sub.6) .delta. 9.32 (s, 1H); 8.40 (s, 1H); 8.32
(d, 1H, J=8.1 Hz); 8.27 (s, 1H); 7.33-7.31 (br s, 1H); 7.27-7.24
(m, 1H); 7.17 (t, 1H, J=7.5 Hz); 7.04 (d, 1H, J=1.7 Hz); 6.92 (dd,
1H, J=1.7, 8.2 Hz); 6.80 (d, 1H, J=7.5 Hz); 3.91 (s, 3H); 2.33 (s,
3H); 2.29 (s, 3H).
EXAMPLE 75
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-(3,
5-dimethylphenyl)urea
[0283] The desired product was prepared by substituting Example 70A
and 3,5-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS(ESI(+)) m/e 434
(M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6) .delta. 9.25 (s, 1H); 8.38
(s, 1H); 8.31 (d, 2H, J=8.1 Hz); 8.27 (s, 1H); 7.10 (s, 2H); 7.03
(d, 1H, J=1.7 Hz); 6.91 (dd, 2H, J=1.7, 8.1 Hz); 6.63 (s, 1H); 3.91
(s, 3H); 2.33 (s, 3H); 2.24 (s, 6H).
EXAMPLE 76
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-2,3-di-
chlorobenzenesulfonamide
[0284] The desired product was prepared by substituting Example 70A
for and 2,3-dichlorobenzenesulfonyl chloride for Example 1E and
benzenesulfonyl chloride, respectively, in Example 2. MS(ESI(+))
m/e 495 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6) .delta. 10.03 (s,
1H); 8.26 (s. 1H); 7.91 (d, 1H, J=7.8 Hz); 7.80-7.77 (m, 1H); 7.48
(t, 1H, J=7.8 Hz); 7.33 (d, 1H, J=8.8 Hz); 6.93-6.90 (m, 2H); 3.46
(s, 3H); 2.26 (s, 3H).
EXAMPLE 77
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]quinoli-
n-2-amine
[0285] A mixture of Example 70A (100 mg, 0.35 mmol) and
2-chloroquinoline (62 mg, 0.38 mmol) was heated to 200.degree. C.
under nitrogen for 20 minutes, cooled to room temperature, and
partitioned between saturated NaHCO.sub.3 and dichloromethane. The
aqueous phase was extracted three times with dichloromethane and
the combined organic extracts were dried (Na.sub.2SO.sub.4),
filtered, and concentrated. The concentrate was triturated with
diethyl ether to provide 6 mg (5%) of the desired product.
MS(ESI(+)) m/e 414 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6) .delta.
9.08 (d, 1H, J=8.2 Hz); 8.70 (s, 1H); 8.28 (s, 1H); 8.08 (d, 1H,
J=8.8 Hz); 7.73 (t, 2H, J=8.8 Hz); 7.61-7.56 (m, 1H); 7.44 (d, 1H,
J=9.1 Hz); 7.34-7.29 (m, 1H); 7.06 (d, 1H, J=2.0 Hz); 7.02-6.99 (m,
1H); 3.93 (s, 3H); 2.37 (s, 3H).
EXAMPLE 78
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylpheny-
l)urea
EXAMPLE 78A
5-(4-aminophenyl)-6-ethylthieno[2,3-d]pyrimidin-4-amine
[0286] The desired product was prepared by subsituting
n-propylmagnesium chloride for ethylmagnesium chloride in Examples
1A-1E. .sup.1H NMR (DMSO-d.sub.6) .delta. 8.22 (s, 1H); 7.00 (d,
J=8.4 Hz, 2H); 6.68 (d, J=8.4 Hz, 2H); 5.39 (s, 2H); 2.63 (q, J=7.5
Hz, 2H); 1.17 (t, J=7.5 Hz, 3H).
EXAMPLE 78B
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylpheny-
l)urea
[0287] The desired product was prepared substituting Example 78A
and 3-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+)) m/e 404.10 (M+H).sup.+;
.sup.1H NMR (DMSO-d.sub.6) .delta. 8.84 (s,1H); 8.64 (s,1H); 8.24
(s, 1H); 7.62 (d, J=8.5 Hz, 2H); 7.10-7.35 (m, 5H); 6.80 (d, J=7.2
Hz, 1H); 2.62 (q, J=7.5 Hz, 2H); 2.24 (s,3H); 1.18 (t, J=7.5 Hz,
3H).
EXAMPLE 79
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-fluoro-5-me-
thylphenyl)urea
[0288] The desired product was prepared by substituting Example 78A
and 2-fluoro-5-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. .sup.1H NMR (DMSO-d.sub.6)
.delta. 9.24 (s, 1H); 8.59 (d, J=2 Hz, 1H); 8.24 (s, 1H); 8.00 (dd,
J=8.1, 2.4 Hz, 1H); 7.63 (d, J=8.4 Hz, 2H); 7.32 (d, J=8.4 Hz, 2H);
7.12 (dd, J=12.0, 8.5 Hz, 2H); 6.92 (m,1H); 3.24 (s,3H); 2.64 (q,
J=7.5 Hz, 2H); 1.19 (t, J=7.5 Hz, 3H).
EXAMPLE 80
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-methoxyphen-
yl)urea
[0289] The desired product was prepared by substituting Example 78A
and 4-methoxyphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. .sup.1H NMR (DMSO-d.sub.6)
.delta. 8.81 (s, 1H); 8.58 (s, 1H); 8.23 (s,1H); 7.61 (d, J=8.7 Hz,
2H); 7.38 (d, J=9.2 Hz, 2H); 7.29(d, J=8.7 Hz, 2H); 6.88 (d, J=9.2
Hz, 2H); 3.66 (s,3H); 2.63 (q, J=7.5 Hz, 2H); 1.18 (t, J=7.5 Hz,
3H).
EXAMPLE 81
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N-(4-chlorophenyl-
)urea
[0290] The desired product was prepared by substituting Example 78A
and 4-chlorophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. .sup.1H NMR (DMSO-d.sub.6) .delta.
8.93 (s,1H); 8.90 (s,1H); 7.62 (d, J=8.7 Hz, 2H); 7.51 (d, J=9.0
Hz, 2H); 7.20-7.40 (m, 4H); 2.63 (q, J=7.5 Hz, 2H); 1.16 (t, J=7.5
Hz, 3H).
EXAMPLE 82
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[4-fluoro-3-(t-
rifluoromethyl)phenyl]urea
[0291] The desired product was prepared by substituting Example 78A
and 3-trifluoromethyl-4-fluorophenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. .sup.1H NMR
(DMSO-d.sub.6) .delta. 9.16 (s,1H); 9.07 (s,1H); 8.31 (s, 1H); 8.28
(dd, J=6.3, 2.5 Hz, 1H); 7.64 (d, J=8.4 Hz, 3H); 7.45 (t, J=9.9 Hz,
1H); 7.33 (d, J=8.4 Hz, 2H); 2.64 (q, J=7.5 Hz, 2H); 1.18 (t, J=7.5
Hz, 3H).
EXAMPLE 83
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2,5-difluorop-
henyl)urea
[0292] The desired product was prepared by substituting Example 78A
and 2,5-difluorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. .sup.1H NMR (DMSO-d.sub.6)
.delta. 9.38 (s, 1H); 8.83 (s, 1H); 8.32 (s, 1H); 8.0-8.10 (m, 1H);
7.62 (d, J=8.4 Hz, 2H); 7.35 (d, J=8.4 Hz, 2H); 7.26 (m, 1H);
6.8-6.90 (m, 1H); 2.63 (q, J=7.5 Hz, 2H); 1.18 (t, J=7.5 Hz,
3H).
EXAMPLE 84
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-fluoropheny-
l)urea
[0293] The desired product was prepared by substituting Example 78A
and 2-fluorophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. .sup.1H NMR (DMSO-d.sub.6) .delta.
9.30 (s, 1H); 8.62 (d, J=2.7 Hz, 1H); 8.32 (s, 1H); 8.17 (dt,
J=8.7, 1.5 Hz, 1H); 7.63 (d, J=8.4 Hz, 2H); 7.35 (d, J=8.4 Hz, 2H);
7.0-7.32 (m, 3H); 2.66 (q, J=7.5 Hz, 2H); 1.98 (t, J=7.5 Hz,
3H).
EXAMPLE 85
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2,4-difluorop-
henyl)urea
[0294] The desired product was prepared by substituting Example 78A
and 2,4-difluorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. .sup.1H NMR (DMSO-d.sub.6)
.delta. 9.25 (s, 1H); 8.60 (d, J=2.0 Hz, 1H); 8.32 (s, 1H);
8.00-8.15 (m, 1H); 7.62 (d, J=8.4 Hz, 2H); 7.25-8.00 (m,3H);
7.00-7.16 (m, 1H); 2.63 (q, J=7.5 Hz, 2H); 1.98 (t, J=7.5 Hz,
3H).
EXAMPLE 86
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2,6-difluorop-
henyl)urea
[0295] The desired product was prepared by substituting Example 78A
and 2,6-difluorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. .sup.1H NMR (DMSO-d.sub.6)
.delta. 9.22 (s, 1H); 8.32 (s, 1H); 8.22 (s, 1H); 7.63 (d, J=8.4
Hz, 2H); 7.22-7.40 (m, 3H); 7.10-7.20 (m, 2H); 2.62 (q, J=7.5 Hz,
2H); 1.98 (t, J=7.5 Hz, 3H).
EXAMPLE 87
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methoxyphen-
yl)urea
[0296] The desired product was prepared by substituting Example 78A
and 3-methoxyphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. .sup.1H NMR (DMSO-d.sub.6)
.delta. 8.95 (s, 1H); 8.80 (s, 1H); 8.32 (s, 1H); 7.62 (d, J=8.4
Hz, 2H); 7.32 (d, J=8.4 Hz, 2H); 7.12-7.22 (m, 2H); 6.90-7.00 (m,
1H); 6.50-6.60 (m, 1H); 3.75 (s, 3H); 2.62 (q, J=7.5 Hz, 2H); 1.98
(t, J=7.5 Hz, 3H).
EXAMPLE 88
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[3-(trifluorom-
ethyl)phenyl]urea
[0297] The desired product was prepared by substituting Example 78A
and 3-trifluoromethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. .sup.1H NMR (DMSO-d.sub.6)
.delta. 9.18 (s, 1H); 9.06 (s, 1H); 8.32 (s, 1H); 8.02 (s, 1H);
7.50-7.70 (m, 4H); 7.32 (d, J=8.4 Hz, 3H); 2.62 (q, J=7.5 Hz, 2H);
1.98 (t, J=7.5 Hz, 3H).
EXAMPLE 89
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methoxyphen-
yl)urea
[0298] The desired product was prepared by substituting Example 78A
and 2-methoxyphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. .sup.1H NMR(DMSO-d.sub.6)
.delta. 9.58 (s, 1H); 8.30 (s, 2H); 8.17 (dd, J=9.0, 1.5 Hz, 1H);
7.62 (d, J=8.4 Hz, 2H); 7.32 (d, J=8.4 Hz, 2H); 6.80-7.10 (m, 3H);
3.92 (s, 3H); 2.62 (q, J=7.5 Hz, 2H); 1.98 (t, J=7.5 Hz, 3H).
EXAMPLE 90
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-bromophenyl-
)urea
[0299] The desired product was prepared by substituting Example 78A
and 3-bromophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. .sup.1H NMR (DMSO-d.sub.6) .delta.
9.04 (s, 1H); 9.01 (s, 1H); 8.35 (s, 1H); 7.88 (t, J=1.8 Hz, 1H);
7.62 (d, J=8.4 Hz, 2H); 7.10-7.40 (m, 5H); 2.62 (q, J=7.5 Hz, 2H);
1.98 (t, J=7.5 Hz, 3H).
EXAMPLE 91
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[4-(trifluorom-
ethyl)phenyl]urea
[0300] The desired product was prepared by substituting Example 78A
and 4-trifluoromethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. .sup.1H NMR (DMSO-d.sub.6)
.delta. 9.22 (s, 1H); 9.03 (s, 1H); 8.35 (s,1H); 7.60-7.80 (m, 6H);
7.37 (d, J=8.4 Hz, 2H); 2.62 (q, J=7.5 Hz, 2H); 1.98 (t, J=7.5 Hz,
3H).
EXAMPLE 92
5-[4-(1,3-benzoxazol-2-ylamino)phenyl]-6-ethylthieno[2,3-d]pyrimidin-4-ami-
ne
[0301] The desired product was prepared by substituting Example 78A
for Example 1E in Example 3. .sup.1H NMR (DMSO-d.sub.6) .delta.
10.90 (s, 1H); 8.28 (s, 1H); 7.96 (d, J=8.4 Hz, 2H); 7.50 (dd,
J=12, 7.4 Hz, 2H); 7.42 (d, J=8.4 Hz, 2H); 7.10-7.30 (m, 2H);
2.62(q, J=7.5 Hz, 2H); 1.98 (t, J=7.5 Hz, 3H).
EXAMPLE 93
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]benzamide
[0302] The desired product was prepared by substituting Example 78A
for Example 1E in Example 4. m.p. 213-214.degree. C.; .sup.1H NMR
(DMSO-d.sub.6) .delta. 10.46 (s, 1H); 8.26 (s, 1H); 7.98 (d, J=8.4
Hz, 4H); 7.50-7.70 (m, 3H); 7.40 (d, J=8.4 Hz, 2H); 2.66 (q, J=7.5
Hz, 2H); 1.17 (t, J=7.5 Hz, 3H).
EXAMPLE 94
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfonamide
[0303] The desired product was prepared by substituting Example 78A
for Example 1E in Example 2. m.p. 209-210.degree. C.; .sup.1H NMR
(DMSO-d.sub.6) .delta. 10.44 (s, 1H); 8.22 (s, 1H); 7.70-7.80 (m,
2H); 7.50-7.70 (m, 3H); 7.10-7.30 (m, 4H); 2.56 (q, J=7.5 Hz, 2H);
1.04 (t, J=7.5 Hz, 3H).
EXAMPLE 95
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-2-(3-methylphenyl-
)acetamide
[0304] The desired product was prepared by substituting Example 78A
and 3-methylphenylacetyl chloride for Example 1E and benzoyl
chloride, respectively, in Example 4. .sup.1H NMR (DMSO-d.sub.6)
10.36 (s, 1H); 8.26 (s, 1H); 7.78 (d, J=9.0 Hz, 2H); 7.33 (d, J=9.0
Hz, 2H); 7.00-7.30 (m, 4H); 3.63 (s, 2H); 2.62 (q, J=7.5 Hz, 2H);
2.31 (s, 3H); 1.14 (t, J=7.5 Hz, 3H).
EXAMPLE 96
3-(4-nitrophenyl)isothiazolo[5,4-d]pyrimidin-4-amine
EXAMPLE 96A
2-[hydroxy(4-nitrophenyl)methylene]malononitrile
[0305] A 0.degree. C. solution of 4-nitrobenzoyl chloride (24.12 g,
130 mmol) and malononitrile (8.60 g, 130 mmol) in dichloromethane
(200 mL) was treated with PhCH.sub.2N(CH.sub.2CH.sub.3).sub.3Cl
(3.0 g), treated dropwise with 10N NaOH (30 mL), stirred at
0.degree. C. for 1 hour, and filtered. The filter cake was washed
with dichloromethane and diethyl ether, dissolved in 5% HCl, and
extracted with ethyl acetate. The extract was dried (MgSO.sub.4),
filtered, and concentrated. The concentrate was recrystallized from
ethyl acetate/hexanes to provide 23 g of the desired product.
MS(ESI(-)) m/e 214 (M-H).sup.-.
EXAMPLE 96B
2-[chloro(4-nitrophenyl)methylene]malononitrile
[0306] A mixture of PCl.sub.5 (16.6 g, 80 mmol) in dichloromethane
(500 mL) was added dropwise to a suspension of Example 96A (8.6 g,
40 mmol) in dichloromethane (80 mL). The resulting mixture was
heated to reflux for 20 hours, cooled to room temperature, and
concentrated. The residue was dissolved in a minimal amount of
dichloromethane and filtered through a plug of silica gel. The plug
was washed with dichloromethane and the filtrate was concentrated.
The concentrate was recrystallized from dichloromethane/hexanes to
provide 5.4 g (57% yield) of the desired product. R.sub.f=0.7 (5%
methanol/dichloromethane).
EXAMPLE 96C
2-[amino(4-nitrophenyl)methylene]malononitrile
[0307] A suspension of Example 96B (5.4 g) in ethanol (100 mL) at
room temperature was treated dropwise with concentrated NH.sub.4OH
(100 mL), stirred for 4 hours, poured into ice water, and filtered.
The filter cake was dried to provide 4.7 g (93% yield) the desired
product. MS(ESI(-)) m/e 213 (M-H).sup.-.
EXAMPLE 96D
(2Z)-3-amino-2-cyano-3-(4-nitrophenyl)prop-2-enethioamide
[0308] A suspension of Example 96C (2.1 g, 9.8 mmol) and 90%
diethyl dithiophosphate (1.8 mL, 10.8 mmol) in ethanol (15 mL) and
water (15 mL) was heated to reflux for 24 hours, cooled to room
temperature, poured into ice water (300 mL), and filtered. The
filter cake was dried to provide 2.3 g (95% yield) of the desired
product. MS(ESI(-)) m/e 247 (M-H).sup.-.
EXAMPLE 96E
5-amino-3-(4-nitrophenyl)isothiazole-4-carbonitrile
[0309] A suspension of Example 96D (23 g, 9.26 mmol) in ethanol
(100 mL) was treated with 31% H.sub.2O.sub.2 (2 mL, 1.85 mmol),
stirred at room temperature overnight, poured into ice water, and
filtered. The filter cake was washed with water and dried to
provide 2.2 g (96% yield) of the desired product. MS(ESI(-)) m/e
245 (M-H).sup.-.
EXAMPLE 96F
3-(4-nitrophenyl)isothiazolo[5,4-d]pyrimidin-4-amine
[0310] A mixture of Example 96E (200 mg) in formamide (5 mL) in a
capped vial was heated to 210.degree. C. in a Smith microwave oven
at 300 W for 25 minutes, poured into water, and filtered. The
filter cake was dried to provide 2.02 g (84% yield) of the desired
product. MS(ESI(+)) m/e 274 (M+H).sup.+.
EXAMPLE 97
3-(4-aminophenyl)isothiazolo[5,4-d]pyrimidin-4-amine
[0311] A mixture of Example 96F (0.95 g, 3.5 mmol), iron (0.78 g,
13.9 mmol), and NH.sub.4Cl (0.19 g, 3.5 mmol) in 9:1 ethanol/water
(80 mL) was heated to 60.degree. C. for 4 hours, cooled to room
temperature, and filtered through a pad of diatomaceous earth
(Celite.RTM.). The pad was washed with THF and the filtrate was
concentrated. The concentrate was suspended in water and filtered.
The filter cake was washed with water and dried to provide 0.82 g
(97% yield) of the desired product.
EXAMPLE 98
N-[4-(4-aminoisothiazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-[3-(trifluorometh-
yl)phenyl]urea
[0312] The desired product was prepared by substituting Example 97
and 3-trifluoromethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS(ESI(-)) m/e 429
(M-H).sup.-; .sup.1H NMR (DMSO-d.sub.6) .delta. 9.18 (s, 1H); 9.12
(s, 1H); 8.46 (s, 1H); 8.04 (s, 1H); 7.50-7.80 (m, 6H); 7.35 (d,
1H, J=8.4 Hz).
EXAMPLE 99
N-[4-(4-aminoisothiazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-(3-methylphenyl)u-
rea
[0313] The desired product was prepared by substituting Example 97
and 3-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(-)) m/e 375 (M-H).sup.-;
.sup.1H NMR (DMSO-d.sub.6) .delta. 8.80 (s, 1H); 8.65 (s, 1H); 8.44
(s, 1H); 7.50-7.80 (m, 4H); 7.10-7.40 (m, 3H). 6.80 (d, J=8.4 Hz,
1H); 2.28 (s, 3H).
EXAMPLE 100
N-[4-(4-aminoisothiazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-(3-chlorophenyl)u-
rea
[0314] The desired product was prepared by substituting Example 97
and 3-chlorophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(-)) m/e 395 (M-H).sup.-;
.sup.1H NMR (DMSO-d.sub.6) .delta. 9.08 (s, 1H); 9.00 (s, 1H); 8.42
(s, 1H); 7.50-8.00 (m, 5H); 7.20-7.40 (m, 2H); 7.00-7.10 (m,
1H).
EXAMPLE 101
N-[4-(4-aminoisothiazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-(3-ethylphenyl)ur-
ea
[0315] The desired product was prepared by substituting Example 97
and 3-ethylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+) m/e 391 (M+H).sup.+; .sup.1H
NMR (DMSO-d.sub.6) .delta. 8.98 (s, 1H); 8.72 (s, 1H); 8.45 (s,
1H); 7.50-7.80 (m, 4H); 7.10-7.40 (m, 3H); 6.84 (d, 1H); 2.58 (q,
J=7.2 Hz, 2H); 1.18 (t, J=7.2 Hz, 3H); Anal. Calcd. for
C.sub.20H.sub.18N.sub.6OS.0.7H.sub.2O: C, 59.60; H, 4.85; N, 20.85.
Found: C, 60.07; H, 4.65; N, 20.34.
EXAMPLE 102
3-(4-phenoxyphenyl)isothiazolo[5,4-d]pyrimidin-4-amine
EXAMPLE 102A
2-[amino(4-phenoxyphenyl)methylene]malononitrile
[0316] The desired product was prepared by substituting
4-phenoxybenzoyl chloride for 4-nitrobenzoyl chloride in Examples
96A-C.
EXAMPLE 102B
(2E)-3-amino-2-cyano-3-(4-phenoxyphenyl)prop-2-enethioamide
[0317] A solution of Example 102A (1.6 g, 6.12 mmol) in pyridine
(10 mL) was treated with triethylamine (0.76 mL, 5.5 mmol) and
heated to 80.degree. C. H.sub.2S gas was bubbled through the
solution for 4 hours, the mixture was cooled to room temperature,
and partitioned between water and ethyl acetate. The organic phase
was dried (MgSO.sub.4), filtered, and concentrated. The concentrate
was purified by flash column chromatography on silica gel with 5%
ethyl acetate/hexanes to provide 1.4 g (77% yield) of the desired
product. MS(DCI/NH.sub.3) m/e 296 (M+H).sup.+.
EXAMPLE 102C
3-(4-phenoxyphenyl)isothiazolo[5,4-d]pyrimidin-4-amine
[0318] The desired product was prepared by substituting Example
102B for Example 96D in Example 96E and Example 96F. MS(ESI(+)) m/e
321 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6) .delta. 8.45 (s, 1H);
7.60-7.70 (m,2H); 7.40-7.50 (m, 2H); 7.10-7.30 (m, 5H).
EXAMPLE 103
N-[4-(4-aminoisothiazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-[2-fluoro-5-(trif-
luoromethyl)phenyl]urea
[0319] The desired product was prepared by substituting Example 97
and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS(ESI(+)) m/e 449
(M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6) .delta. 9.44 (s,1H); 9.00
(d, J=3 Hz, 1H); 9.63 (dd, J=7.2, 2.0 Hz, 1H); 8.47 (s, 1H);
7.30-7.80 (m, 6H).
EXAMPLE 104
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
methylphenyl)urea
EXAMPLE 104A
4-{[tert-butyl(dimethyl)silyl]oxy}-1-(4-nitrophenyl)butan-1-one
[0320] A mixture of Zn--Cu couple (2.68 g, 41.3 mmol) and
tert-butyl(3-iodopropoxy)dimethylsilane (8.26 g, 27.5 mmol) in
benzene (55 mL) and DMF (3.6 mL) was stirred vigorously at room
temperature for 1 hour, heated to 60.degree. C. for 4 hours, cooled
to room temperature, and treated with a solution of 4-nitrobenzoyl
chloride (3.4 g, 18.3 mmol) and (Ph.sub.3P).sub.4Pd (0.847 g, 0.73
mmol) in benzene (36 mL) by cannula. The mixture was stirred for 1
hour, filtered through diatomaceous earth (Celite.RTM.), and
partitioned between saturated NH.sub.4Cl and ethyl acetate. The
aqueous phase was extracted three times with ethyl acetate and the
combined extracts were washed with water and brine, dried
(Na.sub.2SO.sub.4), filtered, and concentrated. The concentrate was
purified by flash column chromatography on silica gel with 5% ethyl
acetate/hexanes to provide 2.81 g of the desired product.
MS(ESI(-)) m/e 322 (M-H).sup.-.
EXAMPLE 104B
5-(4-aminophenyl)-6-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)thieno[2,3-d]-
pyrimidin-4-amine
[0321] The desired product was prepared by substituting Example
104A for Example 1A in Examples 1B-1E.
EXAMPLE 104C
N-{4-[4-amino-6-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)thieno[2,3-d]pyri-
midin-5-yl]phenyl}-N'-(3-methylphenyl)urea
[0322] The desired product was prepared by substituting Example
104B and 3-methylphenyl isocyanate for phenyl isocyanate and
Example 1E, respectively, in Example 1F.
EXAMPLE 104D
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
methylphenyl)urea
[0323] A solution of Example 104C (92 mg, 0.17 mmol) in THF (5 mL)
at room temperature was treated dropwise with a solution of 1M TBAF
in THF (0.3 mL, 0.3 mmol), stirred overnight, and partitioned
between water and ethyl acetate. The aqueous phase was extracted
three times with ethyl acetate and the combined extracts were dried
(Na.sub.2SO.sub.4), filtered, and concentrated. The concentrate was
recrystallized from dichloromethane to provide 54 mg (75%) of the
desired product. MS(ESI) m/e 420 (M+H).sup.+, 418 (M-H).sup.-;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.29 (s, 3H); 2.75-2.80
(t, J=6.6 Hz, 2H); 3.54-3.60 (m, 2H); 4.85-4.89 (t, J=5.7 Hz, 1H);
6.79-6.82 (d, J=7.5 Hz, 2H); 7.14-7.19 (t, J=7.5 Hz, 1H); 7.24-7.32
(m, 4H); 7.61-7.63 (d, J=8.4 Hz, 2H); 8.26 (s, 1H); 8.67 (s, 1H);
8.87 (s, 1H); Anal. Calcd. for
C.sub.22H.sub.21N.sub.5O.sub.2S.0.4H.sub.2O: C, 61.93; H, 5.15; N,
16.41. Found: C, 61.80; H, 4.95; N, 16.31.
EXAMPLE 105
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(4--
methylphenyl)urea
[0324] The desired product was prepared by substituting Example
104B and 4-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F, then substituting the
product for Example 104C in Example 104D. MS(ESI(+)) m/e 420
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.25 (s,
3H); 2.75-2.80 (m, 2H); 3.52-3.63 (m, 2H); 4.53-4.54 (m, 1H);
7.08-7.11 (d, J=7.8 Hz, 2H); 7.29-7.32 (d, J=8.7 Hz, 2H); 7.34-7.37
(d, J=8.1 Hz, 2H); 7.60-7.63 (d, J=8.4 Hz, 2H); 8.26 (s, 1H); 8.64
(s, 1H); 8.84 (s, 1H).
EXAMPLE 106
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
chlorophenyl)urea
[0325] The desired product was prepared by substituting Example
104B and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F, then substituting the
resulting product for Example 104C in Example 104D. MS(ESI(+)) m/e
440, 442 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
2.74-2.79 (t, J=6.3 Hz, 2H); 3.54-3.60 (m, 2H); 4.86-4.89 (t, J=5.1
Hz, 1H); 7.02-7.05 (td, J=2.4, 6.3 Hz, 1H); 7.30-7.35 (m, 4H);
7.61-7.64 (d, J=8.4 Hz, 2H); 7.73-7.74 (m, 1H); 8.27 (s, 1H); 8.98
(s, 2H).
EXAMPLE 107
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(2--
methylphenyl)urea
[0326] The desired product was prepared by substituting Example
104B and 2-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F, then substituting the
resulting product for Example 104C in Example 104D. m.p.
159-162.degree. C.; MS(ESI(+)) m/e 420 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 2.26 (s, 3H); 2.75-2.79 (t, J=6.9
Hz, 2H); 3.54-3.60 (m, 2H); 4.86-4.89 (t, J=5.4 Hz, 1H); 6.94-6.99
(t, J=7.2 Hz, 1H); 7.13-7.21 (m, 2H); 7.29-7.33 (d, J=9 Hz, 2H);
7.62-7.65 (d, J=8.4 Hz, 2H); 7.81-7.83 (d, J=9.2 Hz, 1H); 8.01 (s,
1H); 8.26 (s, 1H); 9.23 (s, 1H).
EXAMPLE 108
5-(4-aminophenyl)-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-4-amine
[0327] The desired product was prepared by substituting
1-iodo-3-methoxypropane for tert-butyl(3-iodopropoxy)dimethylsilane
in Examples 104A and 104B. m.p. 144-146.degree. C.
EXAMPLE 109
N-{4-[4-amino-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
methylphenyl)urea
[0328] The desired product was prepared by substituting Example 108
and 3-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+)) m/e 434 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.29 (s, 3H); 2.83-2.87
(t, J=6.6 Hz, 2H); 3.22 (s, 3H); 3.47-3.52 (t, J=6.6 Hz, 2H);
6.79-6.82 (d, J=7.5 Hz, 2H); 7.14-7.19 (t, J=7.5 Hz, 1H); 7.24-7.32
(m, 4H); 7.61-7.64 (d, J=9 Hz, 2H); 8.27 (s, 1H); 8.67 (s, 1H);
8.87 (s, 1H).
EXAMPLE 110
N-{4-[4-amino-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(4--
methylphenyl)urea
[0329] The desired product was prepared by substituting Example 108
and 4-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. m.p. 128-132.degree. C.; MS(ESI(+))
m/e 434 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
2.25 (s, 3H); 2.83-2.87 (t, J=6.6 Hz, 2H); 3.22 (s, 3H); 3.47-3.52
(t, J=6.6 Hz, 2H); 7.09-7.11 (d, J=8.1 Hz, 2H); 7.28-7.32 (d, J=8.4
Hz, 2H); 7.34-7.37 (d, J=8.4 Hz, 2H); 7.60-7.63 (d, J=9 Hz, 2H);
8.27 (s, 1H); 8.64 (s, 1H); 8.84 (s, 1H).
EXAMPLE 111
N-{4-[4-amino-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}benzene-
sulfonamide
[0330] The desired product was prepared by substituting Example 108
for Example 1E in Example 2. m.p. 206-208.degree. C.; MS(ESI(+))
m/e 441 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
2.72-2.76 (t, J=6.3 Hz, 2H); 3.14 (s, 3H); 3.39-3.44 (t, J=6.6 Hz,
2H); 7.19-7.28 (m, 4H); 7.57-7.59 (m, 3H); 7.74-7.77 (d, J=6.9 Hz,
2H); 8.26 (s, 1H); 10.49 (s, 1H).
EXAMPLE 112
N-{4-[4-amino-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-2-(3-m-
ethylphenyl)acetamide
[0331] The desired product was prepared by substituting Example 108
and 3-methylphenylacetyl chloride for Example 1E and benzoyl
chloride, respectively, in Example 4. m.p. 200-202.degree. C.;
MS(ESI(+)) m/e 433 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 2.31 (s, 3H); 2.80-2.84 (t, J=6.6 Hz, 2H); 3.21 (s, 3H);
3.45-3.49 (t, J=6.6 Hz, 2H); 3.64 (s, 2H); 7.06-7.08 (d, J=7.5 Hz,
1H); 7.13-7.25 (m, 3H); 7.31-7.34 (d, J=8.4 Hz, 2H); 7.75-7.78 (d,
J=9 Hz, 2H); 8.26 (s, 1H); 10.36 (s, 1H).
EXAMPLE 113
N-{4-[4-amino-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}benzami-
de
[0332] The desired product was prepared by substituting Example 108
for Example 1E in Example 4. m.p. 200-202.degree. C.; MS(ESI(+))
m/e 405 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
2.84-2.88 (t, J=6.3 Hz, 2H); 3.23 (s, 3H); 3.48-3.53 (d, J=6.3 Hz,
2H); 7.38-7.41 (d, J=8.4 Hz, 2H); 7.54-7.62 (m, 3H); 7.96-7.99 (m,
4H); 8.28 (s, 1H); 10.47 (s, 1H); Anal. Calcd. for
C.sub.22H.sub.20N.sub.4O.sub.2S.0.4H.sub.2O: C, 64.18; H, 5.09; N,
13.61. Found: C, 64.28; H, 4.96; N, 13.34.
EXAMPLE 114
N-{4-[4-amino-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-[3--
(trifluoromethyl)phenyl]urea
[0333] The desired product was prepared by substituting Example 108
and 3-(trifluoromethyl)phenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS(ESI(+)) m/e 488
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.83-2.87
(t, J=6.3 Hz, 2H); 3.22 (s, 3H); 3.48-3.52 (d, J=6.3 Hz, 2H);
7.31-7.34 (d, J=9 Hz, 3H); 7.51-7.56 (t, J=8.1 Hz, 1H); 7.62-7.67
(m, 3H); 8.04 (s, 1H); 8.27 (s, 1H); 9.02 (s, 1H); 9.14 (s, 1H);
Anal. Calcd. for C.sub.23H.sub.20N.sub.5O.sub.2SF.sub.3: C, 56.67;
H, 4.13; N, 14.37. Found: C, 56.40; H, 4.18; N, 14.15.
EXAMPLE 115
N-{4-[4-amino-6-(pyridin-3-ylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-
-(3-methylphenyl)urea
EXAMPLE 115A
1-(4-nitrophenyl)-3-pyridin-3-ylpropan-1-one
[0334] The desired product was prepared by substituting
3-pyridinecarboxaldehyde for 4-pyridinecarboxaldehyde in Example
14A, then substituting the resulting product for Example 14A in
Example 14B. MS(ESI(+)) m/e 257 (M+H).sup.+.
EXAMPLE 115B
N-{4-[4-amino-6-(pyridin-3-ylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-
-(3-methylphenyl)urea
[0335] The desired product was prepared by substituting Example
115A and 3-methylphenyl isocyanate for Example 1A and phenyl
isocyanate, respectively, in Examples 1B-1F. MS(ESI(+)) m/e 467
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.29 (s,
3H); 4.04 (s, 2H); 6.79-6.82 (d, J=7.5 Hz, 1H); 7.14-7.19 (t, J=7.8
Hz, 1H); 7.24-7.33 (m, 3H); 7.35-7.37 (d, J=8.4 Hz, 2H); 7.53-7.56
(td, J=2.1 Hz, 7.8 Hz, 1H); 7.63-7.66 (d, J=8.4 Hz, 2H); 8.27 (s,
1H); 8.34-8.35 (d, J=1.8 Hz, 1H); 8.42-8.44 (dd, J=1.5, 4.8 Hz,
1H); 8.67 (s, 1H); 8.89 (s, 1H); Anal. Calcd. for
C.sub.26H.sub.22N.sub.6OS.0.2H.sub.2O: C, 66.42; H, 4.80; N, 17.87.
Found: C, 66.38; H, 4.80; N, 17.92.
EXAMPLE 116
N-{4-[4-amino-6-(pyridin-3-ylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-
-(4-methylphenyl)urea
[0336] The desired product was prepared by substituting Example
115A and 4-methylphenyl isocyanate for Example 1A and phenyl
isocyanate, respectively, in Examples 1B-1F. mp: 220-223.degree.
C.; MS(ESI(+)) m/e 467 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 2.25 (s, 3H); 4.04 (s, 2H); 7.08-7.11 (d,
J=8.1 Hz, 2H); 7.29-7.37 (m, 5H); 7.52-7.56 (td, J=2.1, 7.8 Hz,
1H); 7.62-7.65 (d, J=8.7 Hz, 2H); 8.27 (s, 1H); 8.34-8.35 (d, J=2.1
Hz, 1H); 8.41-8.43 (dd, J=1.2, 4.5 Hz, 1H); 8.64 (s, 1H); 8.86 (s,
1H); Anal. Calcd. for C.sub.26H.sub.22N.sub.6OS: C, 66.93; H, 4.75;
N, 18.01. Found: C, 66.69; H, 4.65; N, 18.05.
EXAMPLE 117
N-{4-[4-amino-6-(pyridin-3-ylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-
-(3-chlorophenyl)urea
[0337] The desired product was prepared by substituting Example
115A and 3-chlorophenyl isocyanate for Example 1A and phenyl
isocyanate, respectively, in Examples 1B-1F. m.p. 169-172.degree.
C.; MS(ESI(+)) m/e 487 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 4.04 (s, 2H); 7.02-7.06 (td, 1H, J=2.4, 6.6
Hz); 7.29-7.35(m, 3H); 7.36-7.39 (d, 2H, J=8.7 Hz); 7.52-7.56 (td,
1H, J=1.8, 7.8 Hz); 7.64-7.67 (d, 2H, J=8.7 Hz); 7.72-7.73 (m, 1H);
8.27 (s, 1H); 8.34-8.35 (d, 1H, J=2.4 Hz); 8.41-8.44 (dd, 1H,
J=1.5, 4.8 Hz); 8.97 (s, 1H); 8.99 (s, 1H); Anal. Calcd. for
C.sub.25H.sub.19N.sub.6OSCl 0.4H.sub.2O: C, 60.76; H, 4.04; N,
17.01. Found: C, 60.81; H, 4.04; N, 16.77.
EXAMPLE 118
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-fluorophen-
yl)urea
[0338] The desired product was prepared by substituting
3-fluorophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 394 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.00 (s, 1H); 8.97 (s, 1H); 8.27 (s, 1H); 7.64 (d, J=8.4
Hz, 2H); 7.51 (dt, J=12.0 Hz, 2.1 Hz, 1H); 7.36-7.28 (m, 3H); 7.15
(d, J=8.1 Hz, 1H); 6.80 (td, J=8.1 Hz, 2.4 Hz); 2.30 (s, 3H).
EXAMPLE 119
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-fluorophen-
yl)urea
[0339] The desired product was prepared by substituting
4-fluorophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 394 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.89 (s, 1H); 8.79 (s, 1H); 8.26 (s, 1H); 7.63 (d, J=8.4
Hz, 2H); 7.51-7.46 (m, 2H); 7.31 (d, J=8.4 Hz, 2H); 7.14 (t, J=9.0
Hz, 2H); 2.29 (s, 3H).
EXAMPLE 120
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,5-difluoro-
phenyl)urea
[0340] The desired product was prepared by substituting
3,5-difluorophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 412 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.17 (s, 1H); 9.07 (s, 1H); 8.27 (s, 1H); 7.64 (d, J=8.7
Hz, 2H); 7.33 (d, J=8.7 Hz, 2H); 7.22 (dd, J=9.9 Hz, 2.4 Hz, 2H);
6.81 (tt, J=9.3 Hz, 2.4 Hz); 2.29 (s, 3H).
EXAMPLE 121
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-phenoxyphe-
nyl)urea
[0341] The desired product was prepared by substituting
3-phenoxyphenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 466 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.88 (s, 1H); 8.86 (s, 1H); 8.26 (s, 1H); 7.60 (d, J=9.0
Hz, 2H); 7.41 (t, J=8.1 Hz, 2H); 7.32-7.26 (m, 4H); 7.16 (t, J=7.5
Hz, 2H); 7.05 (d, J=7.5 Hz, 2H); 6.63 (dd, J=8.1 Hz, 2.4 Hz, 1H);
2.29 (s, 3H).
EXAMPLE 122
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-phenoxyphenyl)urea
[0342] The desired product was prepared by substituting Example 58D
and 3-phenoxyphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS(ESI(+)) m/e 454
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.88 (s,
1H); 8.87 (s, 1H); 8.33 (s, 1H); 7.58 (d, J=8.4 Hz, 2H); 7.44-7.36
(m, 5H); 7.32-7.26 (m, 2H); 7.20-7.12 (m, 2H); 7.07-7.03 (m, 2H);
6.65-6.61 (m, 1H).
EXAMPLE 123
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-cyanopheny-
l)urea
[0343] The desired product was prepared by substituting
3-cyanophenyl isocyanate for phenyl isocyanate in Example 1F.
MS(ESI(+)) m/e 401 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.11 (s, 1H); 9.06 (s, 1H); 8.27 (s, 1H); 8.00 (s, 1H);
7.70 (d, J=8.1 Hz, 1H); 7.65 (d, J=8.4 Hz, 2H); 7.52 (t, J=8.1 Hz,
1H); 7.44 (d, J=8.1 Hz, 2H); 7.33 (d, J=8.4 Hz, 2H); 2.30 (s,
3H).
EXAMPLE 124
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[4-(trifluoro-
methyl)phenyl]urea
[0344] The desired product was prepared by substituting
4-(trifluoromethyl)phenyl isocyanate for phenyl isocyanate in
Example 1F. MS(ESI(+)) m/e 444 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 9.29 (s, 1H); 9.02 (s, 1H); 8.27 (s, 1H);
7.71-7.63 (m, 6H); 7.33 (d, J=8.7 Hz, 2H); 2.30 (s, 3H).
EXAMPLE 125
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chlorophenyl)urea
[0345] The desired product was prepared by substituting Example 58D
and 3-chlorophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+)) m/e 396 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.96 (s, 1H); 8.34 (s,
1H); 7.73 (s, 1H); 7.61 (d, J=8.4 Hz, 2H); 7.44 (s, 1H); 7.40 (d,
J=8.4 Hz, 2H); 7.32-7.28 (m, 2H); 7.03 (dt, J=2.1 Hz, 1H).
EXAMPLE 126
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[3-(trifluoromethyl)ph-
enyl]urea
[0346] The desired product was prepared by substituting Example 58D
and 3-(trifluoromethyl)phenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS(ESI(+)) m/e 428
(M-H).sup.-; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 9.18 (s,
1H); 9.06 (s, 1H); 8.36 (s, 1H); 8.03 (s, 1H); 7.65-7.58 (m, 3H);
7.53 (t, J=7.8 Hz, 1H); 7.46 (s, 1H); 7.41 (d, J=8.4 Hz, 2H); 7.33
(d, J=7.8 Hz, 1H).
EXAMPLE 127
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[2-fluoro-5-(trifluoro-
methyl)phenyl]urea
[0347] A suspension of Example 58D (0.04 g, 0.165 mmol) in
dichloromethane (3 mL) under nitrogen was cooled to 0.degree. C.,
treated with 1-fluoro-2-isocyanato-4-(trifluoromethyl)benzene
(0.024 mL, 0.165 mmol), and stirred overnight while gradually
warming to room temperature. The suspension was filtered and the
filter cake was dried in a vacuum oven to provide 0.056 g of the
desired product. MS(ESI(+)) m/e 448 (M+H).sup.+; .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 9.40 (s, 1H); 8.98 (d, J=2.7 Hz, 1H);
8.63 (dd, J=7.2 Hz, 2.1 Hz, 1H); 8.35 (s, 1H); 7.63 (d, J=8.7 Hz,
2H); 7.55-7.39 (m, 5H).
EXAMPLE 128
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[2-fluoro-5-(t-
rifluoromethyl)phenyl]urea
[0348] The desired product was prepared by substituting Example 61B
and 2-fluoro-5-(trifluoromethyl)phenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS(ESI(+)) m/e
526, 528 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
9.43 (s, 1H); 9.00 (d, J=2.7 Hz, 1H); 8.63 (dd, J=7.5 Hz, 2.1 Hz,
1H); 8.33 (s, 1H); 7.68 (d, J=8.7 Hz, 2H); 7.52 (t, J=8.7 Hz, 1H);
7.45-7.37 (m, 3H).
EXAMPLE 129
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[3-(trifluorom-
ethyl)phenyl]urea
[0349] The desired product was prepared by substituting Example 61B
and 3-(trifluoromethyl)phenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS(ESI(+)) m/e 508, 510
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 9.15 (s,
1H); 9.06 (s, 1H); 8.33 (s, 1H); 8.04 (s, 1H); 7.68 (d, J=8.7 Hz,
2H); 7.61 (d, J=8.1 Hz, 1H); 7.53 (t, J=8.1 Hz, 1H); 7.38 (d, J=8.7
Hz, 2H); 7.33 (d, J=8.1 Hz, 1H).
EXAMPLE 130
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chloropheny-
l)urea
[0350] The desired product was prepared by substituting Example 61B
and 3-chlorophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS(ESI(+)) m/e 474, 476 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 9.02 (s, 1H); 8.99 (s,
1H); 8.33 (s, 1H); 7.73 (s, 1H); 7.66 (d, J=8.7 Hz, 2H); 7.37 (d,
J=8.7 Hz, 2H); 7.33-7.30 (m, 2H); 7.04 (dt, J=6.6 Hz, 2.4 Hz,
1H).
EXAMPLE 131
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-1H-indole-2-carb-
oxamide
[0351] The desired compound was prepared by substituting
1H-indole-2-carbonyl chloride for benzoyl chloride in Example 4.
MS(ESI(+)) m/e 400 (M+H).sup.+; .sup.1H NMR(300 MHz, DMSO-d.sub.6)
.delta. 11.80 (s, 1H); 10.40 (s, 1H); 8.28 (s, 1H); 8.01 (d, J=8.7
Hz, 2H); 7.70 (d, J=7.5 Hz, 1H); 7.48 (d, J=7.5 Hz, 2H); 7.42 (d,
J=8.7 Hz, 2H); 7.24 (t, J=7.5 Hz, 1H); 7.08 (t, J=7.5 Hz, 1H); 2.32
(s, 3H).
EXAMPLE 132
phenyl
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-cyanoi-
midocarbamate
[0352] A solution of Example 1E (0.4 g, 1.56 mmol) and diphenyl
cyanocarbonimidate (0.372 g, 1.56 mmol) in DMF (10 mL) was heated
to 90.degree. C. for 2 days, cooled to room temperature, quenched
with water, and filtered. The filter cake was suspended in ethanol
and filtered. The filtrate was concentrated and purified by flash
column chromatography on silica gel with 5 to 8%
methanol/dichloromethane to provide the desired product (150 mg).
MS(ESI(+)) m/e 401(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 11.06 (s, 1H); 8.27 (s, 1H); 7.67 (d, J=8.4 Hz, 2H);
7.50-7.43 (m, 4H); 7.36-7.29 (m, 3H); 2.29 (s, 3H).
EXAMPLE 133
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N''-cyano-N'-(3--
methylphenyl)guanidine
[0353] A solution of Example 132 (40 mg, 0.01 mmol) and
3-methylaniline (0.012 mL, 0.01 mmol) in DMF (1 mL) was heated in a
Smith synthesizer microwave to 180.degree. C. for 22 minutes and
partitioned between water and ethyl acetate. The aqueous phase was
extracted three times with ethyl acetate and the combined extracts
were washed with water and brine, dried (Na.sub.2SO.sub.4),
filtered and concentrated. The concentrate was purified by flash
column chromatography on silica gel with 8%
methanol/dichloromethane to provide the desired product (15 mg).
MS(ESI(+)) m/e 414 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.65 (s, 1H); 9.48 (s, 1H); 8.26 (s, 1H); 7.45 (d, J=8.4
Hz, 2H); 7.35 (d, J=8.4 Hz, 2H); 7.23 (t, J=7.8 Hz, 1H); 7.15-7.10
(m, 2H); 6.96 (d, J=7.8 Hz, 1H); 2.29 (s, 6H).
EXAMPLE 134
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N-methyl-N'-(3-m-
ethylphenyl)urea
EXAMPLE 134A
6-methyl-5-[4-(methylamino)phenyl]thieno[2,3-d]pyrimidin-4-amine
[0354] A -20.degree. C. suspension of Example 1E (400 mg, 1.56
mmol) in dichloromethane (10 mL) and THF (10 mL) was treated with
formic acetic anhydride (0.135 mL, 1.7 mmol), stirred for 1 hour,
and concentrated. The concentrate was suspened in benzene (50 mL),
treated with 65% Red-Al in toluene (2.4 mL, 7.8 mmol), stirred at
room temperature for 20 minutes than heated to reflux for 6 hours.
The reaction was cooled to room temperature and partitioned between
Rochelle's salt and ethyl acetate. The aqueous phase was extracted
three times with ethyl acetate and the combined extracts were
washed with water and brine, dried (Na.sub.2SO.sub.4), filtered,
and concentrated. The concentrate was purified by flash column
chromatography on silica gel with 7% methanol/dichloromethane to
provide the desired product (86 mg). MS(ESI(+)) m/e 271
(M+H).sup.+.
EXAMPLE 134B
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N-methyl-N'-(3-m-
ethylphenyl)urea
[0355] The desired product was prepared by substituting Example
134A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS(ESI(+)) m/e 404
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.32 (s,
1H); 8.28 (s, 1H); 7.47 (d, J=8.4 Hz, 2H); 7.40 (d, J=8.4 Hz, 2H);
7.29-7.23 (m, 2H); 7.12 (t, J=7.8 Hz, 1H); 6.78 (d, J=7.8 Hz, 1H);
3.33 (s, 3H); 2.33 (s, 3H); 2.25 (s, 3H).
EXAMPLE 135
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N-methyl-N'-[3-(-
trifluoromethyl)phenyl]urea
[0356] The desired product was prepared by substituting Example
134A and 3-(trifluoromethyl)phenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS(ESI(+)) m/e 458
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.73 (s,
1H); 8.28 (s, 1H); 7.97 (s, 1H); 7.69 (d, J=7.5 Hz, 1H); 7.53-7.40
(m, 5H); 7.30 (d, J=7.5 Hz, 1H); 2.33 (s, 3H).
EXAMPLE 136
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphen-
yl)thiourea
[0357] A solution of Example 1E (60 mg, 0.23 mmol) and
3-methylphenyl isothiocyanate in DMF (2 mL) was stirred at room
temperature. for 48 hours, quenched with water, and filtered. The
filter cake was dried to provide the desired product (75 mg, 80%).
MS(ESI(+)) m/e 406 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 9.96 (s, 1H); 9.84 (s, 1H); 8.27 (s, 1H); 7.65 (d, J=8.4
Hz, 2H); 7.35 (d, J=8.4 Hz, 2H); 7.30-7.18 (m, 3H); 6.97 (d, J=6.9
Hz, 1H); 2.30 (s, 6H).
EXAMPLE 137
N-{4-[4-amino-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(2--
methylphenyl)urea
[0358] The desired product was prepared by substituting Example 108
and 2-methylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. m.p. 217-219.degree. C.; MS(ESI(+))
m/e 434 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
2.26 (s, 3H); 2.83-2.87 (t, J=6.6 Hz, 2H); 3.22 (s, 3H); 3.48-3.52
(t, J=6.6 Hz, 2H); 6.95-6.99 (t, J=7.5 Hz, 1H); 7.14-7.21 (m, 2H);
7.29-7.32 (d, J=8.7 Hz, 2H); 7.63-7.65 (d, J=8.7 Hz, 2H); 7.81-7.83
(d, J=8.1 Hz, 1H); 8.01 (s, 1H); 8.27 (s, 1H); 9.23 (s, 1H).
EXAMPLE 138
N-{4-[4-amino-6-(pyridin-3-ylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-
-[3-(trifluoromethyl)phenyl]urea
[0359] The desired product was prepared by substituting Example
115A and 3-trifluoromethylphenyl isocyanate for Example 1A and
phenyl isocyanate, respectively, in Examples 1B-1F. MS(ESI(+)) m/e
521 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 4.04
(s, 2H); 7.29-7.34 (m, 2H); 7.37-7.39 (d, 2H, J=8.4 Hz); 7.50-7.62
(m, 3H); 7.65-7.68 (d, 2H, J=8.7 Hz); 8.03 (s, 1H); 8.28 (s, 1H);
8.34-8.35 (d, 1H, J=2.1 Hz); 8.42-8.44 (dd, 1H, J=1.5, 4.8 Hz);
9.05 (s, 1H); 9.15 (s, 1H).
EXAMPLE 139
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-[3--
(trifluoromethyl)phenyl]urea
[0360] The desired product was prepared by substituting Example
104B and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F, then substituting
the resulting product for Example 104C in Example 104D. m.p.
155-158.degree. C.; MS(ESI(+)) m/e 474 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 2.75-2.79 (t, J=6.9 Hz, 2H);
3.56-3.57 (m, 2H); 4.85-4.90 (m, 1H); 7.32-7.34 (d, J=8.7 Hz, 3H);
7.50-7.59 (m 2H); 7.62-7.65 (d, J=9 Hz, 2H); 8.03 (s, 1H); 8.27 (s,
1H); 9.03 (s, 1H); 9.15 (s, 1H).
EXAMPLE 140
N-{4-[4-amino-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-[2--
fluoro-5-(trifluoromethyl)phenyl]urea
[0361] The desired product was prepared by substituting Example 108
and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. m.p.
209-211.degree. C.; MS(ESI(+)) m/e 506 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 2.83-2.87 (t, J=6 Hz, 2H); 3.22 (s,
3H); 3.48-3.52 (t, J=6.3 Hz, 2H); 7.33-7.36 (d, J=8.7 Hz, 2H);
7.40-7.55 (m, 2H); 7.63-7.66 (d, J=8.4 Hz, 2H); 8.27 (s, 1H);
8.62-8.65 (dd, J=2.1, 6.9 Hz, 1H); 8.98-8.99 (d, J=2.7 Hz, 1H);
9.39 (s, 1H).
EXAMPLE 141
N-{4-[4-amino-6-(pyridin-3-ylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-
-[2-fluoro-5-(trifluoromethyl)phenyl]urea
[0362] The desired product was prepared by substituting Example
115A and 3-trifluoromethylphenyl isocyanate for Example 1A and
phenyl isocyanate, respectively, in Examples 1B-1F. MS(ESI(+)) m/e
539 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 4.04
(s, 2H); 7.29-7.33 (m, 1H); 7.38-7.44 (m, 3H), 7.48-7.57 (m, 2H);
7.65-7.68 (d, J=8.7 Hz, 2H); 8.28 (s, 1H); 8.34-8.35(d, J=1.8 Hz,
1H); 8.42-8.44 (dd, J=1.8, 4.8 Hz, 1H); 8.62-8.65 (dd, J=2.4, 7.5
Hz, 1H); 8.98-8.99 (d, J=2.7 Hz, 1H); 9.41 (s, 1H).
EXAMPLE 142
N-{4-[4-amino-6-(pyridin-4-ylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-
-[3-(trifluoromethyl)phenyl]urea
[0363] The desired product was prepared by substituting Example 14B
and 3-trifluoromethylphenyl isocyanate for Example 1A and phenyl
isocyanate, respectively, in Examples 1B-1F. m.p. 162-166.degree.
C.; MS(ESI(+)) m/e 521 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 4.04 (s, 2H); 7.15-7.16 (m, 2H); 7.32-7.37
(m, 3H), 7.50-7.66 (m, 4H); 8.03 (s, 1H); 8.29 (s, 1H); 8.38-8.54
(m, 2H); 9.03 (s, 1H); 9.14 (s, 1H).
EXAMPLE 143
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-(3-m-
ethylphenyl)urea
EXAMPLE 143A
5-(3-chlorophenyl)-6-methylthieno[2,3-d]pyrimidin-4-amine
[0364] The desired product was prepared by substituting
1-(3-chlorophenyl)propan-1-one for Example 1A in Examples 1B-1D.
MS(ESI(+)) m/e 276, 278 (M+H).sup.+.
EXAMPLE 143B
5-(3-chloro-4-nitrophenyl)-6-methylthieno[2,3-d]pyrimidin-4-amine
[0365] A 0.degree. C. suspension of Example 143A (2.13 g, 7.74
mmol) in concentrated H.sub.2SO.sub.4 (15 mL) was treated dropwise
over 3 minutes with a solution of fuming nitric acid (0.38 mL) in
concentrated H.sub.2SO.sub.4 (5 mL). The mixture was stirred for 30
minutes while warming to room temperature, poured onto ice,
adjusted to pH 7 with solid Na.sub.2CO.sub.3, and extracted with
ethyl acetate. The extract was dried (MgSO.sub.4), filtered, and
concentrated to provide 2.31 g (93% yield) of the desired product.
MS(ESI(+)) m/e 321 (M+H).sup.+.
EXAMPLE 143C
5-(4-amino-3-chlorophenyl)-6-methylthieno[2,3-d]pyrimidin-4-amine
[0366] The desired product was prepared by substituting Example
143B for Example 1D in Example 1E. MS(ESI(+)) m/e 276, 278
(M+H).sup.+.
EXAMPLE 143D
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-(3-m-
ethylphenyl)urea
[0367] The desired product was prepared by substituting Example
143C and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 424.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.30 (s,
3H); 2.31 (s, 3H); 6.83 (d, J=7.5 Hz, 1H); 7.19 (t, J=7.5 Hz, 1H);
7.24-7.29 (m, 1H); 7.32-7.34 (m, 2H); 7.53 (d, J=2.0 Hz, 1H); 8.27
(s, 1H); 8.37 (d, J=8.5 Hz, 1H); 8.46 (s, 1H); 9.45 (s, 1H).
EXAMPLE 144
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-(3,5-
-dimethylphenyl)urea
[0368] The desired product was prepared by substituting Example
143C and 3,5-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 438.1
(M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.25 (s,
6H); 2.31 (s, 3H); 6.66 (s, 1H); 7.11 (s, 2H); 7.31 (dd, J=8.4, 2.0
Hz, 1H); 7.52 (d, J=2.1 Hz, 1H); 8.28 (s, 1H); 8.37 (d, J=8.6 Hz,
1H); 8.44 (s, 1H); 9.37 (s, 1H).
EXAMPLE 145
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-[2-f-
luoro-5-(trifluoromethyl)phenyl]urea
[0369] The desired product was prepared by substituting Example
143C and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
496.0 (M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.32
(s, 3H); 7.34 (dd, J=8.6, 2.1 Hz, 1H); 7.41-7.45 (m, 1H); 7.52 (d,
J=10.7 Hz, 1H); 7.55 (d, J=2.1 Hz, 1H); 8.28 (s, 1H); 8.35 (d,
J=8.3 Hz, 1H); 8.66 (dd, J=7.4, 2.1 Hz, 1H); 9.09 (s, 1H); 9.79 (s,
1H).
EXAMPLE 146
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-(3-e-
thylphenyl)urea
[0370] The desired product was prepared by substituting Example
143C and 3-ethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 438.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.19 (t,
J=7.6 Hz, 3H); 2.31 (s, 3H); 2.60 (q, J=7.6 Hz, 2H); 6.87 (d, J=7.1
Hz, 1H); 7.22 (t, J=7.8 Hz, 1H); 7.28-7.37 (m, 3H); 7.53 (d, J=2.0
Hz, 1H); 8.27 (s, 1H); 8.37 (d, J=8.5 Hz, 1H); 8.46 (s, 1H); 9.47
(s, 1H).
EXAMPLE 147
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-[3-(-
trifluoromethyl)phenyl]urea
[0371] The desired product was prepared by substituting Example
143C and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
478.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.31
(s, 3H); 7.34 (dd, J=8.5, 2.0 Hz, 1H); 7.35-7.37 (m, 1H); 7.53-7.60
(m, 3H); 8.06 (s, 1H); 8.28 (s, 1H); 8.35 (d, J=8.5 Hz, 1H); 8.55
(s, 1H); 9.86 (s, 1H).
EXAMPLE 148
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-[4-f-
luoro-3-(trifluoromethyl)phenyl]urea
[0372] The desired product was prepared by substituting Example
143C and 4-fluoro-3-trifluromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 2.31 (s, 3H); 7.34 (dd, J=8.5, 2.0
Hz, 1H); 7.48 (app t, J=9.2 Hz, 1H); 7.55 (d, J=2.0 Hz, 1H); 7.64
(ddd, J=8.7, 3.8, 3.0 Hz, 1H); 8.04 (dd, J=6.3, 2.5 Hz, 1H); 8.28
(s, 1H); 8.33 (d, J=8.5 Hz, 1H); 8.53 (s, 1H); 9.84 (s, 1H).
EXAMPLE 149
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-(3-f-
luorophenyl)urea
[0373] The desired product was prepared by substituting Example
143C and 3-fluorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 428.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.31 (s,
3H); 6.83 (td, J=8.2, 2.2 Hz, 1H); 7.13 (ddd, J=8.2, 1.9, 0.7 Hz,
1H); 7.31-7.36 (m, 2H); 7.53 (dt, J=12.2, 2.4 Hz, 1H); 7.54 (d,
J=2.0 Hz, 1H); 8.28 (s, 1H); 8.34 (d, J=8.5 Hz, 1H); 8.53 (s, 1H);
9.73 (s, 1H).
EXAMPLE 150
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-(3,
4-dimethylphenyl)urea
[0374] The desired product was prepared by substituting Example
143C and 3,4-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 438.1
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.17 (s,
3H); 2.21 (s, 3H); 2.31 (s, 3H); 7.06 (d, J=8.1 Hz, 1H); 7.20 (dd,
J=8.5, 2.4 Hz, 1H); 7.26 (d, J=2.0 Hz, 1H); 7.31 (dd, J=8.5, 2.0
Hz, 1H); 7.52 (d, J=2.0 Hz, 1H); 8.27 (s, 1H); 8.37 (d, J=8.5 Hz,
1H); 8.42 (s, 1H); 9.35 (s, 1H).
EXAMPLE 151
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-(3-c-
hlorophenyl)urea
[0375] The desired product was prepared by substituting Example
143C and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 443.9
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.31 (s,
3H); 7.07 (ddd, J=7.7, 2.1, 1.0 Hz, 1H); 7.26 (ddd, J=8.3, 2.0, 1.2
Hz, 1H); 7.33 (d, J=8.1 Hz, 1H); 7.35 (dd, J=8.5, 5.1 Hz, 1H); 7.54
(d, J=2.0 Hz, 1H); 7.76 (t, J=2.0 Hz, 1H); 8.27 (s, 1H); 8.34 (d,
J=8.5 Hz, 1H); 8.53 (s, 1H); 9.70 (s, 1H).
EXAMPLE 152
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-(3-m-
ethylphenyl)urea
EXAMPLE 152A
5-(4-amino-3-fluorophenyl)-6-methylthieno[2,3-d]pyrimidin-4-amine
[0376] The desired product was prepared by substituting
1-(3-fluorophenyl)propan-1-one for 1-(3-chlorophenyl)propan-1-one)
in Examples 143A-C. MS (ESI(+)) m/e 275 (M+H).sup.+.
EXAMPLE 152B
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N-(3-me-
thylphenyl)urea
[0377] The desired product was prepared by substituting Example
152A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 408.1
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.30 (s,
3H); 2.31 (s, 3H); 6.83 (d, J=7.1 Hz, 1H); 7.15-7.37 (m, 5H); 8.27
(s, 1H); 8.35 (t, J=8.5 Hz, 1H); 8.73 (s, 1H); 9.08 (s, 1H).
EXAMPLE 153
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-(3,
5-dimethylphenyl)urea
[0378] The desired product was prepared by substituting Example
152A and 3,5-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 422.1
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.25 (s,
6H); 2.31 (s, 3H); 6.65 (s, 1H); 7.09 (s, 2H); 7.15 (dd, J=8.3, 1.5
Hz, 1H); 7.34 (dd, J=12.0, 1.9 Hz, 1H); 8.27 (s, 1H); 8.35 (t,
J=8.5 Hz, 1H); 8.71 (d, J=2.4 Hz, 1H); 9.01 (s, 1H).
EXAMPLE 154
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-(3-c-
hlorophenyl)urea
[0379] The desired product was prepared by substituting Example
152A and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 428.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.31 (s,
3H); 7.06 (ddd, J=7.8, 2.0, 1.0 Hz, 1H); 7.18 (dd, J=8.5, 1.4 Hz,
1H); 7.26 (ddd, J=8.1, 2.0, 1.4 Hz, 1H); 7.31-7.38 (m, 2H); 7.75
(t, J=2.0 Hz, 1H); 8.27 (s, 1H); 8.31 (t, J=8.5 Hz, 1H); 8.80 (d,
J=2.4 Hz, 1H); 9.34 (s, 1H).
EXAMPLE 155
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-[3-(-
trifluoromethyl)phenyl]urea
[0380] The desired product was prepared by substituting Example
152A and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
462.1 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.31
(s, 3H); 7.18 (d, J=8.5 Hz, 1H); 7.35-7.39 (m, 2H); 7.52-7.56 (m,
2H); 8.06 (s, 1H); 8.27 (s, 1H); 8.31 (t, J=8.5 Hz, 1H); 8.83 (s,
1H); 9.49 (s, 1H).
EXAMPLE 156
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-(3,
4-dimethylphenyl)urea
[0381] The desired product was prepared by substituting Example
152A and 3,4-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 422.1
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.17 (s,
3H); 2.21 (s, 3H); 2.31 (s, 3H); 7.05 (d, J=8.1 Hz, 1H); 7.15 (dd,
J=8.7, 1.5 Hz, 1H); 7.19 (dd, J=8.1, 2.0 Hz, 1H); 7.25 (d, J=2.0
Hz, 1H); 7.33 (dd, J=11.9, 1.7 Hz, 1H); 8.27 (s, 1H); 8.35 (t,
J=8.5 Hz, 1H); 8.68 (d, J=2.7 Hz, 1H); 8.98 (s, 1H).
EXAMPLE 157
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-(3-e-
thylphenyl)urea
[0382] The desired product was prepared by substituting Example
152A and 3-ethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 422.1
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.19 (t,
J=7.5 Hz, 3H); 2.31 (s, 3H); 2.59 (q, J=7.5 Hz, 2H); 6.86 (d, J=7.1
Hz, 1H); 7.16 (dd, J=8.1, 1.7 Hz, 1H); 7.21 (t, J=7.6 Hz, 1H);
7.33-7.35 (m, 1H); 7.34 (dd, J=11.7, 2.2 Hz, 1H); 8.27 (s, 1H);
8.35 (t, J=8.7 Hz, 1H); 8.72 (d, J=2.4 Hz, 1H); 9.10 (s, 1H).
EXAMPLE 158
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-phen-
ylurea
[0383] The desired product was prepared by substituting Example
152A for Example 1E in Example 1F. MS (ESI(+)) m/e 394.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.31 (s,
3H); 7.01 (m, 1H); 7.17 (dd, J=8.3, 1.5 Hz, 1H); 7.31 (t, J=8.5 Hz,
2H); 7.35 (dd, J=12.0, 1.9 Hz, 1H); 7.48 (dd, J=7.8, 1.0 Hz, 2H);
8.27 (s, 1H); 8.35 (t, J=8.5 Hz, 1H); 8.74 (d, J=2.7 Hz, 1H); 9.15
(s, 1H).
EXAMPLE 159
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-[2-f-
luoro-5-(trifluoromethyl)phenyl]urea
[0384] The desired product was prepared by substituting Example
152A and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
480.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.31
(s, 3H); 7.18 (dd, J=8.3, 1.5 Hz, 1H); 7.38 (dd, J=11.9, 2.0 Hz,
1H); 7.44 (dd, J=4.2, 2.2 Hz, 1H); 7.53 (dd, J=10.9, 8.8 Hz, 1H);
8.27 (s, 1H); 8.36 (t, J=8.7 Hz, 1H); 8.66 (dd, J=7.5, 2.0 Hz, 1H);
9.35 (d, J=2.0 Hz, 1H); 9.46 (d, J=2.7 Hz, 1H).
EXAMPLE 160
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-(3-f-
luorophenyl)urea
[0385] The desired product was prepared by substituting Example
152A and 3-fluorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 412.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.31 (s,
3H); 6.82 (tdd, J=8.5, 2.7, 0.7 Hz, 1H); 7.12 (ddd, J=8.2, 2.0, 0.7
Hz, 1H); 7.17 (ddd, J=8.5, 2.0, 0.7 Hz, 1H); 7.30-7.38 (m, 2H);
7.53 (dt, J=11.9, 2.4 Hz, 1H); 8.27 (s, 1H); 8.32 (t, J=8.5 Hz,
1H); 8.79 (d, J=2.7 Hz, 1H); 9.36 (s, 1H).
EXAMPLE 161
5-[4-(1,3-benzoxazol-2-ylamino)-3-fluorophenyl]-6-methylthieno[2,3-d]pyrim-
idin-4-amine
[0386] The desired product was prepared by substituting Example
152A for Example 1E in Example 3. MS (ESI(+)) m/e 392.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.33 (s,
3H); 7.17 (td, J=7.7, 1.2 Hz, 1H); 7.22-7.31 (m, 2H); 7.40 (dd,
J=11.7, 1.9 Hz, 1H); 7.50 (d, J=7.1 Hz, 1H); 7.54 (d, J=7.8 Hz,
1H); 8.28 (s, 1H); 8.51 (t, J=8.5 Hz, 1H); 10.66 (s, 1H).
EXAMPLE 162
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-methylphenyl]-N'-(3-c-
hlorophenyl)urea
EXAMPLE 162A
5-(4-amino-3-methylphenyl)-6-methylthieno[2,3-d]pyrimidin-4-amine
[0387] The desired product was prepared by substituting
3-methyl-4-nitrobenzoyl chloride for 4-nitrobenzoyl chloride in
Examples 1A-1E. MS(ESI(+)) m/e 271 (M+H).sup.+.
EXAMPLE 162B
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-methylphenyl]-N'-(3-c-
hlorophenyl)urea
[0388] The desired product was prepared by substituting Example
162A and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 424.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.30 (s,
3H); 2.32 (s, 3H); 7.04 (ddd, J=7.5, 2.0, 1.4 Hz, 1H); 7.19 (dd,
J=8.3, 2.2 Hz, 1H); 7.24-7.28 (m, 2H); 7.33 (t, J=7.8 Hz, 1H); 7.77
(t, J=2.0 Hz, 1H); 8.06 (d, J=8.1 Hz, 1H); 8.15 (s, 1H); 8.26 (s,
1H); 9.33 (s, 1H).
EXAMPLE 163
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-methylphenyl]-N'-[3-(-
trifluoromethyl)phenyl]urea
[0389] The desired product was prepared by substituting Example
162A and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
458.1 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.30
(s, 3H); 2.33 (s, 3H); 7.19 (dd, J=8.3, 1.9 Hz, 1H); 7.25 (d, J=1.7
Hz, 1H); 7.31-7.34 (m, 1H); 7.53 (t, J=8.1 Hz, 1H); 7.58 (dt,
J=8.5, 1.7 Hz, 1H); 8.04-8.08 (m, 2H); 8.18 (s, 1H); 8.27 (s, 1H);
9.49 (s, 1H).
EXAMPLE 164
N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)-2-methylphenyl]-N'-[2-f-
luoro-5-(trifluoromethyl)phenyl]urea
[0390] The desired product was prepared by substituting Example
162A and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
476.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.30
(s, 3H); 2.34 (s, 3H); 7.20 (dd, J=8.5, 2.0 Hz, 1H); 7.26 (d, J=2.0
Hz, 1H); 7.40 (ddd, J=8.8, 4.0, 2.4 Hz, 1H); 7.52 (dd, J=10.5, 8.8
Hz, 1H); 8.10 (d, J=8.5 Hz, 1H); 8.27 (s, 1H); 8.64 (s, 1H); 8.68
(dd, J=7.6, 2.2 Hz, 1H); 9.45 (d, J=2.7 Hz, 1H).
EXAMPLE 165
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-(3-chlorophe-
nyl)urea
EXAMPLE 165A
1-(3-methoxy-4-nitrophenyl)ethanone
[0391] A suspension of MgCl.sub.2 (932 mg, 9.8 mmol) in toluene (13
mL) was treated with triethylamine (4.65 mL, 33.4 mmol), dimethyl
malonate (1.9 mL, 16.6 mmol), stirred for 1.5 hours, and treated
portionwise over 30 minutes with 3-methoxy-4-nitrobenzoyl chloride
(3 g, 13.9 mmol). The reaction mixture was stirred for 45 minutes,
then carefully treated with concentrated HCl (4 mL). The layers
were separated and the organic phase was dried (Na.sub.2SO.sub.4),
filtered, and concentrated. The residue was dissolved in DMSO (11.5
mL) and water (0.5 mL), heated to reflux overnight, cooled to room
temperature, and partitioned between water and ethyl acetate. The
organic phase was washed sequentially with saturated NaHCO.sub.3,
water, and brine, dried (MgSO.sub.4), filtered, and concentrated to
provide 1.63 g (60% yield) of the desired product. MS (ESI(-)) m/e
194 (M-H).sup.-.
EXAMPLE 165B
2-[1-(3-methoxy-4-nitrophenyl)ethylidene]malononitrile
[0392] A flask equipped with a condenser and a drying tube was
charged with acetic acid (35 mL) and hexamethyldisilazane (11.2 mL,
53.1 mmol). The mixture was stirred while cooling to room
temperature, treated with Example 165A (6.89 g, 35.3 mmol) and
malononitrile (4.66 g, 70.5 mmol), stirred at 65.degree. C. for 3
hour, cooled to room temperature, stirred overnight, and
partitioned between water and toluene. The organic phase was washed
with saturated NaHCO.sub.3, water, brine, dried (MgSO.sub.4),
filtered, and concentrated. The concentrate was recrystallized from
ethanol to provide 6.11 g (71% yield) of the desired product. MS
(ESI(-)) m/e 242 (M-H).sup.-.
EXAMPLE 165C
2-amino-4-(3-methoxy-4-nitrophenyl)-3-thiophenecarbonitrile
[0393] A solution of Example 165B (6.11 g, 25.1 mmol) in THF (38
mL) was treated with sulfur powder (305 mg, 25.1 mmol) and a
solution of NaHCO.sub.3 (422 mg, 5 mmol) in water (12 mL). The
suspension was stirred at room temperature for 4 hours and filtered
to provide 4.71 g (68% yield) of the desired product. .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 3.98 (s, 3H); 6.85 (s, 1H); 7.28
(dd, J=8.53, 1.7 Hz, 1H); 7.40 (s, 2H); 7.48 (d, J=1.7 Hz, 1H);
7.97 (d, J=8.5 Hz, 1H).
EXAMPLE 165D
5-(4-amino-3-methoxyphenyl)thieno[2,3-d]pyrimidin-4-amine
[0394] The desired product was prepared by substituting Example
165C for Example 1C in Examples 1D-1E. MS(ESI(+)) m/e 273
(M+H).sup.+.
EXAMPLE 165E
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-(3-chlorophe-
nyl)urea
[0395] The desired product was prepared by substituting Example
165D and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 426.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 3.94 (s,
3H); 7.02 (dd, J=8.3, 2.0 Hz, 1H); 7.03 (ddd, J=7.8, 2.0, 1.3 Hz,
1H); 7.14 (d, J=2.0 Hz, 1H); 7.24 (ddd, J=8.3, 2.0, 1.3 Hz, 1H);
7.32 (t, J=7.8 Hz, 1H); 7.47 (s, 1H); 7.75 (t, J=2.0 Hz, 1H); 8.27
(d, J=8.1 Hz, 1H); 8.34 (s, 1H); 8.44 (s, 1H); 9.59 (s, 1H).
EXAMPLE 166
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-[3-(trifluor-
omethyl)phenyl]urea
[0396] The desired product was prepared by substituting Example
165D and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
460.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 3.94
(s, 3H); 7.02 (dd, J=8.3, 1.9 Hz, 1H); 7.15 (d, J=1.7 Hz, 1H);
7.31-7.35 (m, 1H); 7.47 (s, 1H); 7.53-7.56 (m, 2H); 8.05 (s, 1H);
8.28 (d, J=8.1 Hz, 1H); 8.34 (s, 1H); 8.46 (s, 1H); 9.75 (s,
1H).
EXAMPLE 167
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-[2-fluoro-5--
(trifluoromethyl)phenyl]urea
[0397] The desired product was prepared by substituting Example
165D and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
478.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 3.94
(s, 3H); 7.02 (dd, J=8.3, 1.9 Hz, 1H); 7.15 (d, J=1.7 Hz, 1H); 7.39
(m, 1H); 7.51 (m, 2H); 8.28 (d, J=8.5 Hz, 1H); 8.34 (s, 1H); 8.68
(dd, J=7.1, 2.0 Hz, 1H); 9.08 (s, 1H); 9.65 (d, J=2.7 Hz, 1H).
EXAMPLE 168
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-(2-fluoro-5--
methylphenyl)urea
[0398] The desired product was prepared by substituting Example
165D and 2-fluoro-5-methylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
424.1 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) d 2.28 (s,
3H); 3.93 (s, 3H); 6.78-6.83 (m, 1H); 7.01 (dd, J=8.3, 1.9 Hz, 1H);
7.07-7.15 (m, 2H); 7.47 (s, 1H); 8.02 (dd, J=8.1, 2.0 Hz, 1H); 8.28
(d, J=8.5 Hz, 1H); 8.34 (s, 1H); 8.92 (s, 1H); 9.24 (d, J=2.0 Hz,
1H).
EXAMPLE 169
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-(4-chloro-3--
methylphenyl)urea
[0399] The desired product was prepared by substituting Example
165D and 4-chloro-3-methylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
440.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.27
(s, 3H); 3.93 (s, 3H); 7.01 (dd, J=8.3, 1.9 Hz, 1H); 7.13 (d, J=2.0
Hz, 1H); 7.16 (dd, J=8.1, 2.0 Hz, 1H); 7.26 (d, J=8.5 Hz, 1H); 7.46
(s, 1H); 7.73 (d, J=2.0 Hz, 1H); 8.26 (d, J=8.1 Hz, 1H); 8.34 (s,
1H); 8.39 (s, 1H); 9.47 (s, 1H).
EXAMPLE 170
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-(4-bromo-3-m-
ethylphenyl)urea
[0400] The desired product was prepared by substituting Example
165D and 4-bromo-3-methylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
483.9, 485.9, (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 2.33 (s, 3H); 3.93 (s, 3H); 7.01 (dd, J=8.3, 1.9 Hz, 1H);
7.13 (d, J=1.7 Hz, 1H); 7.26 (dd, J=8.8, 2.7 Hz, 1H); 7.45-7.48 (m,
3H); 8.27 (d, J=8.1 Hz, 1H); 8.34 (s, 1H); 8.41 (s, 1H); 9.45 (s,
1H).
EXAMPLE 171
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-(4-chloro-3--
methoxyphenyl)urea
[0401] The desired product was prepared by substituting Example
165D and 4-chloro-3-methoxyphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
456.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 3.82
(s, 3H); 3.93 (s, 3H); 7.01 (dd, J=8.3, 1.9 Hz, 1H); 7.10 (d, J=9.1
Hz, 1H); 7.13 (d, J=1.7 Hz, 1H); 7.24 (dd, J=8.8, 2.7 Hz, 1H); 7.46
(s, 1H); 7.69 (d, J=2.4 Hz, 1H); 8.26 (d, J=8.5 Hz, 1H); 8.34 (app
s, 2H); 9.36 (s, 1H).
EXAMPLE 172
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-methoxyphenyl]-N'-(3-methylphe-
nyl)urea
[0402] The desired product was prepared by substituting Example
165D and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 406.1
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.29 (s,
3H); 3.94 (s, 3H); 6.80 (d, J=7.5 Hz, 1H); 7.01 (dd, J=8.3, 1.7 Hz,
1H); 7.12 (d, J=1.7 Hz, 1H); 7.17 (t, J=7.8 Hz, 1H); 7.24 (d, J=8.5
Hz, 1H); 7.32 (s, 1H); 7.46 (s, 1H); 8.29 (d, J=8.5 Hz, 1H); 8.34
(s, 1H); 8.38 (s, 1H); 9.31 (s, 1H).
EXAMPLE 173
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-[2-fluoro-5-(-
trifluoromethyl)phenyl]urea
EXAMPLE 173A
5-(4-amino-3-fluorophenyl)thieno[2,3-d]pyrimidin-4-amine
[0403] The desired product was prepared by substituting
1-(3-fluorophenyl)propan-1-one for 1-(3-chlorophenyl)propan-1-one
Examples 143A-C. MS(ESI(+)) m/e 261 (M+H).sup.+.
EXAMPLE 173B
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-[2-fluoro-5-(-
trifluoromethyl)phenyl]urea
[0404] The desired product was prepared by substituting Example
173A and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
466.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.27
(dd, J=8.7, 1.5 Hz, 1H); 7.40-7.45 (m, 2H); 7.51 (s, 1H); 7.53 (dd,
J=10.5, 9.2 Hz, 1H); 8.33 (t, J=8.5 Hz, 1H); 8.34 (s, 1H); 8.66
(dd, J=7.1, 2.4 Hz, 1H); 9.33 (d, J=1.7 Hz, 1H); 9.45 (d, J=2.4 Hz,
1H).
EXAMPLE 174
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-[3-(trifluoro-
methyl)phenyl]urea
[0405] The desired product was prepared by substituting Example
173A and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
447.9 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.26
(dd, J=8.5, 1.4 Hz, 1H); 7.34-7.37 (m, 1H); 7.41 (dd, J=12.2, 2.0
Hz, 1H); 7.51 (s, 1H); 7.54-7.58 (m, 2H); 8.06 (s, 1H); 8.29 (t,
J=8.3 Hz, 1H); 8.34 (s, 1H); 8.81 (d, J=2.7 Hz, 1H); 9.47 (s,
1H).
EXAMPLE 175
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-fluorophenyl]-N'-(3-methylphen-
yl)urea
[0406] The desired product was prepared by substituting Example
173A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 394.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.30 (s,
3H); 6.83 (d, J=7.1 Hz, 1H); 7.18 (t, J=7.6 Hz, 1H); 7.23-7.27 (m,
2H); 7.32 (br. s, 1H); 7.39 (dd, J=12.0, 1.9 Hz, 1H); 7.49 (s, 1H);
8.30 (d, J=8.5 Hz, 1H); 8.34 (s, 1H); 8.70 (d, J=2.7 Hz, 1H); 9.06
(s, 1H).
EXAMPLE 176
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-(3-methylphen-
yl)urea
EXAMPLE 176A
2-amino-4-(3-chlorophenyl)-3-thiophenecarbonitrile
[0407] The desired product was prepared by substituting
1-(3-chlorophenyl)ethanone for Example 165A in Examples 165B-C. MS
(ESI(+)) m/e 233 (M-H).sup.-.
EXAMPLE 176B
5-(3-chlorophenyl)thieno[2,3-d]pyrimidin-4-amine
[0408] The desired product was prepared by substituting Example
176A for Example 1C in Example 1D.
EXAMPLE 176C
5-(4-amino-3-chlorophenyl)thieno[2,3-d]pyrimidin-4-amine
[0409] The desired product was prepared by substituting Example
176B for Example 143A in Examples 143B and 143C.
EXAMPLE 176D
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-(3-methylphen-
yl)urea
[0410] The desired product was prepared by substituting Example
176C and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 409.9
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.30 (s,
3H); 6.83 (d, J=7.1 Hz, 1H); 7.19 (app t, J=7.6 Hz, 1H); 7.26 (d,
J=8.1 Hz, 1H); 7.33 (s, 1H); 7.39 (dd, J=8.7, 2.2 Hz, 1H); 7.52 (s,
1H); 7.58 (d, J=2.0 Hz, 1H); 8.34 (d, J=8.8 Hz, 1H); 8.34 (s, 1H);
8.44 (s, 1H); 9.43 (s, 1H).
EXAMPLE 177
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-[2-fluoro-5-(-
trifluoromethyl)phenyl]urea
[0411] The desired product was prepared by substituting Example
176C and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
481.9 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.42
(dd, J=8.5, 2.0 Hz, 1H); 7.41-7.45 (m, 1H); 7.50-7.57 (m, 2H); 7.61
(d, J=2.0 Hz, 1H); 8.32 (d, J=8.8 Hz, 1H); 8.35 (s, 1H); 8.66 (dd,
J=7.6, 2.2 Hz, 1H); 9.08 (s, 1H); 9.78 (d, J=2.0 Hz, 1H).
EXAMPLE 178
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]-N'-[3-(trifluoro-
methyl)phenyl]urea
[0412] The desired product was prepared by substituting Example
176C and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
463.9 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
7.34-7.38 (m, 1H); 7.41 (dd, J=8.5, 2.0 Hz, 1H); 7.53 (s, 1H);
7.55-7.59 (m, 2H); 7.61 (d, J=2.0 Hz, 1H); 8.06 (s, 1H); 8.32 (d,
J=8.5 Hz, 1H); 8.35 (s, 1H); 8.54 (s, 1H); 9.83 (s, 1H).
EXAMPLE 179
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylbutyl)urea
[0413] A 0.degree. C. solution of Example 58D (150 mg, 0.62 mmol)
in THF (5 mL) was treated with triethylamine (0.09 mL) and
4-nitrophenyl chloroformate (137 mg, 0.68 mmol), stirred at
0.degree. C. for 1 hour, treated with 3-methylbutylamine (0.145 mL,
1.2 mmol) and triethylamine (0.09 mL), warmed to room temperature,
and stirred overnight. The reaction mixture was concentrated and
the residue was purified by preparative HPLC on a Waters Symmetry
C8 column (25 mm.times.100 mm, 7 .mu.m particle size) using a
gradient of 10% to 100% acetonitrile:0.1% aqueous TFA over 8
minutes (10 minute run time) at a flow rate of 40 mL/minute to
provide 24 mg (11% yield) of the desired product. MS (ESI(+)) m/e
356.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.90
(d, J=6.4 Hz, 6H); 1.34 (q, J=6.9 Hz, 2H); 1.57-1.66 (m, 1H); 3.12
(q, J=6.4 Hz, 2H); 6.16 (t, J=5.8 Hz, 1H); 7.32 (d, J=8.8 Hz, 2H);
7.39 (s, 1H); 7.53 (d, J=8.8 Hz, 2H); 8.33 (s, 1H); 8.60 (s,
1H).
EXAMPLE 180
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-ethylbutyl)urea
[0414] The desired product was prepared by substituting
2-ethylbutylamine for 3-methylbutylamine in Example 179. MS
(ESI(+)) m/e 370.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 0.81-0.90 (m, 6H); 1.25-1.33 (m, 5H); 3.07 (t, J=5.7 Hz,
2H); 6.19 (t, J=5.7 Hz, 1H); 7.32 (d, J=8.8 Hz, 2H); 7.39 (s, 1H);
7.53 (d, J=8.8 Hz, 2H); 8.33 (s, 1H); 8.60 (s, 1H).
EXAMPLE 181
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-N'-(3-methylphen-
yl)urea
EXAMPLE 181A
5-(4-amino-2-fluorophenyl)thieno[2,3-d]pyrimidin-4-amine
[0415] The desired product was prepared by substituting
2-fluoro-4-nitrobenzoyl chloride for 3-methoxy-4-nitrobenzoyl
chloride in Examples 165A-D. MS (ESI(+)) m/e 260.9 (M+H).sup.+.
EXAMPLE 181B
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-N'-(3-methylphen-
yl)urea
[0416] The desired product was prepared by substituting Example
181A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 394.0
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 2.29 (s,
3H); 6.82 (d, J=7.5 Hz, 1H); 7.18 (t, J=7.8 Hz, 1H); 7.25 (d,
J=10.0 Hz, 1H); 7.27 (dd, J=8.6, 2.0 Hz, 1H); 7.32 (s, 1H); 7.37
(t, J=8.4 Hz, 1H); 7.52 (s, 1H); 7.66 (dd, J=12.6, 2.0 Hz, 1H);
8.34 (s, 1H); 8.75 (s, 1H); 9.09 (s, 1H).
EXAMPLE 182
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-N-[2-fluoro-5-(t-
rifluoromethyl)phenyl]urea
[0417] The desired product was prepared by substituting Example
181A and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
466.0 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 7.28
(dd, J=8.4, 2.2 Hz, 1H); 7.40 (t, J=8.4 Hz, 1H); 7.40-7.43 (m, 1H);
7.50 (d, J=10.6 Hz, 1H); 7.52 (s, 1H); 7.66 (dd, J=12.2, 1.9 Hz,
1H); 8.33 (s, 1H); 8.58 (dd, J=7.5, 2.2 Hz, 1H); 9.04 (s, 1H); 9.57
(s, 1H).
EXAMPLE 183
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-N'-[3-(trifluoro-
methyl)phenyl]urea
[0418] The desired product was prepared by substituting Example
181A and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
448.0 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 7.31
(dd, J=8.4, 2.2 Hz, 1H); 7.33 (d, J=7.8 Hz, 1H); 7.38 (t, J=8.4 Hz,
1H); 7.52 (s, 1H); 7.53 (t, J=8.1 Hz, 1H); 7.61 (d, J=8.4 Hz, 1H);
7.65 (dd, J=12.3, 2.0 Hz, 1H); 8.01 (s, 1H); 8.33 (s, 1H); 9.20 (s,
1H); 9.22 (s, 1H).
EXAMPLE 184
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-N'-(2-fluoro-5-m-
ethylphenyl)urea
[0419] The desired product was prepared by substituting Example
181A and 2-fluoro-5-methylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
412.0 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 2.27
(s, 3H); 6.83 (ddd, J=8.4, 4.7, 1.6 Hz, 1H); 7.11 (dd, J=11.4, 8.3
Hz, 1H); 7.24 (dd, J=8.5, 1.9 Hz, 1H); 7.37 (t, J=8.5 Hz, 1H); 7.51
(s, 1H); 7.66 (dd, J=12.3, 2.0 Hz, 1H); 7.94 (dd, J=8.0, 1.7 Hz,
1H); 8.33 (s, 1H); 8.62 (s, 1H); 9.47 (s, 1H).
EXAMPLE 185
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-N'-(3-chlorophen-
yl)urea
[0420] The desired product was prepared by substituting Example
181A and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(-)) m/e 412.0
(M-H).sup.-; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 7.04 (td,
J=4.4, 2.2 Hz, 1H); 7.28-7.33 (m, 3H); 7.37 (t, J=8.4 Hz, 1H); 7.51
(s, 1H); 7.64 (dd, J=12.3, 2.0 Hz, 1H); 7.71 (s, 1H); 8.33 (s, 1H);
9.06 (s, 1H); 9.20 (s, 1H).
EXAMPLE 186
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-N'-(3,
5-dimethylphenyl)urea
[0421] The desired product was prepared by substituting Example
181A and 3,5-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 408.0
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 2.23 (s,
6H); 6.64 (s, 1H); 7.08 (s, 2H); 7.25 (dd, J=8.4, 2.2 Hz, 1H); 7.36
(t, J=8.4 Hz, 1H); 7.50 (s, 1H); 7.65 (dd, J=12.5, 2.2 Hz, 1H);
8.32 (s, 1H); 8.67 (s, 1H); 9.08 (s, 1H).
EXAMPLE 187
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-N'-(4-chloro-3-m-
ethylphenyl)urea
[0422] The desired product was prepared by substituting Example
181A and 4-chloro-3-methylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(-)) m/e
426.0 (M-H).sup.-; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 2.27
(s, 3H); 7.23 (dd, J=8.3, 2.0 Hz, 1H); 7.26 (d, J=8.4 Hz, 1H); 7.29
(dd, J=8.3, 2.0 Hz, 1H); 7.38 (t, J=8.4 Hz, 1H); 7.52 (s, 1H); 7.64
(dd, J=12.2, 1.9 Hz, 1H); 7.70 (d, J=1.9 Hz, 1H); 8.34 (s, 1H);
8.97 (s, 1H); 9.19 (s, 1H).
EXAMPLE 188
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-fluorophenyl]-N'-(3-cyanopheny-
l)urea
[0423] The desired product was prepared by substituting Example
181A and 3-cyanophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(-)) m/e 403.0
(M-H).sup.-; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 7.32 (dd,
J=8.4, 2.2 Hz, 1H); 7.40 (t, J=8.4 Hz, 1H); 7.45 (ddd, J=7.6, 1.3,
1.1 Hz, 1H); 7.52 (t, J=8.0 Hz, 1H); 7.53 (s, 1H); 7.65 (dd,
J=12.3, 2.0 Hz, 1H); 7.71 (ddd, J=8.1, 2.2, 0.9 Hz, 1H); 7.99 (s,
1H); 8.34 (s, 1H); 9.19 (s, 1H); 9.28 (s, 1H).
EXAMPLE 189
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methylbenzyl)urea
[0424] The desired product was prepared substituting
2-methylbenzylamine for 3-methylbutylamine in Example 179. MS
(ESI(+)) m/e 390.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 2.31 (s, 3H); 4.30 (d, J=5.4 Hz, 2H); 6.58 (t, J=5.6 Hz,
1H); 7.17-7.19 (m, 3H); 7.25-7.29 (m, 1H); 7.33 (d, J=8.5 Hz, 2H);
7.39 (s, 1H); 7.55 (d, J=8.5 Hz, 2H); 8.33 (s, 1H); 8.73 (s,
1H).
EXAMPLE 190
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-butylurea
[0425] The desired product was prepared substituting butylamine for
3-methylbutylamine in Example 179. MS (ESI(+)) m/e 342.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.90 (t,
J=7.1 Hz, 3H); 1.26-1.47 (m, 4H); 3.10 (q, J=6.4 Hz, 2H); 6.20 (t,
J=5.3 Hz, 1H); 7.32 (d, J=8.8 Hz, 2H); 7.43 (s, 1H); 7.54 (d, J=8.8
Hz, 2H); 8.36 (s, 1H); 8.61 (s, 1H).
EXAMPLE 191
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methylbutyl)urea
[0426] The desired product was prepared substituting
2-methylbutylamine for 3-methylbutylamine in Example 179. MS
(ESI(+)) m/e 356.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 0.87 (d, J=6.8 Hz, 3H); 0.88 (t, J=7.8 Hz, 3H); 1.05-1.19
(m, 1H); 1.32-1.57 (m, 2H); 2.89-2.98 (m, 1H); 3.01-3.10 (m, 1H);
6.23 (t, J=5.9 Hz, 1H); 7.32 (d, J=8.5 Hz, 2H); 7.39 (s, 1H); 7.53
(d, J=8.5 Hz, 2H); 8.32 (s, 1H); 8.60 (s, 1H).
EXAMPLE 192
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methoxy-1-methyleth-
yl)urea
[0427] The desired product was prepared substituting
1-methyl-2-methoxyethylamine for 3-methylbutylamine in Example 179.
MS (ESI(+)) m/e 358.0 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 1.10 (d, J=6.8 Hz, 3H); 3.25-3.37 (m, 2H);
3.30 (s, 3H); 3.82-3.90 (m, 1H); 6.16 (d, J=8.1 Hz, 1H); 7.32 (d,
J=8.5 Hz, 2H); 7.40 (s, 1H); 7.52 (d, J=8.5 Hz, 2H); 8.34 (s, 1H);
8.65 (s, 1H).
EXAMPLE 193
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylbenzyl)urea
[0428] The desired product was prepared substituting
3-methylbenzylamine for 3-methylbutylamine in Example 179. MS
(ESI(+)) m/e 390.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 2.30 (s, 3H); 4.28 (d, J=5.8 Hz, 2H); 6.67 (t, J=6.1 Hz,
1H); 7.05-7.13 (m, 3H); 7.23 (t, J=7.3 Hz, 1H); 7.34 (d, J=8.8 Hz,
2H); 7.42 (s, 1H); 7.56 (d, J=8.8 Hz, 2H); 8.35 (s, 1H); 8.77 (s,
1H).
EXAMPLE 194
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[4-(dimethylamino)phen-
yl]urea
[0429] The desired product was prepared as the TFA salt by
substituting 4-N,N-dimethyl aniline for 3-methylbutylamine in
Example 179. MS (ESI(+)) m/e 405.0 (M+H).sup.+; .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 2.84 (s, 6H); 6.71 (d, J=9.2 Hz, 2H);
7.27 (d, J=9.2 Hz, 2H); 7.37 (d, J=8.8 Hz, 2H); 7.42 (s, 1H); 7.59
(d, J=8.8 Hz, 2H); 8.33 (s, 1H); 8.37 (s, 1H); 8.74 (s, 1H).
EXAMPLE 195
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-hydroxyphenyl)urea
[0430] The desired product was prepared as the TFA salt by
substituting 3-hydroxyaniline for 3-methylbutylamine in Example
179. MS (ESI(+)) m/e 378.0 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 6.39 (dd, J=8.1, 2.4 Hz, 1H); 6.81 (dd,
J=7.6, 1.5 Hz, 1H); 7.00-7.08 (m, 2H); 7.39 (d, J=8.5 Hz, 2H); 7.47
(s, 1H); 7.60 (d, J=8.5 Hz, 2H); 8.38 (s, 1H); 8.65 (s, 1H); 8.83
(s, 1H); 9.34 (s, 1H).
EXAMPLE 196
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-isobutylurea
[0431] The desired product was prepared substituting
2-methylpropylamine for 3-methylbutylamine in Example 179. MS
(ESI(+)) m/e 342.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 0.88 (d, J=6.4 Hz, 6H); 1.66-1.75 (m, 1H); 2.94 (app t,
J=6.3 Hz, 2H); 6.26 (t, J=5.9 Hz, 1H); 7.33 (d, J=8.5 Hz, 2H); 7.44
(s, 1H); 7.54 (d, J=8.5 Hz, 2H); 8.38 (s, 1H); 8.62 (s, 1H).
EXAMPLE 197
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-chlorophenyl]-N'-[3-(trifluoro-
methyl)phenyl]urea
EXAMPLE 197A
2-amino-4-(2-chloro-4-nitrophenyl)-3-thiophenecarbonitrile
[0432] The desired product was prepared substituting
2-chloro-4-nitrobenzoyl chloride for 3-methoxy-4-nitrobenzoyl
chloride in Examples 165A-C. MS (ESI(+)) m/e 277.9 (M+H).sup.+.
EXAMPLE 197B
5-(2-chloro-4-nitrophenyl)thieno[2,3-d]pyrimidin-4-amine
[0433] A suspension of Example 197A (3.95 g, 141.1 mmol) in
triethylorthoformate (50 mL) was treated with ammonium sulfate (186
mg, 1.4 mmol), heated to reflux for 4 hours, cooled to room
temperature, treated with 2M ammonia in ethanol (100 mL), stirred
for 2 hours, and filtered. The filter cake (2.6 g) was suspended in
o-dichlorobenzene (30 mL) and heated to reflux until all the
material dissolved (about 2 hours). The solution of was cooled to
room temperature and filtered. The filter cake was dried to provide
2.14 g of the desired product. MS (ESI(+)) m/e 306.9, 308.9
(M+H).sup.+.
EXAMPLE 197C
5-(4-amino-2-chlorophenyl)thieno[2,3-d]pyrimidin-4-amine
[0434] The desired product was prepared by substituting Example
197B for Example 1D in Example 1E. MS (ESI(+)) m/e 277, 279
(M+H).sup.+.
EXAMPLE 197D
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-chlorophenyl]-N'-[3-(trifluoro-
methyl)phenyl]urea
[0435] The desired product was prepared by substituting Example
197C and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
463.9, 465.9 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 7.35 (d, J=7.5 Hz, 1H); 7.43 (d, J=8.1 Hz, 1H); 7.47 (dd,
J=8.5, 2.0 Hz, 1H); 7.49 (s, 1H); 7.54 (t, J=8.1 Hz, 1H); 7.62 (d,
J=8.5 Hz, 1H); 7.91 (d, J=1.7 Hz, 1H); 8.03 (br. s, 1H); 8.34 (s,
1H); 9.20 (s, 1H); 9.22 (s, 1H).
EXAMPLE 198
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-chlorophenyl]-N'-(3-chlorophen-
yl)urea
[0436] The desired product was prepared by substituting Example
197C and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 429.9,
431.9 (M+H).sup.+, .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
7.04-7.07 (m, 1H); 7.31-7.33 (m, 2H); 7.42-7.44 (m, 2H); 7.49 (s,
1H); 7.72 (dd, J=2.7, 1.7 Hz, 1H); 7.90 (d, J=1.0 Hz, 1H); 8.33 (s,
1H); 9.05 (s, 1H); 9.16 (s, 1H).
EXAMPLE 199
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-chlorophenyl]-N'-[2-fluoro-5-(-
trifluoromethyl)phenyl]urea
[0437] The desired product was prepared by substituting Example
197C and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
481.9, 483.9 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 7.40-7.47 (m, 3H); 7.50 (s, 1H); 7.51-7.58 (m, 1H); 7.92
(d, J=1.4 Hz, 1H); 8.34 (s, 1H); 8.59 (dd, J=7.5, 2.0 Hz, 1H); 9.03
(d, J=2.7 Hz, 1H); 9.52 (s, 1H).
EXAMPLE 200
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-chlorophenyl]-N'-(3-methylphen-
yl)urea
[0438] The desired product was prepared by substituting Example
197C and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 409.9,
411.9 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.29
(s, 3H); 6.82 (d, J=7.5 Hz, 1H); 7.18 (t, J=7.5 Hz, 1H); 7.23-7.26
(m, 1H); 7.31-7.34 (br. s, 1H); 7.41-7.42 (m, 2H); 7.49 (s, 1H);
7.91 (br. s, 1H); 8.33 (s, 1H); 8.75 (s, 1H); 9.05 (s, 1H).
EXAMPLE 201
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-methoxyphenyl]-N'-(3-methylphe-
nyl)urea
EXAMPLE 201A
5-(4-amino-2-methoxyphenyl)thieno[2,3-d]pyrimidin-4-amine
[0439] The desired product was prepared by substituting
2-methoxy-4-nitrobenzoyl chloride for 3-methoxy-4-nitrobenzoyl
chloride in Examples 165A-D. MS (ESI(+)) m/e 273 (M+H).sup.+.
EXAMPLE 201B
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-methoxyphenyl]-N'-(3-methylphe-
nyl)urea
[0440] The desired product was prepared by substituting Example
201A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 406.0 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.29 (s, 3H); 3.72 (s,
3H); 6.81 (d, J=7.1 Hz, 1H); 7.05 (dd, J=8.1, 2.0 Hz, 1H);
7.14-7.25 (m, 3H); 7.34 (s, 1H); 7.38 (s, 1H); 7.50 (d, J=2.0 Hz,
1H); 8.36 (s, 1H); 8.67 (s, 1H); 8.93 (s, 1H).
EXAMPLE 202
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-methoxyphenyl]-N'-[3-(trifluor-
omethyl)phenyl]urea
[0441] The desired product was prepared by substituting Example
201A and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
460.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 3.72
(s, 3H); 7.08 (dd, J=8.3, 1.9 Hz, 1H); 7.23 (d, J=8.1 Hz, 1H);
7.32-7.35 (m, 2H); 7.49 (d, J=2.0 Hz, 1H); 7.53 (t, J=8.0 Hz, 1H);
7.60 (d, J=8.5 Hz, 1H); 8.04 (s, 1H); 8.32 (s, 1H); 9.05 (s, 1H);
9.12 (s, 1H).
EXAMPLE 203
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-methoxyphenyl]-N'-(3-chlorophe-
nyl)urea
[0442] The desired product was prepared by substituting Example
201A and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 425.9
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 3.72 (s,
3H); 7.04 (dt, J=6.7, 2.0 Hz, 1H); 7.07 (dd, J=8.1, 2.0 Hz, 1H);
7.23 (d, J=8.1 Hz, 1H); 7.27-7.35 (m, 2H); 7.39 (s, 1H); 7.49 (d,
J=1.7 Hz, 1H); 7.75 (t, J=2.0 Hz, 1H); 8.36 (s, 1H); 9.00 (s, 1H);
9.06 (s, 1H).
EXAMPLE 204
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-methoxyphenyl]-N'-[2-fluoro-5--
(trifluoromethyl)phenyl]urea
[0443] The desired product was prepared by substituting Example
201A and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
478.0 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 3.74
(s, 3H); 7.06 (dd, J=8.1, 2.0 Hz, 1H); 7.24 (d, J=8.1 Hz, 1H); 7.35
(s, 1H); 7.42 (ddd, J=8.5, 4.4, 2.4 Hz, 1H); 7.47 (d, J=2.0 Hz,
1H); 7.52 (dd, J=10.5, 8.8 Hz, 1H); 8.31 (s, 1H); 8.62 (dd, J=7.3,
2.2 Hz, 1H); 8.96 (d, J=3.0 Hz, 1H); 9.43 (s, 1H).
EXAMPLE 205
N-[5-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-pyridinyl]-N'-(3-methylphenyl)-
urea
EXAMPLE 205A
5-(6-chloro-3-pyridinyl)thieno[2,3-d]pyrimidin-4-amine
[0444] The desired product was prepared by substituting
6-chloronicotinoyl chloride for 3-methoxy-4-nitrobenzoyl chloride
in Examples 197A-B. MS (ESI(+)) m/e 263 (M+H).sup.+.
EXAMPLE 205B
5-(6-amino-3-pyridinyl)thieno[2,3-d]pyrimidin-4-amine
[0445] A solution of Example 205A (1.64 g, 6.25 mmol) in dioxane
(75 mL) and NH.sub.4OH (75 mL) was heated to 175.degree. C. in a
sealed tube for 2.5 days. The crude solution was filtered and the
filtrate was concentrated under a stream of nitrogen. The residue
was purified by silica gel chromatography with 3 to 5%
methanol/dichloromethane to provide 0.69 g (45% yield) of Example
205B as a yellow solid. MS (ESI(+)) m/e 244 (M+H).sup.+.
EXAMPLE 205C
N-[5-(4-aminothieno[2,3-d]pyrimidin-5-yl)-2-pyridinyl]-N'-(3-methylphenyl)-
urea
[0446] The desired product was prepared by substituting Example
205B and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 377.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.30 (s,
3H); 6.85 (d, J=7.5 Hz, 1H); 7.20 (t, J=7.5 Hz, 1H); 7.35 (d, J=8.1
Hz, 1H); 7.37 (s, 1H); 7.54 (s, 1H); 7.62 (d, J=8.5 Hz, 1H); 7.83
(dd, J=8.5, 2.4 Hz, 1H); 8.35 (s, 1H); 8.39 (d, J=2.4 Hz, 1H); 9.60
(s, 1H); 10.42 (s, 1H).
EXAMPLE 206
N-{4-[4-amino-6-(3-hydroxypropyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3-
-methylphenyl)urea
[0447] The desired product was prepared by substituting
tert-butyl(4-iodobutoxy)dimethylsilane) for
tert-butyl(3-iodopropoxy)dimethylsilane) in Examples 104A-D. MS
(ESI(+)) m/e 434 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 1.70 (m, 2H); 2.29 (s, 3H); 2.68 (m, J=6.27 Hz, 2H); 3.37
(t, J=6.27 Hz, 2H); 6.81 (d, J=7.80 Hz, 1H); 7.17 (t, J=7.63 Hz,
1H); 7.23-7.33 (m, 4H); 7.62 (d, J=8.81 Hz, 2H); 8.27 (s, 1H); 8.69
(s, 1H); 8.90 (s, 1H).
EXAMPLE 207
N-{4-[4-amino-6-(3-hydroxypropyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-[3-
-(trifluoromethyl)phenyl]urea
[0448] The desired product was prepared by substituting
tert-butyl(4-iodobutoxy)dimethylsilane) and 3-trifluoromethylphenyl
isocyanate for tert-butyl(3-iodopropoxy)dimethylsilane) and
3-methylphenyl isocyanate, respectively, in Examples 104A-D. MS
(ESI(+)) m/e 488 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 1.70 (m, 2H); 2.68 (t, J=7.5 Hz, 2H); 3.37 (q, J=6.0 Hz,
2H); 4.48 (t, J=5.09 Hz, 1H); 7.32 (m, 3H); 7.29-7.35 (t, J=7.97
Hz, 1H); 7.58-7.67 (m, 3H); 8.03 (s, 1H); 8.27 (s, 1H); 9.03 (s,
1H); 9.15 (s, 1H).
EXAMPLE 208
N-{4-[4-amino-6-(3-hydroxypropyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3-
-chlorophenyl)urea
[0449] The desired product was prepared by substituting
tert-butyl(4-iodobutoxy)dimethylsilane) and 3-chloromethylphenyl
isocyanate for tert-butyl(3-iodopropoxy)dimethylsilane) and
3-methylphenyl isocyanate respectively, in Examples 104A-D. MS
(ESI(+)) m/e 454 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 1.71 (m, 2H); 2.68 (t, J=6.0 Hz, 2H); 3.37 (m, 1H); 4.48
(t, J=6.0 Hz, 1H); 7.04 (m, 1H); 7.31 (m, 4H); 7.63 (d, J=8.48 Hz,
2H); 7.73 (t, J=1.86 Hz, 1H); 8.26 (s, 1H); 8.98 (s, 2H).
EXAMPLE 209
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-fluorophenyl)urea
[0450] The desired product was prepared by substituting Example 58D
and 3-fluorophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 380 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 6.80 (m, 1H); 7.14 (m,
J=7.29, 1H); 7.32 (m, 1H); 7.40 (m, 3H); 7.51 (m, 1H); 7.60 (m,
2H); 8.34 (s, 1H); 8.96 (s, 1H); 8.99 (s, 1H).
EXAMPLE 210
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-cyanophenyl)urea
[0451] The desired product was prepared by substituting Example 58D
and 3-cyanophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 3878 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.38-7.47 (m, 3H); 7.51
(t, J=7.80 Hz, 2H); 7.62 (d, J=8.82 Hz, 2H); 7.71 (m, 1H); 7.99 (s,
1H); 8.34 (s, 1H); 9.06 (s, 1H); 9.10 (s, 1H).
EXAMPLE 211
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,
5-dimethylphenyl)urea
[0452] The desired product was prepared by substituting Example 58D
and 3,5-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 390
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 6.63 (s,
1H); 7.09 (s, 2H); 7.39 (d, J=8.48 Hz, 2H); 7.43 (s, 1H); 7.60 (d,
J=8.82 Hz, 2H); 8.34 (s, 1H); 8.58 (s, 1H); 8.84 (s, 1H).
EXAMPLE 212
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-bromophenyl)urea
[0453] The desired product was prepared by substituting Example 58D
and 3-bromophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 440, 442 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.17 (d, J=7.80 Hz,
1H); 7.25 (t, J=7.80 Hz, 1H); 7.34 (m, 1H); 7.40 (d, J=8.48 Hz,
2H); 7.44 (s, 1H); 7.61 (d, J=8.82 Hz, 2H); 7.87 (t, J=1.87 Hz,
1H); 8.34 (s, 1H); 8.95 (s, 1H); 8.97 (s, 1H).
EXAMPLE 213
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,
4-dimethylphenyl)urea
[0454] The desired product was prepared by substituting Example 58D
and 3,4-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 390
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.16 (s,
3H); 2.20 (s, 3H); 7.03 (d, J=8.14 Hz, 1H); 7.18 (m, 1H); 7.24 (s,
1H); 7.38 (d, J=8.81 Hz, 2H); 7.43 (s, 1H); 7.60 (d, J=8.48 Hz,
2H); 8.34 (s, 1H); 8.55 (s, 1H); 8.82 (s, 1H).
EXAMPLE 214
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-2,3-dihydro-1H-inden-5-
-ylurea
[0455] The desired product was prepared by substituting Example 58D
and 5-isocyanatoindane for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 402 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.00 (m, 2H); 2.82 (m,
4H); 7.14 (m, 2H); 7.38 (d, J=8.82 Hz, 2H); 7.40 (s, 1H); 7.43 (s,
1H); 7.60 (d, J=8.48 Hz, 2H); 8.34 (s, 1H); 8.60 (s, 1H); 8.83 (s,
1H).
EXAMPLE 215
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-bromo-3-methylpheny-
l)urea
[0456] The desired product was prepared by substituting Example 58D
and 4-bromo-3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 454, 456
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.32 (s,
3H); 7.28 (m, 1H); 7.39 (d, J=8.82 Hz, 2H); 7.43 (s, 1H); 7.47 (m,
2H); 7.61 (d, J=8.48 Hz, 2H); 8.34 (s, 1H); 8.81 (s, 1H); 8.92 (s,
1H).
EXAMPLE 216
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-fluorophenyl)urea
[0457] The desired product was prepared by substituting Example 58D
and 4-fluorophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 380 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.13 (t, J=8.81 Hz,
2H); 7.39 (d, J=8.81 Hz, 2H); 7.43 (s, 1H); 7.48 (m, J=9.15, 5.09
Hz, 2H); 7.60 (d, J=8.81 Hz, 2H); 8.34 (s, 1H); 8.78 (s, 1H); 8.88
(s, 1H).
EXAMPLE 217
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-fluoropheny-
l)urea
[0458] The desired product was prepared by substituting Example 61B
and 4-fluorophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 458, 460 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.14 (t, J=8.82 Hz,
2H); 7.36 (d, J=8.48 Hz, 2H); 7.49 (dd, J=8.99, 4.92 Hz, 2H); 7.65
(d, J=8.48 Hz, 2H); 8.33 (s, 1H); 8.81 (s, 1H); 8.94 (s, 1H).
EXAMPLE 218
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-fluoropheny-
l)urea
[0459] The desired product was prepared by substituting Example 61B
and 3-fluorophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 458, 460 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 6.81 (m, 1H); 7.15 (d,
J=7.80 Hz, 1H); 7.34 (m, 3H); 7.51 (d, J=11.87 Hz, 1H); 7.66 (d,
J=8.48 Hz, 2H); 8.33 (s, 1H); 9.02 (s, 2H).
EXAMPLE 219
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-cyanophenyl-
)urea
[0460] The desired product was prepared by substituting Example 61B
and 3-cyanophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 465, 467 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.38 (d, J=8.48 Hz,
2H); 7.45 (d, J=7.80 Hz, 1H); 7.52 (t, J=7.80 Hz, 1H); 7.67 (d,
J=8.48 Hz, 2H); 7.71 (d, J=8.82 Hz, 1H); 8.00 (s, 1H); 8.33 (s,
1H); 9.12 (s, 1H); 9.14 (s, 1H).
EXAMPLE 220
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,
5-dimethylphenyl)urea
[0461] The desired product was prepared by substituting Example 61B
and 3,5-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 468, 470
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.24 (s,
6H); 6.64 (s, 1H); 7.09 (s, 2H); 7.35 (d, J=8.48 Hz, 2H); 7.65 (d,
J=8.82 Hz, 2H); 8.33 (s, 1H); 8.61 (s, 1H); 8.90 (s, 1H).
EXAMPLE 221
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N-(3-bromophenyl)-
urea
[0462] The desired product was prepared by substituting Example 61B
and 3-bromophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 520 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 7.17 (d, J=7.80 Hz,
1H); 7.26 (t, J=7.97 Hz, 1H); 7.34 (d, J=7.80 Hz, 1H); 7.37 (d,
J=8.48 Hz, 2H); 7.66 (d, J=8.48 Hz, 2H); 7.88 (s, 1H); 8.33 (s,
1H); 8.99 (s, 1H); 9.03 (s, 1H).
EXAMPLE 222
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,
4-dimethylphenyl)urea
[0463] The desired product was prepared by substituting Example 61B
and 3,4-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 466, 468
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.16 (s,
3H); 2.20 (s, 3H); 7.04 (d, J=8.48 Hz, 1H); 7.19 (d, J=10.17 Hz,
1H); 7.25 (s, 1H); 7.34 (d, J=8.48 Hz, 2H); 7.64 (d, J=8.48 Hz,
2H); 8.32 (s, 1H); 8.58 (s, 1H); 8.88 (s, 1H).
EXAMPLE 223
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[4-fluoro-3-(t-
rifluoromethyl)phenyl]urea
[0464] The desired product was prepared by substituting Example 61B
and 3-fluoro-4-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
526, 528 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
7.37 (d, J=8.82 Hz, 2H); 7.46 (t, J=9.83 Hz, 1H); 7.66 (m, 3H);
8.03 (dd, J=6.44, 2.71 Hz, 1H); 8.33 (s, 1H); 9.08 (s, 1H); 9.15
(s, 1H).
EXAMPLE 224
N-[4-(4-amino-6-bromothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-bromo-3-met-
hylphenyl)urea
[0465] The desired product was prepared by substituting Example 61B
and 4-bromo-3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 534
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.32 (d,
J=5.09 Hz, 3H); 7.28 (dd, J=8.48, 2.71 Hz, 1H); 7.36 (d, J=8.48 Hz,
2H); 7.47 (m, 2H); 7.65 (d, J=8.48 Hz, 2H); 8.33 (s, 1H); 8.85 (s,
1H); 8.98 (s, 1H).
EXAMPLE 225
N-{4-[4-amino-6-(4-pyridinylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'--
(3-cyanophenyl)urea
[0466] The desired product was prepared by substituting Example 14B
and 3-cyanophenyl isocyanate for Example 1A and phenyl isocyanate,
respectively, in Examples 1B-1F. MS (ESI(+)) m/e 478 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 4.04 (s, 2H); 7.28-7.33
(m, 1H); 7.37-7.40 (d, 2H, J=8.4 Hz); 7.42-7.46 (td, 1H, J=1.2, 9
Hz); 7.49-7.56 (m, 2H); 7.65-7.67 (d, 2H, J=8.7 Hz); 7.68-7.72 (m,
1H); 7.99-7.80 (t, 1H, J=1.8 Hz); 8.27 (s, 1H); 8.33-8.34 (d, 1H,
J=1.5 Hz); 8.41-8.44 (dd, 1H, J=1.5, 4.8 Hz); 9.09 (s, 1H); 9.12
(s, 1H).
EXAMPLE 226
N-{4-[4-amino-6-(3-pyridinylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'--
(3-bromophenyl)urea
[0467] The desired product was prepared by substituting Example
115A and 3-bromophenyl isocyanate for Example 1A and phenyl
isocyanate, respectively, in Examples 1B-1F. MS (ESI(+)) m/e 531,
533 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 4.04
(s, 2H); 7.15-7.35 (m, 4H); 7.36-7.39 (d, 2H, J=8.7 Hz); 7.52-7.56
(td, 1H, J=2.4, 7.5 Hz); 7.64-7.67 (d, 2H, J=9 Hz); 7.87-7.88 (t,
1H, J=2.1 Hz); 8.27 (s, 1H); 8.34-8.35 (d, 1H, J=1.5 Hz); 8.41-8.44
(dd, 1H, J=1.8, 4.8 Hz); 8.97 (s, 1H); 8.99 (s, 1H).
EXAMPLE 227
N-{4-[4-amino-6-(3-pyridinylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'--
(3-ethylphenyl)urea
[0468] The desired product was prepared by substituting Example
115A and 3-ethylphenyl isocyanate for Example 1A and phenyl
isocyanate, respectively, in Examples 1B-1F. MS(ESI(+)) m/e 481
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.16-1.21
(t, 3H, J=7.5 Hz); 2.55-2.62 (q, 2H, J=7.5 Hz); 4.04 (s, 2H);
6.83-6.86 (d, 1H, J=7.5 Hz); 7.17-7.22 (t, 1H, J=7.5 Hz); 7.26-7.38
(m, 5H); 7.53-7.56 (td, 1H, J=1.5, 8.1 Hz); 7.63-7.66 (d, 2H, J=9
Hz); 8.27 (s, 1H); 8.34-8.35 (d, 1H, J=1.5 Hz); 8.42-8.44 (dd, 1H,
J=1.8, 4.8 Hz); 8.70 (s, 1H); 8.9 (s, 1H).
EXAMPLE 228
N-{4-[4-amino-6-(3-pyridinylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'--
(2-fluoro-5-methylphenyl)urea
[0469] The desired product was prepared by substituting Example
115A and 5-methyl-2-fluorophenyl isocyanate for Example 1A and
phenyl isocyanate, respectively, in Examples 1B-1F. MS(ESI(+)) m/e
485 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.28
(s, 3H); 4.04 (s, 2H); 6.79-6.85 (m 1H); 7.08-7.15 (dd, 1H, J=8.4,
11.7 Hz); 7.30-7.34 (dd, 1H, J=4.5, 7.2 Hz); 7.36-7.39 (d, 2H,
J=8.4 Hz); 7.53-7.57 (td, 1H, J=1.8, 7.8 Hz); 7.63-7.66 (d, 2H,
J=8.7 Hz); 7.97-8.01 (dd, 1H, J=2.1, 7.8 Hz); 8.27 (s, 1H);
8.34-8.35 (d, 1H, J=1.8 Hz); 8.42-8.44 (dd, 1H, J=1.5, 4.8 Hz);
8.56-8.57 (d, 1H, J=2.4 Hz); 9.30 (s, 1H).
EXAMPLE 229
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-[2--
fluoro-5-(trifluoromethyl)phenyl]urea
EXAMPLE 229A
N-{4-[4-amino-6-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)thieno[2,3-d]pyri-
midin-5-yl]phenyl}-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea
[0470] The desired product was prepared by substituting Example
104B and 5-trifluoromethyl-2-fluorophenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F.
EXAMPLE 229B
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-[2--
fluoro-5-(trifluoromethyl)phenyl]urea
[0471] The desired product was prepared by substituting Example
229A for Example 104C in Example 104D. MS (ESI(+)) m/e 492
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.74-2.79
(t, 2H, J=6.6 Hz); 3.54-3.60 (q, 2H, J=6.6 Hz); 4.87-4.91 (t, 1H,
J=5.4 Hz); 7.33-7.36 (d, 2H, J=8.7 Hz); 7.38-7.44 (m, 1H);
7.49-7.55 (m, 1H); 7.63-7.66 (d, 2H, J=8.4 Hz); 8.27 (s, 1H);
8.62-8.65 (dd, 1H, J=1.8, 6.9 Hz); 8.98-8.99 (d, 1H, J=3.7 Hz);
9.39 (s, 1H).
EXAMPLE 230
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
ethylphenyl)urea
EXAMPLE 230A
N-{4-[4-amino-6-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)thieno[2,3-d]pyri-
midin-5-yl]phenyl}-N'-(3-ethylphenyl)urea
[0472] The desired product was prepared by substituting Example
104B and 3-ethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F.
EXAMPLE 230B
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
ethylphenyl)urea
[0473] The desired product was prepared by substituting Example
230A for Example 104C in Example 104D. MS (ESI(+)) m/e 434
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.16-1.21
(t, 3H, J=7.8 Hz); 2.55-2.62 (q, 2H, J=7.8 Hz); 2.75-2.79 (t, 2H,
J=6.3 Hz); 3.54-3.58 (q, 2H, J=5.4 Hz); 4.85-4.89 (t, 1H, J=5.7
Hz); 6.83-6.85 (d, 1H, J=7.2 Hz); 7.17-7.22 (t, 1H, J=7.5 Hz);
7.26-7.34 (m, 4H,), 7.61-7.64 (d, 2H, J=8.4 Hz); 8.26 (s, 1H); 8.68
(s, 1H); 8.86 (s, 1H).
EXAMPLE 231
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
cyanophenyl)urea
EXAMPLE 231A
N-{4-[4-amino-6-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)thieno[2,3-d]pyri-
midin-5-yl]phenyl}-N'-(3-cyanophenyl)urea
[0474] The desired product was prepared by substituting Example
104B and 3-cyanophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F.
EXAMPLE 231B
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
cyanophenyl)urea
[0475] The desired product was prepared by substituting Example
231A for Example 104C in Example 104D. MS (ESI(+)) m/e 431
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.75-2.79
(t, 2H, J=6.9 Hz); 3.54-3.60 (q, 2H, J=5.1 Hz); 4.86-4.89 (t, 1H,
J=5.1 Hz); 7.32-7.35 (d, 2H, J=8.7 Hz); 7.42-7.46 (td, 1H, J=1.2,
7.5 Hz); 7.49-7.54 (t, 1H, J=7.8 Hz); 7.62-7.65 (d, 2H, J=8.4 Hz);
7.69-7.73 (td, 1H, J=1.2, 8.1 Hz); 7.99-8.00 (t, 1H, J=1.8 Hz);
8.27 (s, 1H); 9.07 (s, 1H); 9.12 (s, 1H).
EXAMPLE 232
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
bromophenyl)urea
EXAMPLE 232A
N-{4-[4-amino-6-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)thieno[2,3-d]pyri-
midin-5-yl]phenyl}-N'-(3-bromophenyl)urea
[0476] The desired product was prepared by substituting Example
104B and 3-bromophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F.
EXAMPLE 232B
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
bromophenyl)urea
[0477] The desired product was prepared by substituting Example
232A for Example 104C in Example 104D. MS (ESI(+)) m/e 484, 486
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.74-2.79
(t, 2H, J=6.3 Hz); 3.54-3.59 (t, 2H, J=6.0 Hz); 4.81-4.90 (br, 1H);
7.15-7.18 (m, 1H); 7.23-7.28 (t, 1H, J=7.8 Hz); 7.31-7.36 (m, 3H);
7.61-7.64 (d, 2H, J=8.7 Hz); 7.87-7.88 (t, 1H, J=1.8 Hz); 8.27 (s,
1H); 8.96 (s, 1H); 8.98 (s, 1H).
EXAMPLE 233
N-{4-[4-amino-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
cyanophenyl)urea
[0478] The desired product was prepared by substituting Example 108
and 3-cyanophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 445 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.83-2.87 (t, 2H, J=6.3
Hz); 3.22 (s, 3H); 3.47-3.52 (t, 2H, J=6.3 Hz); 7.32-7.35 (d, 2H,
J=8.7 Hz); 7.43-7.46 (td, 1H, J=1.2, 7.8 Hz); 7.49-7.54 (t, 1H,
J=7.8 Hz); 7.63-7.66 (d, 2H, J=8.7 Hz); 7.68-7.73 (m, 1H);
7.99-8.00 (t, 1H, J=1.8 Hz); 8.27 (s, 1H); 9.08 (s, 1H); 9.12 (s,
1H).
EXAMPLE 234
N-{4-[4-amino-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
ethylphenyl)urea
[0479] The desired product was prepared by substituting Example 108
and 3-ethylphenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 448 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.16-1.21 (t, 3H, J=7.5
Hz); 2.55-2.62 (q, 2H, J=7.5 Hz); 2.83-2.87 (t, 2H, J=6.0 Hz); 3.22
(s, 3H); 3.48-3.52 (t, 2H, J=6.6 Hz); 6.83-6.86 (d, 1H, J=7.5 Hz);
7.17-7.22 (t, 1H, J=7.5 Hz); 7.26-7.34 (m, 4H); 7.61-7.64 (d, 2H,
J=8.4 Hz); 8.27 (s, 1H); 8.70 (s, 1H); 8.75 (s, 1H).
EXAMPLE 235
N-{4-[4-amino-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
bromophenyl)urea
[0480] The desired product was prepared by substituting Example 108
and 3-bromophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 498, 500 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.83-2.87 (t, 2H, J=6
Hz); 3.22 (s, 3H); 3.47-3.52 (t, 2H, J=6.3 Hz); 7.15-7.19 (td, 1H,
J=1.5, 8.1 Hz); 7.23-7.28 (t, 1H, J=7.8 Hz); 7.31-7.36 (m, 3H);
7.62-7.65 (d, 2H, J=9 Hz); 7.87-7.88 (t, 1H, J=1.8 Hz); 8.27(s,
1H); 8.97 (s, 1H); 8.98 (s, 1H).
EXAMPLE 236
N-{4-[4-amino-6-(2-methoxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3--
chlorophenyl)urea
[0481] The desired product was prepared by substituting Example 108
and 3-chlorophenyl isocyanate for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 454, 456 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.83-2.87 (t, 2H, J=6.3
Hz); 3.22 (s, 3H); 3.48-3.52 (t, 2H, J=6.6 Hz); 7.02-7.06 (td, 1H,
J=2.1, 6.6 Hz); 7.30-7.34 (m, 4H); 7.62-7.65 (d,2H, J=8.7 Hz);
7.72-7.75 (br, 1H); 8.27(s, 1H); 8.99 (s, 2H).
EXAMPLE 237
N-{4-[4-amino-6-(3-pyridinylmethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'--
(3,5-dimethylphenyl)urea
[0482] The desired product was prepared by substituting Example
115A and 3,5-dimethylphenyl isocyanate for Example 1A and phenyl
isocyanate, respectively, in Examples 1B-1F. MS(ESI(+)) m/e 481
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 3.24 (s,
6H); 4.04 (s, 2H); 6.63 (s, 1H); 7.09 (s, 2H); 7.29-7.37 (m, 3H);
7.52-7.56 (td, 1H, J=1.8, 7.8 Hz); 7.62-7.65 (d, 2H, J=8.7 Hz);
8.27 (s, 1H); 8.34-8.35 (d, 1H, J=1.5 Hz); 8.41-8.44 (dd, 1H,
J=1.8, 4.8 Hz); 8.59 (s, 1H); 8.88 (s, 1H).
EXAMPLE 238
3-(4-amino-5-{4-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amin-
o]phenyl}thieno[2,3-d]pyrimidin-6-yl)propanamide
EXAMPLE 238A
3-[4-amino-5-(4-aminophenyl)thieno[2,3-d]pyrimidin-6-yl]propanamide
[0483] The desired product was prepared by substituting
5-oxo-5-phenyl-pentanoic acid for 1-(3-chlorophenyl)propan-1-one in
Examples 143A-C. MS (ESI(+)) m/e 314 (M+H).sup.+.
EXAMPLE 238B
3-(4-amino-5-{4-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amin-
o]phenyl}thieno[2,3-d]pyrimidin-6-yl)propanamide
[0484] The desired product was prepared by substituting Example
238A and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
519 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.36
(t, J=7.63 Hz, 2H); 2.84 (t, J=7.46 Hz, 2H); 6.84 (s, 1H); 7.34 (s,
1H); 7.35 (d, J=8.48 Hz, 2H); 7.42 (m, J=4.41, 2.71 Hz, 1H); 7.52
(m, 1H); 7.65 (d, J=8.81 Hz, 2H); 8.27 (s, 1H); 8.64 (dd, J=6.95,
2.20 Hz, 1H); 8.99 (d, J=2.71 Hz, 1H); 9.41 (s, 1H).
EXAMPLE 239
3-{4-amino-5-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d]pyrimidin-6-yl}propanamide
[0485] The desired product was prepared by substituting Example
238A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 447 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.29 (s, 3H); 2.36 (t, J=7.63
Hz, 2H); 2.85 (t, J=7.46 Hz, 2H); 6.81 (d, J=7.46 Hz, 1H); 6.85 (m,
1H); 7.17 (t, J=7.80 Hz, 1H); 7.26 (d, J=9.00 Hz, 1H); 7.32 (m,
4H); 7.64 (d, J=8.81 Hz, 2H); 8.33 (s, 1H); 8.71 (s, 1H); 8.93 (s,
1H).
EXAMPLE 240
3-(4-amino-5-{4-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyl}-
thieno[2,3-d]pyrimidin-6-yl)propanamide
[0486] The desired product was prepared by substituting Example
238A and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. The product was
purified by HPLC using the conditions described in Example 179 to
provide the trifluoroacetate salt. MS (ESI(+)) m/e 501 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.36 (t, J=7.46 Hz,
2H); 2.84 (t, J=7.63 Hz, 2H); 6.85 (s, 1H); 7.34 (m, 4H); 7.53 (t,
J=7.80 Hz, 1H); 7.61 (d, J=10.17 Hz, 1H); 7.65 (d, J=8.48 Hz, 2H);
8.04 (s, 1H); 8.29 (s, 1H); 9.05 (s, 1H); 9.17 (s, 1H).
EXAMPLE 241
3-{4-amino-5-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenyl]th-
ieno[2,3-d]pyrimidin-6-yl}propanamide
[0487] The desired product was prepared by substituting Example
238A and 2-fluoro-5-methylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. The product was
purified by HPLC using the conditions described in Example 179 to
provide the trifluroacetate salt. MS (ESI(+)) m/e 465 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.28 (s, 3H); 2.36 (t,
J=7.46 Hz, 2H); 2.85 (t, J=7.29 Hz, 2H); 6.82 (m, 2H); 7.12 (dd,
J=11.36, 8.31 Hz, 1H); 7.33 (m, 3H); 7.64 (d, J=8.48 Hz, 2H); 7.99
(dd, J=7.80, 2.03 Hz, 1H); 8.33 (s, 1H); 8.57 (d, J=2.37 Hz, 1H);
9.31 (s, 1H).
EXAMPLE 242
3-{4-amino-5-[4-({[(3,5-dimethylphenyl)amino]carbonyl}amino)phenyl]thieno[-
2,3-d]pyrimidin-6-yl}propanamide
[0488] The desired product was prepared by substituting Example
238A and 3,5-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 461 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.24 (s, 6H); 2.36 (t, J=7.46
Hz, 2H); 2.85 (t, J=7.46 Hz, 2H); 6.63 (s, 1H); 6.85 (s, 1H); 7.09
(s, 2H); 7.29-7.35 (m, 3H); 7.63 (d, J=8.48 Hz, 2H); 8.33 (s, 1H);
8.63 (s, 1H); 8.91 (s, 1H).
EXAMPLE 243
3-{4-amino-5-[4-({[(3-chlorophenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d]pyrimidin-6-yl}propanamide
[0489] The desired product was prepared by substituting Example
238A and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 467 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.36 (t, J=7.63 Hz, 2H); 2.85
(t, J=7.63 Hz, 2H); 6.85 (s, 1H); 7.04 (m, 1H); 7.29-7.37 (m, 5H);
7.64 (d, J=8.81 Hz, 2H); 7.74 (m, 1H); 8.33 (s, 1H); 9.03 (s, 1H);
9.04 (s, 1H).
EXAMPLE 244
3-{4-amino-5-[4-({[(3-bromophenyl)amino]carbonyl}amino)phenyl]thieno[2,3-d-
]pyrimidin-6-yl}propanamide
[0490] The desired product was prepared by substituting Example
238A and 3-bromophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 511, 513 (M+H); .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.36 (t, J=7.63 Hz, 2H); 2.85
(t, J=7.63 Hz, 2H); 6.85 (s, 1H); 7.17 (m, 1H); 7.26 (t, J=7.97 Hz,
1H); 7.31-7.37 (m, 4H); 7.64 (d, J=8.81 Hz, 2H); 7.88 (t, J=2.03
Hz, 1H); 8.32 (s, 1H); 9.00 (s, 1H); 9.03 (s, 1H).
EXAMPLE 245
3-{4-amino-5-[4-({[(3-fluorophenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d]pyrimidin-6-yl}propanamide
[0491] The desired product was prepared by substituting Example
238A and 3-fluorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 451 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 6.81 (m, 1H); 6.85 (s, 1H);
7.15 (m, 1H); 7.28-7.37 (m, 4H); 7.52 (m, 1H); 7.52 (dt, J=11.70,
2.30 Hz, 1H); 7.64 (d, J=8.48 Hz, 2H); 8.33 (s, 1H); 9.03 (s, 1H);
9.04 (s, 1H).
EXAMPLE 246
3-{4-amino-5-[4-({[(3-ethylphenyl)amino]carbonyl}amino)phenyl]thieno[2,3-d-
]pyrimidin-6-yl}propanamide
[0492] The desired product was prepared by substituting Example
238A and 3-ethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 461 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 1.19 (t, J=7.63 Hz, 3H); 2.36
(t, J=7.46 Hz, 2H); 2.59 (q, J=7.46 Hz, 2H); 2.85 (t, J=7.46 Hz,
2H); 6.84-6.87(m, 2H); 7.19 (t, J=7.80 Hz, 1H); 7.28 (d, J=9.49 Hz,
1H); 7.30-7.37 (m, J=8.81 Hz, 4H); 7.62 (s, 1H); 7.65 (s, 1H); 8.33
(s, 1H); 8.72 (s, 1H); 8.92 (s, 1H).
EXAMPLE 247
3-(4-amino-5-{4-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyl}-
thieno[2,3-d]pyrimidin-6-yl)-N,N-dimethylpropanamide
EXAMPLE 247A
6,6-dicyano-N,N-dimethyl-5-phenyl-5-hexenamide
[0493] The desired product was prepared by substituting
6,6-dicyano-5-phenyl-5-hexenoic acid (prepared by substituting
5-oxo-5-phenylpentanoic acid for Example 1A in Example 1B) and
dimethylamine hydrochloride for Example 66B and aniline,
respectively, in Example 66C. MS (ESI(-)) m/e 266 (M-H).sup.-.
EXAMPLE 247B
3-(4-amino-5-phenylthieno[2,3-d]pyrimidin-6-yl)-N,N-dimethylpropanamide
[0494] The desired product was prepared by substituting Example
247A for Example 1B in Examples 1C-D
EXAMPLE 247C
3-[4-amino-5-(4-aminophenyl)thieno[2,3-d]pyrimidin-6-yl]-N,N-dimethylpropa-
namide
[0495] The desired product was prepared by substituting Example
247B for Example 143A in Examples 143B-C. MS (ESI(+)) m/e 342
(M+H).sup.+.
EXAMPLE 247D
3-(4-amino-5-{4-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyl}-
thieno[2,3-d]pyrimidin-6-yl)-N,N-dimethylpropanamide
[0496] The desired product was prepared by substituting Example
247C and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. The product was
purified by HPLC using the conditions described in Example 179 to
provide the trifluoroacetate salt. MS (ESI(+)) m/e 529 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.60 (t, J=7.29 Hz,
2H); 2.80 (s, 3H); 2.86 (t, J=7.12 Hz, 2H); 2.89 (s, 3H); 7.33 (d,
J=8.14 Hz, 1H); 7.36 (d, J=8.81 Hz, 2H); 7.53 (t, J=6.95 Hz, 1H);
7.61 (d, J=9.83 Hz, 1H); 7.66 (d, J=8.81 Hz, 2H); 8.04 (s, 1H);
8.33 (s, 1H); 9.09 (s, 1H); 9.20 (s, 1H).
EXAMPLE 248
3-(4-amino-5-{4-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amin-
o]phenyl}thieno[2,3-d]pyrimidin-6-yl)-N,N-dimethylpropanamide
[0497] The desired product was prepared by substituting Example
247C and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. The product was
purified by HPLC using the conditions described in Example 179 to
provide the trifluoroacetate salt. MS (ESI(+)) m/e 493 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.28 (s, 3H); 2.60 (t,
J=7.29 Hz, 2H); 2.80 (s, 3H); 2.85 (t, J=7.12 Hz, 2H); 2.89 (s,
3H); 6.83 (m, 1H); 7.12 (dd, J=11.36, 8.31 Hz, 1H); 7.35 (d, J=8.82
Hz, 2H); 7.64 (d, J=8.82 Hz, 2H); 7.99 (dd, J=7.80, 2.03 Hz, 1H);
8.34 (s, 1H); 8.57 (d, J=2.71 Hz, 1H); 9.30 (s, 1H).
EXAMPLE 249
3-{4-amino-5-[4-({[(3-chlorophenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d]pyrimidin-6-yl}-N,N-dimethylpropanamide
[0498] The desired product was prepared by substituting Example
247C and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 495 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.60 (t, J=7.29 Hz, 2H); 2.80
(s, 3H); 2.85 (t, J=7.12 Hz, 2H); 2.89 (s, 3H); 7.04 (m, 1H);
7.29-733 (m, 2H); 7.35 (d, J=8.82 Hz, 2H); 7.65 (d, J=8.81 Hz, 2H);
7.73 (m, 1H); 8.34 (s, 1H); 9.05 (s, 1H); 9.06 (s, 1H).
EXAMPLE 250
3-(4-amino-5-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amin-
o]phenyl}thieno[2,3-d]pyrimidin-6-yl)-N,N-dimethylpropanamide
[0499] The desired product was prepared by substituting Example
247C and 3-trifluoromethyl-4-chlorophenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. The product was
purified by HPLC using the conditions described in Example 179 to
provide the trifluoroacetate salt. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 2.59 (t, J=7.29 Hz, 2H); 2.80 (s, 3H); 2.84
(d, J=7.46 Hz, 2H); 2.89 (s, 3H); 7.36 (d, J=8.48 Hz, 2H);
7.60-7.68 (m, 4H); 8.14 (d, J=2.37 Hz, 1H); 8.33 (s, 1H); 9.13 (s,
1H); 9.31 (s, 1H).
EXAMPLE 251
3-{4-amino-5-[4-({[(4-fluorophenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d]pyrimidin-6-yl}-N,N-dimethylpropanamide
[0500] The desired product was prepared by substituting Example
247C and 4-fluorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 479 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.60 (t, J=7.29 Hz, 2H); 2.80
(s, 3H); 2.86 (t, J=7.46 Hz, 2H); 2.89 (s, 3H); 7.13 (m, 2H); 7.34
(d, J=8.48 Hz, 2H); 7.49 (m, 2H); 7.64 (d, J=8.48 Hz, 2H); 8.35 (s,
1H); 8.85 (s, 1H); 8.96 (s, 1H).
EXAMPLE 252
3-{4-amino-5-[4-({[(3-chlorophenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d]pyrimidin-6-yl}-N,N-dimethylpropanamide
[0501] The desired product was prepared by substituting Example
247C and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 475 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.29 (s, 3H); 2.60 (t, J=7.12
Hz, 2H); 2.80 (s, 3H); 2.87 (t, J=7.12 Hz, 2H); 2.89 (s, 3H); 6.81
(d, J=7.12 Hz, 1H); 7.17 (m, 1H); 7.26 (d, J=6.0 Hz, 1H); 7.32 (s,
1H); 7.34 (d, J=8.48 Hz, 2H); 7.64 (d, J=8.48 Hz, 2H); 8.36 (s,
1H); 8.73 (s, 1H); 8.94 (s, 1H).
EXAMPLE 253
3-{4-amino-5-[4-({[(3-bromophenyl)amino]carbonyl}amino)phenyl]thieno[2,3-d-
]pyrimidin-6-yl}-N,N-dimethylpropanamide
[0502] The desired product was prepared by substituting Example
247C and 3-bromophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 as the
trifluoroacetate salt. MS (ESI(+)) m/e 561 (M+Na).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.60 (t, J=7.29 Hz, 2H); 2.80
(s, 3H); 2.86 (t, J=7.46 Hz, 2H); 2.89 (s, 3H); 7.14-7.19 (m, 1H);
7.26 (t, J=7.97 Hz, 1H); 7.32-7.38 (m, 3H); 7.65 (d, J=8.81 Hz,
2H); 7.88 (t, J=2.03 Hz, 1H); 8.36 (s, 1H); 9.04 (s, 1H); 9.06 (s,
1H).
EXAMPLE 254
3-{4-amino-5-[4-({[(3-fluorophenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d]pyrimidin-6-yl}-N,N-dimethylpropanamide
[0503] The desired product was prepared by substituting Example
247C and 3-fluorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 as the
trifluoroacetate salt. MS (ESI(+)) m/e 479 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 2.60 (t, J=7.46 Hz, 2H); 2.80 (s,
3H); 2.86 (t, J=7.46 Hz, 2H); 2.89 (s, 3H); 6.80 (m, 1H); 7.15 (m,
1H); 7.26-7.38 (m, 3H); 7.47-7.55 (m, 1H); 7.64 (d, J=8.81 Hz, 2H);
8.34 (s, 1H); 9.03 (s, 1H); 9.05 (s, 1H).
EXAMPLE 255
3-{4-amino-5-[4-({[(3-fluoro-4-methylphenyl)amino]carbonyl}amino)phenyl]th-
ieno[2,3-d]pyrimidin-6-yl}-N,N-dimethylpropanamide
[0504] The desired product was prepared by substituting Example
247C and 3-fluoro-4-methylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. The product was
purified by HPLC using the conditions described in Example 179 to
provide the trifluoroacetate salt. MS (ESI(+)) m/e 493 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.60 (t, J=7.46 Hz,
2H); 2.80 (s, 3H); 2.86 (t, J=7.46 Hz, 2H); 2.89 (s, 3H); 6.80 (m,
1H); 7.15 (m, 1H); 7.33 (m, 3H); 7.51 (m, 1H); 7.64 (d, J=8.81 Hz,
2H); 8.34 (s, 1H); 9.03 (s, 1H); 9.05 (s, 1H).
EXAMPLE 256
3-{4-amino-5-[4-({[(3-chloro-4-fluorophenyl)amino]carbonyl}amino)phenyl]th-
ieno[2,3-d]pyrimidin-6-yl}-N,N-dimethylpropanamide
[0505] The desired product was prepared by substituting Example
247C and 3-chloro-4-fluorophenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. The product was
purified by HPLC using the conditions described in Example 179 to
provide the trifluoroacetate salt. MS (ESI(+)) m/e 513 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.60 (t, J=7.12 Hz,
2H); 2.80 (s, 3H); 2.86 (t, J=7.46 Hz, 2H); 2.89 (s, 3H); 7.32-7.38
(m, 4H); 7.65 (d, J=8.48 Hz, 2H); 7.83 (m, 1H); 8.36 (s, 1H); 9.06
(s, 1H); 9.08 (s, 1H).
EXAMPLE 257
3-(4-amino-5-{4-[(anilinocarbonyl)amino]phenyl}thieno[2,3-d]pyrimidin-6-yl-
)-N,N-dimethylpropanamide
[0506] The desired product was prepared by substituting Example
247C for Example 1E in Example 1F. The product was purified by HPLC
using the conditions described in Example 179 to provide the
trifluoroacetate salt. MS (ESI(+)) m/e 461 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 2.60 (t, J=7.29 Hz, 2H); 2.80 (s,
3H); 2.86 (t, J=7.46 Hz, 2H); 2.89 (s, 3H); 6.99 (t, J=7.29 Hz,
1H); 7.30 (m, 2H); 7.34 (d, J=8.48 Hz, 2H); 7.48 (d, J=7.46 Hz,
2H); 7.64 (d, J=8.48 Hz, 2H); 8.34 (s, 1H); 8.79 (s, 1H); 8.94 (s,
1H).
EXAMPLE 258
3-[4-amino-5-(4-{[(2,3-dihydro-1H-inden-5-ylamino)carbonyl]amino}phenyl)th-
ieno[2,3-d]pyrimidin-6-yl]-N,N-dimethylpropanamide
[0507] The desired product was prepared by substituting Example
247C and 5-isocyanatoindane for Example 1E and phenyl isocyanate,
respectively, in Example 1F. The product was purified by HPLC using
the conditions described in Example 179 to provide the
trifluoracetate salt. MS (ESI(+)) m/e 501 (M+H).sup.+; .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 2.01 (m, 2H); 2.59 (t, J=7.29 Hz,
2H); 2.80 (s, 3H); 2.75-2.90 (m, 6H); 2.89 (s, 3H); 7.14 (m, 2H);
7.33 (d, J=8.48 Hz, 2H); 7.39 (s, 1H); 7.63 (d, J=8.81 Hz, 2H);
8.33 (s, 1H); 8.65 (s, 1H); 8.89 (s, 1H).
EXAMPLE 259
3-{4-amino-5-[4-({[(3-cyanophenyl)amino]carbonyl}amino)phenyl]thieno[2,3-d-
]pyrimidin-6-yl}-N,N-dimethylpropanamide
[0508] The desired product was prepared by substituting Example
247C and 3-cyanophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 486 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.60 (t, J=7.29 Hz, 2H); 2.80
(s, 3H); 2.86 (t, J=7.12 Hz, 2H); 2.89 (s, 3H); 7.36 (d, J=8.81 Hz,
2H); 7.44 (m, 1H); 7.52 (t, J=7.80 Hz, 1H); 7.66 (d, J=8.48 Hz,
2H); 7.70 (m, 1H); 8.00 (t, J=1.70 Hz, 1H); 8.34 (s, 1H); 9.15 (s,
1H); 9.19 (s, 1H).
EXAMPLE 260
3-(4-amino-5-{4-[({[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl)amin-
o]phenyl}thieno[2,3-d]pyrimidin-6-yl)-N,N-dimethylpropanamide
[0509] The desired product was prepared by substituting Example
247C and 4-fluoro-3-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. The product was
purified by HPLC using the conditions described in Example 179 to
provide the trifluoroacetate salt. MS (ESI(+)) m/e 547 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.59 (t, J=7.29 Hz,
2H); 2.80 (s, 3H); 2.86 (t, J=7.46 Hz, 2H); 2.89 (s, 3H); 7.36 (d,
J=8.48 Hz, 2H); 7.46 (m, 1H); 7.60-7.71 (m, 3H); 8.03 (dd, J=6.44,
2.71 Hz, 1H); 8.33 (s, 1H); 9.09 (s, 1H); 9.18 (s, 1H).
EXAMPLE 261
3-{4-amino-5-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d]pyrimidin-6-yl}-N-methylpropanamide
EXAMPLE 261A
3-[4-amino-5-(4-aminophenyl)thieno[2,3-d]pyrimidin-6-yl]-N-methylpropanami-
de
[0510] The desired product was prepared by substituting methylamine
hydrochloride for dimethylamine hydrochloride in Examples 247A-C.
MS (ESI(+)) m/e 328 (M+H).sup.+.
EXAMPLE 261B
3-{4-amino-5-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d]pyrimidin-6-yl}-N-methylpropanamide
[0511] The desired product was prepared by substituting Example
261A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 461 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.29 (s, 3H); 2.36 (t, J=7.46
Hz, 2H); 2.54 (d, J=4.75 Hz, 3H); 2.86 (t, J=7.29 Hz, 2H); 6.81 (d,
J=7.46 Hz, 1H); 7.17 (t, J=7.80 Hz, 1H); 7.26 (m, 1H); 7.29-7.34
(m, 3H); 7.64 (d, J=8.81 Hz, 2H); 7.80 (m, 1H); 8.33 (s, 1H); 8.71
(s, 1H); 8.93 (s, 1H).
EXAMPLE 262
3-(4-amino-5-{4-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyl}-
thieno[2,3-d]pyrimidin-6-yl)-N-methylpropanamide
[0512] The desired product was prepared by substituting Example
261A and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. The product was
purified by HPLC using the conditions described in Example 179 to
provide the trifluoroacetate salt. MS (ESI(+)) m/e 515 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.37 (t, J=7.46 Hz,
2H); 2.55 (d, J=4.75 Hz, 3H); 2.86 (t, J=7.46 Hz, 2H); 7.33 (m,
3H); 7.59 (m, 4H); 7.80 (q, J=4.18 Hz, 1H); 8.04 (s, 1H); 8.33 (m,
1H); 9.08 (s, 1H); 9.19 (s, 1H).
EXAMPLE 263
3-(4-amino-5-{4-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amin-
o]phenyl}thieno[2,3-d]pyrimidin-6-yl)-N-methylpropanamide
[0513] The desired product was prepared by substituting Example
261A and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. The product was
purified by HPLC using the conditions described in Example 179 to
provide the trifluoroacetate salt. MS (ESI(+)) m/e 533 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.36 (t, J=7.63 Hz,
2H); 2.54 (d, J=4.41 Hz, 3H); 2.86 (t, J=7.46 Hz, 2H); 7.35 (d,
J=8.48 Hz, 2H); 7.48-7.45 (m, J=4.24, 2.54 Hz, 1H); 7.46-7.57 (m,
1H); 7.65 (d, J=8.48 Hz, 2H); 7.80 (m, J=4.75 Hz, 1H); 8.32 (s,
1H); 8.63 (dd, J=7.29, 2.20 Hz, 1H); 9.00 (d, J=3.05 Hz, 1H); 9.41
(s, 1H).
EXAMPLE 264
3-{4-amino-5-[4-({[(3,5-dimethylphenyl)amino]carbonyl}amino)phenyl]thieno[-
2,3-d]pyrimidin-6-yl}-N-methylpropanamide
[0514] The desired product was prepared by substituting Example
261A and 3,5-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 475 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.24 (s, 6H); 2.36 (t, J=7.63
Hz, 2H); 2.54 (d, J=4.75 Hz, 3H); 2.86 (t, J=7.29 Hz, 1H); 2.86 (t,
J=7.29 Hz, 2H); 7.09 (s, 2H); 7.31 (d, J=8.48 Hz, 2H); 7.63 (d,
J=8.81 Hz, 2H); 7.80 (q, J=4.07 Hz, 1H); 8.33 (s, 1H); 8.63 (s,
1H); 8.91 (s, 1H).
EXAMPLE 265
3-{4-amino-5-[4-({[(3-chlorophenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d pyrimidin-6-yl}-N-methylpropanamide
[0515] The desired product was prepared by substituting Example
261A and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 481 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 2.37 (t, J=7.46 Hz, 2H); 2.54
(d, J=4.75 Hz, 3H); 2.86 (t, J=7.46 Hz, 2H); 7.04 (m, 1H);
7.27-7.35 (m, 4H); 7.65 (d, J=8.81 Hz, 2H); 7.74 (d, J=2.71 Hz,
1H); 7.80 (q, J=4.18 Hz, 1H); 8.34 (s, 1H); 9.04 (s, 1H); 9.05 (s,
1H).
EXAMPLE 266
3-{4-amino-5-[4-({[(3-bromophenyl)amino]carbonyl}amino)phenyl]thieno[2,3-d
pyrimidin-6-yl]-N-methylpropanamide
[0516] The desired product was prepared by substituting Example
261A and 3-bromophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 2.37 (t, J=7.46 Hz, 2H); 2.55 (d, J=4.75 Hz, 3H); 2.86 (t,
J=7.46 Hz, 2H); 7.17 (m, 1H); 7.26 (t, J=7.97 Hz, 1H); 7.30-7.37
(m, 3H); 7.65 (d, J=8.48 Hz, 2H); 7.80 (m, 1H); 7.88 (t, J=1.86 Hz,
1H); 8.34 (s, 1H); 9.03 (s, 1H); 9.06 (s, 1H).
EXAMPLE 267
N-{4-[4-amino-6-(3-methoxypropyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-[2-
-fluoro-5-(trifluoromethyl)phenyl]urea
EXAMPLE 267A
5-(4-aminophenyl)-6-(3-methoxypropyl)thieno[2,3-d]pyrimidin-4-amine
[0517] The desired product was prepared by substituting
1-iodo-4-methoxybutane for tert-butyl(3-iodopropoxy)dimethylsilane
in Examples 104A and 104B.
EXAMPLE 267B
N-{4-[4-amino-6-(3-methoxypropyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-[2-
-fluoro-5-(trifluoromethyl)phenyl}urea
[0518] The desired product was prepared by substituting Example
267A and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
520 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
1.72-1.82 (m, 2H); 2.66-2.71 (t, 2H, J=7.5 Hz); 3.16 (s, 3H);
3.25-3.29 (t, 2H, J=4.2 Hz); 7.32-7.35 (d, 2H, J=8.7 Hz); 7.38-7.45
(m, 1H); 7.49-7.55 (t, 1H, J=8.7 Hz); 7.63-7.66 (d, 2H, J=8.4 Hz);
8.27 (s, 1H); 8.62-8.65 (dd, 1H, J=2.1, 7.2 Hz); 8.98-8.99 (d, 1H,
J=2.7 Hz); 9.39 (s, 1H); MS (ESI(-)) m/e 518 (M-H).sup.-.
EXAMPLE 268
N-{4-[4-amino-6-(3-methoxypropyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-N'-(3-
-methylphenyl)urea
[0519] The desired product was prepared by substituting Example
267A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 448
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.72-1.82
(m 2H); 2.29 (s, 3H); 2.66-2.71 (t, 2H, J=7.2 Hz); 3.16 (s, 3H);
3.24-3.29 (t, 2H, J=6.3 Hz); 6.79-6.82 (d, 1H, J=7.2 Hz); 7.14-7.19
(t, 1H, J=7.8 Hz); 7.24-7.31 (m 4H); 7.61-7.64 (d, 2H, J=9 Hz);
8.27 (s, 1H); 8.67 (s, 1H); 8.87 (s, 1H).
EXAMPLE 269
N-(4-{4-amino-6-[4-(dimethylamino)benzyl]thieno[2,3-d]pyrimidin-5-yl}pheny-
l)-N]-(3-methylphenyl)urea
EXAMPLE 269A
5-(4-aminophenyl)-6-[4-(dimethylamino)benzyl]thieno[2,3-d]pyrimidin-4-amin-
e
[0520] The desired product was prepared by substituting
N-[4-(2-iodoethyl)phenyl]-N,N-dimethylamine for
tert-butyl(3-iodopropoxy)dimethylsilane in Examples 104A and 104B.
MS (ESI(+)) m/e 376 (M+H).sup.+.
EXAMPLE 269B
N-(4-{4-amino-6-[4-(dimethylamino)benzyl]thieno[2,3-d]pyrimidin-5-yl}pheny-
l)-N'-(3-methylphenyl)urea
[0521] The desired product was prepared by substituting Example
269A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 509
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.29 (s,
3H); 2.85 (s, 6H); 3.85(s, 2H); 6.63-6.66 (d, 2H, J=9 Hz);
6.79-6.82 (d, 1H, J=7.8 Hz); 6.95-6.98 (d, 2H, J=8.7 Hz); 7.14-7.19
(t, 1H, J=7.5 Hz); 7.24-7.31 (m, 2H); 7.35-7.38 (d, 2H, J=9 Hz);
7.63-7.66 (d, 2H, J=8.7 Hz); 8.25 (s, 1H); 8.68 (s, 1H); 8.89 (s,
1H).
EXAMPLE 270
N-(4-{4-amino-6-[4-(dimethylamino)benzyl]thieno[2,3-d]pyrimidin-5-yl}pheny-
l)-N'-[3-(trifluoromethyl)phenyl]urea
[0522] The desired product was prepared by substituting Example
269A and 3-trifluomethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 563
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.85 (s,
6H); 3.85 (s, 2H); 6.63-6.66 (d, 2H, J=9 Hz); 6.95-6.98 (d, 2H,
J=8.7 Hz); 7.32-7.37 (m, 1H); 7.37-7.39 (d, 2H, J=8.7 Hz);
7.50-7.56 (t, 1H, J=7.5 Hz); 7.59-7.63 (m, 1H); 7.66-7.68 (d, 2H,
J=8.4 Hz); 8.04 (s, 1H); 8.25 (s, 1H); 9.03 (s, 1H); 9.14 (s,
1H).
EXAMPLE 271
N-(4-{4-amino-6-[4-(dimethylamino)benzyl]thieno[2,3-d]pyrimidin-5-yl}pheny-
l)-N]-(3-chlorophenyl)urea
[0523] The desired product was prepared by substituting Example
269A and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 529
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.85 (s,
6H); 3.85 (s, 2H); 6.63-6.66 (d, 2H, J=9 Hz); 6.95-6.98 (d, 2H,
J=8.7 Hz); 7.02-7.06 (td, 1H, J=2.1, 6.9 Hz); 7.30-7.32 (m, 2H);
7.36-7.39 (d, 2H, J=8.4 Hz); 7.64-7.67 (d, 2H, J=8.4 Hz); 7.73-7.74
(m, 1H); 8.25 (s, 1H); 8.98 (s, 1H); 8.99 (s, 1H).
EXAMPLE 272
N-(4-{4-amino-6-[4-(dimethylamino)benzyl]thieno[2,3-d]pyrimidin-5-yl}pheny-
l)-N'-(3-ethylphenyl)urea
[0524] The desired product was prepared by substituting Example
269A and 3-ethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 523
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.16-1.21
(t, 3H, J=7.5 Hz); 2.51-2.62 (q, 2H, J=7.2 Hz); 2.85 (s, 6H); 3.85
(s, 2H); 6.63-6.66 (d, 2H, J=9 Hz); 6.83-6.85 (m 1H); 6.95-6.98 (d,
2H, J=8.7 Hz); 7.17-7.22 (t, 1H, J=7.2 Hz); 7.26-7.29 (m, 1H);
7.34-7.38 (m, 3H); 7.64-7.66 (d, 2H, J=8.7 Hz); 8.25 (s, 1H); 8.69
(s, 1H); 8.88 (s, 1H).
EXAMPLE 273
N-(4-{4-amino-6-[4-(dimethylamino)benzyl]thieno[2,3-d]pyrimidin-5-yl}pheny-
l)-N'-(3-bromophenyl)urea
[0525] The desired product was prepared by substituting Example
269A and 3-bromophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 573, 575
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.85 (s,
6H); 3.85 (s, 2H); 6.63-6.66 (d, 2H, J=9 Hz); 6.95-6.98 (d, 2H,
J=8.7 Hz); 7.15-7.18 (td, 1H, J=1.5, 7.8 Hz); 7.23-7.28 (t, 1H,
J=7.8 Hz); 7.32-7.39 (m, 3H); 7.64-7.67 (d, 2H, J=8.4 Hz);
7.87-7.88 (t, 1H, J=1.8 Hz); 8.25 (s, 1H); 8.96 (s, 1H); 8.99 (s,
1H).
EXAMPLE 274
N-(4-{4-amino-6-[4-(dimethylamino)benzyl]thieno[2,3-d]pyrimidin-5-yl}pheny-
l)-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea
[0526] The desired product was prepared by substituting Example
269A and 2-fluoro-5-trifluomethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
581 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.85
(s, 6H); 3.85 (s, 2H); 6.63-6.66 (d, 2H, J=9 Hz); 6.95-6.98 (d, 2H,
J=8.7 Hz); 7.38-7.44 (m, 3H); 7.48-7.55 (m, 1H); 7.66-7.68 (d, 2H,
J=8.4 Hz); 8.25 (s, 1H); 8.62-8.65 (dd, 1H, J=2.4, 7.5 Hz);
8.98-8.99 (d, 1H, J=2.7 Hz); 9.41 (s, 1H).
EXAMPLE 275
N-(4-{4-amino-6-[4-(dimethylamino)benzyl]thieno[2,3-d]pyrimidin-5-yl}pheny-
l)-N'-(3-cyanophenyl)urea
[0527] The desired product was prepared by substituting Example
269A and 3-cyanophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 520
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.85 (s,
6H); 3.85 (s, 2H); 6.63-6.66 (d, 2H, J=9 Hz); 6.95-6.98 (d, 2H,
J=8.7 Hz); 7.37-7.40 (d, 2H, J=8.7 Hz); 7.42-7.46 (td, 1H, J=2.1,
6.6 Hz); 7.48-7.54 (t, 1H, J=7.8 Hz); 7.65-7.73 (m, 3H); 7.99-8.00
(t, 1H, J=1.8 Hz); 8.25 (s, 1H); 9.08 (s, 1H); 9.12 (s, 1H).
EXAMPLE 276
N-(4-{4-amino-6-[4-(dimethylamino)benzyl]thieno[2,3-d]pyrimidin-5-yl}pheny-
l)-N'-(3,5-dimethylphenyl)urea
[0528] The desired product was prepared by substituting Example
269A and 3,5-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 523
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.24 (s,
6H); 2.85 (s, 6H); 3.85 (s, 2H); 6.63-6.66 (d, 3H, J=9 Hz);
6.95-6.98 (d, 2H, J=8.7 Hz); 7.09 (s, 2H); 7.34-7.37 (d, 2H, J=9
Hz); 7.63-7.66 (d, 2H, J=8.7 Hz); 8.25 (s, 1H); 8.59 (s, 1H); 8.87
(s, 1H).
EXAMPLE 277
N-[4-(4-amino-6-{2-[4-(dimethylamino)phenyl]ethyl}thieno[2,3-d]pyrimidin-5-
-yl)phenyl]-N'-(3-methylphenyl)urea
EXAMPLE 277A
5-(4-aminophenyl)-6-{2-[4-(dimethylamino)phenyl]ethyl}thieno[2,3-d]pyrimid-
in-4-amine
[0529] The desired product was prepared by substituting
N-[4-(3-iodopropyl)phenyl]-N,N-dimethylamine for
tert-butyl(3-iodopropoxy)dimethylsilane in Examples 104A and 104B.
MS (ESI(+)) m/e 390 (M+H).sup.+.
EXAMPLE 277B
N-[4-(4-amino-6-{2-[4-(dimethylamino)phenyl]ethyl}thieno[2,3-d]pyrimidin-5-
-yl)phenyl]-N'-(3-methylphenyl)urea
[0530] The desired product was prepared by substituting Example
277A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 523
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.28 (s,
3H); 2.73-2.88 (s and m, 10H); 6.60-6.63 (d, 2H, J=9 Hz); 6.79-6.82
(d, 1H, J=7.5 Hz); 6.87-6.90 (d, 2H, J=8.7 Hz); 7.09-7.12 (d, 2H,
J=6.3 Hz); 7.14-7.19 (t, 1H, J=7.5 Hz); 7.24-7.31 (m, 2H);
7.55-7.58 (d, 2H, J=8.4), 8.25 (s, 1H); 8.66 (s, 1H); 8.86 (s,
1H).
EXAMPLE 278
N-[4-(4-amino-6-{2-[4-(dimethylamino)phenyl]ethyl}thieno[2,3-d]pyrimidin-5-
-yl)phenyl]-N'-[3-(trifluoromethyl)phenyl}urea
[0531] The desired product was prepared by substituting Example
277A and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 577
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.73-2.88
(s and m, 10H); 6.60-6.63 (d, 2H, J=9 Hz); 6.87-6.90 (d, 2H, J=8.4
Hz); 7.11-7.14 (d, 2H, J=8.7 Hz); 7.32-7.34 (d, 1H, J=6.9 Hz);
7.50-7.60 (m, 4H); 8.03 (s, 1H); 8.26 (s, 1H); 9.01 (s, 1H); 9.13
(s, 1H).
EXAMPLE 279
N-[4-(4-amino-6-{2-[4-(dimethylamino)phenyl]ethyl}thieno[2,3-d]pyrimidin-5-
-yl)phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea
[0532] The desired product was prepared by substituting Example
277A and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
595 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
2.73-2.88 (s and m, 10H); 6.60-6.63 (d, 2H, J=9 Hz); 6.87-6.90 (d,
2H, J=8.4 Hz); 7.13-7.16 (d, 2H, J=8.7 Hz); 7.38-7.44 (m, 1H);
7.48-7.55 (m, 1H); 7.58-7.61 (d, 2H, J=8.7 Hz); 8.26 (s, 1H);
8.61-8.65 (dd, 1H, J=2.4, 7.8 Hz); 8.97-8.98 (d, 1H, J=2.7 Hz);
9.38 (s, 1H).
EXAMPLE 280
N-[4-(4-amino-6-{2-[4-(dimethylamino)phenyl]ethyl}thieno[2,3-d]pyrimidin-5-
-yl)phenyl]-N'-(3,5-dimethylphenyl)urea
[0533] The desired product was prepared by substituting Example
277A and 3,5-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 537
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.24 (s,
6H); 2.73-2.89 (s and m, 10H); 6.60-6.63 (d, 3H, J=9 Hz); 6.87-6.90
(d, 2H, J=7.8 Hz); 7.09-7.12 (d, 4H, J=8.4 Hz); 7.55-7.58 (d, 2H,
J=8.7 Hz); 8.26 (s, 1H); 8.58 (s, 1H); 8.84 (s, 1H).
EXAMPLE 281
N-(4-{4-amino-6-[2-(dimethylamino)ethyl]thieno[2,3-d]pyrimidin-5-yl}phenyl-
)-N'-(3-methylphenyl)urea
EXAMPLE 281A
N-(4-{4-amino-6-[2-(dimethylamino)ethyl]thieno[2,3-d]pyrimidin-5-yl}phenyl-
)-N'-(3-methylphenyl)urea
[0534] A 0.degree. C. solution of
4-hydroxy-1-(4-nitrophenyl)-1-butanone (5.68 g, 29.4 mmol, prepared
by substituting Example 104A for Example 104C in Example 104D] in
dichloromethane (60 mL) was treated with triethylamine (4.9 mL, 35
mmol), CH.sub.3SO.sub.2Cl (2.7 mL, 35 mmol), stirred at 0.degree.
C. for 3 hours, poured into water, and extracted three times with
dichloromethane. The combined extracts were washed with brine,
dried (Na.sub.2SO.sub.4), filtered and concentrated. The
concentrate was purified by silica gel chromatography with 50%
ethyl acetate/hexanes to provide 6.42 g (76% yield) of the desired
product. R.sub.f (50% ethyl acetate/hexanes)=0.2.
EXAMPLE 281B
4-(dimethylamino)-1-(4-nitrophenyl)-1-butanone
[0535] A mixture of Example 281A (3 g, 10.5 mmol), dimethylamine
(21 mL, 2M in THF), and triethylamine (2.9 mL, 21 mmol) in DMF (25
mL) was heated to 85-90.degree. C. for 1.5 hours, cooled to room
temperature, diluted with water, and extracted twice with ethyl
acetate. The combined extracts were washed with brine, dried
(Na.sub.2SO.sub.4), filtered, and concentrated. The concentrate was
purified by silica gel chromatography eluting with 10%
methanol/dichloromethane to provide 1.27 g (51% yield) of the
desired product. MS (ESI(+)) m/e 237 (M+H).sup.+.
EXAMPLE 281C
2-amino-5-[2-(dimethylamino)ethyl]-4-(4-nitrophenyl)-3-thiophenecarbonitri-
le
[0536] The desired product was prepared by substituting Example
281B for Example 1A in Examples 1B-C. MS ((ESI(+)) m/e 317
(M+H).sup.+.
EXAMPLE 281D AND 281 E
6-[2-(dimethylamino)ethyl]-5-(4-nitrophenyl)thieno[2,3-d]pyrimidin-4-amine
and 5-(4-nitrophenyl)-6-vinylthieno[2,3-d]pyrimidin-4-amine
[0537] A solution of Example 281C (100 mg) in formamide (3 mL) in a
5 mL capped vial was heated to 200.degree. C. for 15 minutes in a
Smith Synthesizer microwave oven at 300 W. The reaction was
repeated 10 times. The combined solutions were diluted with water
and extracted twice with ethyl acetate. The combined extracts were
washed with brine, dried (Na.sub.2SO.sub.4), filtered, and
concentrated. The residue was purified by silica gel chromatography
with 7% methanol/dichloromethane to provide 0.73 g (59% yield) of
Example 281D, and 0.28 g (26% yield) of Example 281E. Example 281D:
MS ((ESI(+)) m/e 344 (M+H).sup.+; Example 281E: MS ((ESI(+)) m/e
299 (M+H).sup.+.
EXAMPLE 281F
5-(4-aminophenyl)-6-[2-(dimethylamino)ethyl]thieno[2,3-d]pyrimidin-4-amine
[0538] The desired product was prepared by substituting Example
281D for Example 1D in Example 1E. MS ((ESI(+)) m/e 314
(M+H).sup.+.
EXAMPLE 281G
N-(4-{4-amino-6-[2-(dimethylamino)ethyl]thieno[2,3-d]pyrimidin-5-yl}phenyl-
)-N'-(3-methylphenyl)urea
[0539] The desired product was prepared by substituting Example
281F and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 447
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.11 (s,
6H); 2.29 (s, 3H); 2.42-2.46 (t, 2H, J=7.2 Hz); 2.72-2.77 (t, 2H,
J=6 Hz); 6.79-6.82 (d, 1H, J=7.5 Hz); 7.14-7.19 (t, 1H, J=7.5 Hz);
7.24-7.32 (m, 4H); 7.61-7.64 (d, 2H, J=6.6 Hz); 8.26 (s, 1H); 8.67
(s, 1H); 8.87 (s, 1H).
EXAMPLE 282
N-(4-{4-amino-6-[2-(dimethylamino)ethyl]thieno[2,3-d]pyrimidin-5-yl}phenyl-
)-N'-[3-(trifluoromethyl)phenyl]urea
[0540] The desired product was prepared by substituting Example
281F and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 501
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.10 (s,
6H); 2.41-2.46 (t, 2H, J=7.2 Hz); 2.72-2.77 (t, 2H, J=6 Hz);
7.31-7.34 (m, 3H); 7.50-7.56 (t, 1H, J=7.2 Hz); 7.59-7.67 (m, 3H);
8.03 (br s, 1H); 8.26 (s, 1H); 9.02 (s, 1H); 9.14 (s, 1H).
EXAMPLE 283
N-(4-{4-amino-6-[2-(dimethylamino)ethyl]thieno[2,3-d]pyrimidin-5-yl}phenyl-
)-N'-(3-ethylphenyl)urea
[0541] The desired product was prepared by substituting Example
281F and 3-ethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 461
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.16-1.21
(t, 3H, J=7.5 Hz); 2.11 (s, 6H); 2.41-2.46 (t, 2H, J=7.2 Hz);
2.55-2.62 (q, 2H, J=7.5 Hz); 2.72-2.77 (t, 2H, J=6 Hz); 6.83-6.85
(d, 1H, J=7.5 Hz); 7.17-7.22 (t, 1H, J=7.5 Hz); 7.26-7.34 (m, 4H);
7.61-7.64 (d, 2H, J=8.4 Hz); 8.26 (s, 1H); 8.69 (s, 1H); 8.88 (s,
1H).
EXAMPLE 284
N-(4-{4-amino-6-[2-(dimethylamino)ethyl]thieno[2,3-d]pyrimidin-5-yl}phenyl-
)-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea
[0542] The desired product was prepared by substituting Example
281F and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
519 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.10
(s, 6H); 2.41-2.46 (t, 2H, J=7.2 Hz); 2.72-2.77 (t, 2H, J=6 Hz);
7.33-7.36 (d, 2H, J=8.7 Hz); 7.41-7.55 (m, 2H); 7.63-7.66 (d, 2H,
J=8.4 Hz); 8.26 (s, 1H); 8.62-8.65 (dd, 1H, J=1.8, 6.9 Hz);
8.98-8.99 (d, 1H, J=2.7 Hz); 9.39 (s, 1H).
EXAMPLE 285
N-(4-{4-amino-6-[2-(dimethylamino)ethyl]thieno[2,3-d]pyrimidin-5-yl}phenyl-
)-N'-(3-cyanophenyl)urea
[0543] The desired product was prepared by substituting Example
281F and 3-cyanophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 458
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.11 (s,
6H); 2.42-2.47 (t, 2H, J=7.2 Hz); 2.73-2.77 (t, 2H, J=7.2 Hz);
7.32-7.34 (d, 2H, J=8.1 Hz); 7.42-7.46 (td, 1H, J=1.5, 7.2 Hz);
7.49-7.54 (t, 1H, J=7.8 Hz); 7.63-7.66 (d, 2H, J=8.4 Hz); 7.68-7.72
(td, 1H, J=1.2, 9.3 Hz); 7.99-8.00 (t, 1H, J=2.4 Hz); 8.26 (s, 1H);
9.11 (s, 1H); 9.16 (s, 1H).
EXAMPLE 286
N-(4-{4-amino-6-[2-(dimethylamino)ethyl]thieno[2,3-d]pyrimidin-5-yl}phenyl-
)-N'-(2-fluoro-5-methylphenyl)urea
[0544] The desired product was prepared by substituting Example
281F and 2-fluoro-5-methylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 485
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.12 (s,
6H); 2.28 (s, 3H); 2.73-2.76 (t, 2H, J=3.5 Hz); 6.78-6.86 (m 1H);
7.09-7.15 (dd, 1H, J=8.47, 11.4 Hz); 7.30-7.33 (d, 2H, J=8.4 Hz);
7.61-7.64 (d, 2H, J=8.7 Hz); 7.98-9.01 (d, 1H, J=2.1, 8.1 Hz); 8.26
(s, 1H); 8.56-8.57 (d, 1H, J=2.4 Hz); 9.29 (s, 1H).
EXAMPLE 287
N-[4-(4-amino-6-vinylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylpheny-
l)urea
EXAMPLE 287A
5-(4-aminophenyl)-6-vinylthieno[2,3-d]pyrimidin-4-amine
[0545] The desired product was prepared by substituting Example
281E for Example 1D in Example 1E. MS ((ESI(+)) m/e 269
(M+H).sup.+.
EXAMPLE 287B
N-[4-(4-amino-6-vinylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylpheny-
l)urea
[0546] The desired product was prepared by substituting Example
287A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 402
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.29 (s,
3H); 5.28-5.32 (d, 1H, J=11.4 Hz); 5.59-5.64 (d, 1H, J=17.1 Hz);
6.50-6.60 (dd, 1H, J=10.8, 17.1 Hz); 6.80-6.82 (d, 1H, J=7.5 Hz);
7.14-7.20 (t, 1H, J=7.8 Hz); 7.24-7.27 (d, 1H, J=8.4 Hz); 7.30-7.33
(m, 3H); 7.63-7.66 (d, 2H, J=8.4 Hz); 8.31 (s, 1H); 8.68 (s, 1H);
8.91 (s, 1H).
EXAMPLE 288
N-[4-(4-amino-6-vinylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[2-fluoro-5-(t-
rifluoromethyl)phenyl]urea
[0547] The desired product was prepared by substituting Example
287A and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
474 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
5.29-5.32 (d, 1H, J=11.1 Hz); 5.59-5.65 (d, 1H, J=17.1 Hz);
6.50-6.59 (dd, 1H, J=10.8, 17.1 Hz); 7.34-7.37 (d, 2H, J=8.4 Hz);
7.38-7.45 (m, 1H); 7.49-7.55 (t, 1H, J=8.7 Hz); 7.65-7.68 (d, 2H,
J=8.4 Hz); 8.31 (s, 1H); 8.62-8.65 (dd, 1H, J=2.1, 7.2 Hz);
8.98-8.99 (d, 1H, J=2.7 Hz); 9.43 (s, 1H).
EXAMPLE 289
N-[4-(4-amino-6-vinylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[3-(trifluorom-
ethyl)phenyl]urea
[0548] The desired product was prepared by substituting Example
287A and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 456
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 5.29-5.33
(d, 1H, J=11.1 Hz); 5.59-5.65 (d, 1H, J=17.4 Hz); 6.50-6.60 (dd,
1H, J=10.8, 17.4 Hz); 7.32-7.35 (m, 3H); 7.51-7.56 (t, 1H, J=7.5
Hz); 7.59-6.25 (m, 1H); 7.65-7.68 (d, 2H, J=8.4 Hz); 8.04 (s, 1H);
8.31 (s, 1H); 9.07 (s, 1H); 9.15 (s, 1H).
EXAMPLE 290
N-[4-(4-amino-6-propylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chlorophen-
yl)urea
EXAMPLE 290A
5-(4-aminophenyl)-6-propylthieno[2,3-d]pyrimidin-4-amine
[0549] The desired product was prepared by substituting n-butyl
iodide for tert-butyl(3-iodopropoxy)dimethylsilane in Examples 104A
and B. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.84 (t, J=7.46
Hz, 3H); 1.50-1.60 (m, 2H); 2.60 (t, J=7.46 Hz, 2H); 5.39 (s, 2H);
6.69 (d, J=8.48 Hz, 2H); 6.99 (d, J=8.48 Hz, 2H); 8.23 (s, 1H).
EXAMPLE 290B
N-[4-(4-amino-6-propylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chlorophen-
yl)urea
[0550] The desired product was prepared by substituting Example
290A and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 438
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.84 (t,
J=7.29 Hz, 3H); 1.50-1.68 (m, 2H); 2.61 (t, J=7.46 Hz, 2H); 7.04
(dt, J=6.53, 2.33 Hz, 1H); 7.31 (m, 4H); 7.63 (d, J=8.81 Hz, 2H);
7.73 (m, 1H); 8.27 (s, 1H); 8.96 (s, 2H).
EXAMPLE 291
N-[4-(4-amino-6-propylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphen-
yl)urea
[0551] The desired product was prepared by substituting Example
290A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 418
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.85 (t,
J=7.29 Hz, 3H); 1.50-1.68 (m, 2H); 2.29 (s, 3H); 2.61 (t, J=7.63
Hz, 2H); 6.81 (d, J=7.80 Hz, 1H); 7.24 (m, 5H); 7.62 (d, J=8.48 Hz,
2H); 8.26 (s, 1H); 8.67 (s, 1H); 8.87 (s, 1H).
EXAMPLE 292
N-[4-(4-amino-6-propylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-ethylpheny-
l)urea
[0552] The desired product was prepared by substituting Example
290A and 3-ethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 432
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.85 (t,
J=7.29 Hz, 3H); 1.19 (t, J=7.46 Hz, 3H); 1.58 (q, J=7.50 2H);
2.45-2.70 (m, 4H); 6.84 (d, J=7.46 Hz, 1H); 7.15-7.40 (m, 5H); 7.62
(d, J=8.48 Hz, 2H); 8.27 (s, 1H); 8.69 (s, 1H); 8.87 (s, 1H).
EXAMPLE 293
N-[4-(4-amino-6-propylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[4-(trifluoro-
methyl)phenyl]urea
[0553] The desired product was prepared by substituting Example
290A and 4-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 472
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.85 (t,
J=7.29, 3H); 1.50-1.68 (m, J=6.78 Hz, 2H); 2.61 (t, J=7.80 Hz, 2H);
7.32 (d, J=8.48 Hz, 2H); 7.60-7.7.78 (m, 6H); 8.27 (s, 1H); 9.03
(s, 1H); 9.19 (s, 1H).
EXAMPLE 294
N-[4-(4-amino-6-propylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[3-(trifluoro-
methyl)phenyl]urea
[0554] The desired product was prepared by substituting Example
290A and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 472
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.85 (t,
J=7.29 Hz, 3H); 1.50-1.68 (m, 2H); 2.62 (t, J=7.46 Hz, 2H);
7.30-7.40 (m, 3H); 7.50-7.80 (m, 4H); 8.04 (s, 1H); 8.27 (s, 1H);
9.01 (s, 1H); 9.13 (s, 1H).
EXAMPLE 295
N-[4-(4-amino-6-propylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-phenylurea
[0555] The desired product was prepared by substituting Example
290A for Example 1E in Example 1F. MS (ESI(+)) m/e 404 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.85 (t, J=7.29 Hz,
3H); 1.50-1.68 (m, 2H); 2.62 (t, J=7.46 Hz, 2H); 6.99 (t, J=7.29
Hz, 1H); 7.30 (m, 4H); 7.47 (d, J=7.46 Hz, 2H); 7.63 (d, J=8.48 Hz,
2H); 8.27 (s, 1H); 8.75 (s, 1H); 8.89 (s, 1H).
EXAMPLE 296
N-[4-(4-amino-6-propylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-cyclohexylure-
a
[0556] The desired product was prepared by substituting Example
290A and isocyanatocyclohexane for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 410
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.83 (t,
J=7.29 Hz, 3H); 1.00-1.90 (m, 13H); 2.59 (t, J=7.80 Hz, 2H); 6.17
(d, J=7.80 Hz, 1H); 7.22 (d, J=8.48 Hz, 2H); 7.54 (d, J=8.48 Hz,
2H); 8.25 (s, 1H); 8.53 (s, 1H).
EXAMPLE 297
N-[4-(4-amino-6-propylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-phenoxyphe-
nyl)urea
[0557] The desired product was prepared by substituting Example
290A and 3-phenoxyphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 496
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.84 (t,
J=7.46 Hz, 3H); 1.45-1.55 (m, 2H); 2.60 (t, J=7.46 Hz, 2H); 6.63
(dd, J=8.14, 1.70 Hz, 1H); 7.00-7.50 (m, 10H); 7.59 (d, J=8.48 Hz,
2H); 8.26 (s, 1H); 8.86 (s, 1H); 8.88 (s, 1H).
EXAMPLE 298
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-phenylurea
[0558] The desired product was prepared by substituting Example 78A
for Example 1E in Example 1F. MS (ESI(+)) m/e 390 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.17 (t, J=7.63 Hz,
3H); 2.66 (q, J=7.46 Hz, 2H); 6.99 (t, J=7.46 Hz, 1H); 7.30 (t,
J=8.48 Hz, 4H); 7.48 (d, J=7.46 Hz, 2H); 7.63 (d, J=8.48 Hz, 2H);
8.29 (s, 1H); 8.78 (s, 1H); 8.93 (s, 1H).
EXAMPLE 299
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-cyclohexylurea
[0559] The desired product was prepared by substituting Example 78A
and isocyanatocyclohexane for Example 1E and phenyl isocyanate,
respectively, in Example 1F. MS (ESI(+)) m/e 396 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.00-1.90 (m, 14H);
2.63 (q, J=7.69 Hz, 2H); 6.17 (d, J=7.80 Hz, 1H); 7.23 (d, J=8.48
Hz, 2H); 7.54 (d, J=8.48 Hz, 2H); 8.27 (s, 1H); 8.54 (s, 1H).
EXAMPLE 300
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[4-(dimethylam-
ino)phenyl]urea
[0560] The desired product was prepared by substituting Example 78A
and 4-dimethylaminoaniline for Example 58D and 3-methylbutylamine,
respectively, in Example 179. MS (ESI(+)) m/e 433 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.16 (t, J=7.46 Hz,
3H); 2.65 (q, J=7.35 Hz, 2H); 2.84 (s, 6H); 6.71 (d, J=8.82 Hz,
2H); 7.27 (d, J=2.37 Hz, 2H); 7.30 (d, J=2.03 Hz, 2H); 7.61 (d,
J=8.48 Hz, 2H); 8.26 (s, 1H); 8.38 (s, 1H); 8.76 (s, 1H).
EXAMPLE 301
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-{4-[2-(dimethy-
lamino)ethyl]phenyl}urea
[0561] The desired product was prepared by substituting Example 78A
and 4-[2-(dimethylamino)ethyl]aniline for Example 58D and
3-methylbutylamine, respectively, in Example 179. MS (ESI(+)) m/e
461 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.16
(t, J=7.63 Hz, 3H); 2.47 (s, 6H); 2.65 (m, 2H); 2.70-2.90 (m, 4H);
7.17 (d, J=8.81 Hz, 2H); 7.30 (d, J=8.48 Hz, 2H); 7.41 (d, J=8.48
Hz, 2H); 7.62 (d, J=8.48 Hz, 2H); 8.26 (s, 1H); 8.87 (s, 1H); 9.06
(s, 1H).
EXAMPLE 302
N-[4-(4-aminoisothiazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-(2-fluoro-5-methy-
lphenyl)urea
[0562] The desired product was prepared by substituting Example 97
and 2-fluoro-5-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS(ESI(+)) m/e 395
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.28 (s,
3H); 6.75-6.90 (m, 1H); 7.05-7.20 (m, 1H); 7.55-7.70 (m, 4H);
7.95-8.05 (m, 1H); 8.47 (s, 1H); 8.58 (s, 1H); 9.35 (s, 1H).
EXAMPLE 303
3-{4-amino-5-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d]pyrimidin-6-yl}-N-[2-(diethylamino)ethyl]propanamide
EXAMPLE 303A
3-[4-amino-5-(4-aminophenyl)thieno[2,3-d]pyrimidin-6-yl]-N-[2-(diethylamin-
o)ethyl]propanamide
[0563] The desired product was prepared by substituting
N,N-diethylethylenediamine for dimethylamine hydrochloride in
Examples 247A-B. MS (ESI(+)) m/e 413 (M+H).sup.+.
EXAMPLE 303B
3-{4-amino-5-[4-({[(3-methylphenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d]pyrimidin-6-yl}-N-[2-(diethylamino)ethyl]propanamide
[0564] The desired product was prepared by substituting Example
303A and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 546 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 1.15 (t, J=7.29 Hz, 6H); 2.29
(s, 3H); 2.43 (t, J=7.46 Hz, 2H); 2.89 (t, J=7.46 Hz, 2H);
3.00-3.20 (m, 6H); 3.32-3.42 (m, 2H); 6.81 (d, J=6.78 Hz, 1H); 7.17
(t, J=7.63 Hz, 1H); 7.25-7.35 (m, 4H); 7.60-7.68 (m, 2H); 8.19 (t,
J=5.76 Hz, 1H); 8.29 (s, 1H); 8.84 (s, 1H); 9.06 (s, 1H).
EXAMPLE 304
3-{4-amino-5-[4-({[(3-chlorophenyl)amino]carbonyl}amino)phenyl]thieno[2,3--
d]pyrimidin-6-yl}-N-[2-(diethylamino)ethyl]propanamide
[0565] The desired product was prepared by substituting Example
303A and 3-chlorophenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 566 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 1.15 (t, J=7.29 Hz, 6H); 2.43
(t, J=7.63 Hz, 2H); 2.89 (t, J=7.29 Hz, 2H); 3.00-3.20 (m, 6H);
3.37 (q, J=5.99 Hz, 2H); 6.95-7.08 (m, 1H); 7.25-7.38 (m, 4H); 7.66
(d, J=8.48 Hz, 2H); 7.72-7.78 (m, 1H); 8.19 (t, J=5.76 Hz, 1H);
8.29 (s, 1H); 9.26 (s, 1H); 9.27 (s, 1H).
EXAMPLE 305
3-(4-amino-5-{4-[({[3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyl}-
thieno[2,3-d]pyrimidin-6-yl)-N-[2-(diethylamino)ethyl]propanamide
[0566] The desired product was prepared by substituting Example
303A and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 600
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.15 (t,
J=7.29 Hz, 6H); 2.43 (t, J=7.29 Hz, 2H); 2.89 (t, J=7.29 Hz, 2H);
3.00-3.20 (m, 6H); 3.30-3.45 (m, 2H); 7.33 (d, J=8.48 Hz, 3H);
7.45-7.65 (m, 2H); 7.67 (d, J=8.48 Hz, 2H); 8.06 (s, 1H); 8.19 (t,
J=5.76 Hz, 1H); 8.29 (s, 1H); 9.31 (s, 1H); 9.42 (s, 1H).
EXAMPLE 306
3-{4-amino-5-[4-({[(3,5-dimethylphenyl)amino]carbonyl}amino)phenyl]thieno[-
2,3-d]pyrimidin-6-yl}-N-[2-(diethylamino)ethyl]propanamide
[0567] The desired product was prepared by substituting Example
303A and 3,5-dimethylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. The product was purified
by HPLC using the conditions described in Example 179 to provide
the trifluoroacetate salt. MS (ESI(+)) m/e 560 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 1.15 (t, J=7.29 Hz, 6H); 2.24
(s, 6H); 2.43 (t, J=7.46 Hz, 2H); 2.89 (t, J=7.46 Hz, 2H);
3.00-3.20 (m, 6H); 3.32-3.42 (m, 2H); 6.63 (s, 1H); 7.11 (s, 2H);
7.31 (d, J=8.48 Hz, 2H); 7.65 (d, J=8.82 Hz, 2H); 8.20 (t, J=5.26
Hz, 1H); 8.30 (s, 1H); 8.83 (s, 1H); 9.12 (s, 1H).
EXAMPLE 307
3-{4-amino-5-[4-({[(2-fluoro-5-methylphenyl)amino]carbonyl}amino)phenyl]th-
ieno[2,3-d]pyrimidin-6-yl}-N-[2-(diethylamino)ethyl]propanamide
[0568] The desired product was prepared by substituting Example
303A and 2-fluoro-5-methylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. The product was
purified by HPLC using the conditions described in Example 179 to
provide the trifluoroacetate salt. MS (ESI(+)) m/e 564 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.15 (t, J=7.29 Hz,
6H); 2.28 (s, 3H); 2.43 (t, J=7.63 Hz, 2H); 2.89 (t, J=7.63 Hz,
2H); 3.00-3.20 (m, 6H); 3.32-3.42 (m, 2H); 6.78-6.88 (m, 1H); 7.12
(dd, J=11.53, 8.48 Hz, 1H); 7.33 (d, J=8.48 Hz, 2H); 7.64 (d,
J=8.81 Hz, 2H); 7.98 (dd, J=7.46, 2.03 Hz, 1H); 8.19 (t, J=5.59 Hz,
1H); 8.29 (s, 1H); 8.60 (d, J=2.37 Hz, 1H); 9.34 (s, 1H).
EXAMPLE 308
3-(4-amino-5-{4-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amin-
o]phenyl}thieno[2,3-d]pyrimidin-6-yl)-N-[2-(diethylamino)ethyl]propanamide
[0569] The desired product was prepared by substituting Example
303A and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
618 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.16
(t, J=7.29 Hz, 6H); 2.43(t, J=7.63 Hz, 2H); 2.89 (t, J=7.63 Hz,
2H); 3.00-3.20 (m, 6H); 3.32-3.42 (m, 2H); 7.36 (d, J=8.48 Hz, 2H);
7.36-7.60 (m, 2H); 7.67 (d, J=8.48 Hz, 2H); 8.27 (t, J=5.60 Hz,
1H); 8.31 (s, 1H); 8.63 (dd, J=7.29, 2.20 Hz, 1H); 9.14 (d, J=2.03
Hz, 1H); 9.75 (s, 1H).
[0570] Examples 309-334 were synthesized in an automated parallel
fashion as follows: Example 78A (10 mg, 0.04 mmol) was dissolved in
dichloromethane (2 mL) and added to a reaction vessel containing
PS-diethylamine (23 mg). The solution was treated with a solution
of p-nitrophenylchloroformate (9 mg) in dichloromethane (1 mL),
mixed for 2 hours, treated with a solution of the desired amine
(0.06 mmol), mixed for 16 hours, treated with the scavenger resins
PS-trisamine (12 mg) and PS-isocyanate (12 mg), and concentrated.
The product was purified by HPLC using the conditions described in
Example 179.
EXAMPLE 309
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-ethylphenyl-
)urea
[0571] Amine: 4-ethylaniline. MS (ESI(+)) m/e 418 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16 (t, J=7.64 Hz,
6H); 2.55 (q, J=7.49 Hz, 2H); 2.65 (q, J=7.70 Hz, 2H); 7.13 (d,
J=8.42 Hz, 2H); 7.30 (d, J=8.73 Hz, 2H); 7.37 (d, J=8.42 Hz, 2H);
7.62 (d, J=8.73 Hz, 2H); 8.28 (s, 1H); 8.65 (s, 1H); 8.86 (s,
1H).
EXAMPLE 310
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-isopropylph-
enyl)urea
[0572] Amine: 4-isopropylaniline. MS (ESI(+)) m/e 432 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.10-1.25 (m, 9H); 2.65
(q, J=7.49 Hz, 2H); 2.84 (m, 1H); 7.16 (d, J=8.42 Hz, 2H); 7.30 (d,
J=8.42 Hz, 2H); 7.38 (d, J=8.42 Hz, 2H); 7.62 (d, J=8.42 Hz, 2H);
8.28 (s, 1H); 8.65 (s, 1H); 8.85 (s, 1H).
EXAMPLE 311
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-tert-butylp-
henyl)urea
[0573] Amine: 3-tert-butylaniline. MS (ESI(+)) m/e 446 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.17 (t, J=7.49 Hz,
3H); 1.28 (s, 9H); 2.66 (q, J=7.49 Hz, 2H); 7.03 (d, J=7.80 Hz,
1H); 7.21 (t, J=7.96 Hz, 1H); 7.31 (d, J=8.73 Hz, 3H); 7.48 (t,
J=1.87 Hz, 1H); 7.63 (d, J=8.42 Hz, 2H); 8.29 (s, 1H); 8.73 (s,
1H); 8.86 (s, 1H).
EXAMPLE 312
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-tert-butylp-
henyl)urea
[0574] Amine: 4-tert-butylaniline. MS (ESI(+)) m/e 446 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.15 (t, J=7.49 Hz,
3H); 1.26 (s, 9H); 2.64 (q, J=7.49 Hz, 2H); 7.25-7.32 (m, 4H);
7.35-7.40 (m, 2H); 7.56-7.65 (m, 2H); 8.27 (s, 1H); 8.65 (s, 1H);
8.84 (s, 1H).
EXAMPLE 313
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-fluoro-2-me-
thylphenyl)urea
[0575] Amine: 2-methyl-3-fluoroaniline. MS (ESI(+)) m/e 422
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.17 (t,
J=7.49 Hz, 3H); 2.17 (s, 3H); 2.65 (q, J=7.49 Hz, 2H); 6.88 (t,
J=8.89 Hz, 1H); 7.15-7.25 (m, 1H); 7.32 (d, J=8.42 Hz, 2H);
7.60-7.72(m, 3H); 8.19 (s, 1H); 8.28 (s, 1H); 9.27 (s, 1H).
EXAMPLE 314
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-fluoro-4-me-
thylphenyl)urea
[0576] Amine: 2-fluoro-4-methylaniline. MS (ESI(+)) m/e 422
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16 (t,
J=7.49 Hz, 3H); 2.32 (s, 3H); 2.65 (q, J=7.49 Hz, 2H); 6.96 (d,
J=9.36 Hz, 1H); 7.07 (d, J=12.17 Hz, 1H); 7.25-7.35 (m, 2H);
7.55-7.65 (m, 2H); 7.98 (t, J=8.58 Hz, 1H); 8.28 (s, 1H); 8.50 (d,
J=2.18 Hz, 1H); 9.22 (s, 1H).
EXAMPLE 315
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-fluoro-5-me-
thylphenyl)urea
[0577] Amine: 3-fluoro-5-methylaniline. MS (ESI(+)) m/e 422
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16 (t,
J=7.49 Hz, 3H); 2.30 (s, 3H); 2.65 (q, J=7.49 Hz, 2H); 7.05 (dd,
J=8.27, 2.03 Hz, 1H); 7.17 (t, J=8.73 Hz, 1H); 7.31 (d, J=8.73 Hz,
2H); 7.44 (dd, J=12.48, 2.18 Hz, 1H); 7.62 (d, J=8.74 Hz, 2H); 8.27
(s, 1H); 8.89 (s, 1H); 8.95 (s, 1H).
EXAMPLE 316
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-fluoro-2-me-
thylphenyl)urea
[0578] Amine: 4-fluoro-2-methylaniline. MS (ESI(+)) m/e 422
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16 (t,
J=7.49 Hz, 3H); 2.28 (s, 3H); 2.65 (q, J=7.49 Hz, 2H); 6.99 (td,
J=8.73, 3.12 Hz, 1H); 7.08 (dd, J=9.51, 2.96 Hz, 1H); 7.30 (d,
J=8.42 Hz, 2H); 7.63 (d, J=8.42 Hz, 2H); 7.72 (dd, J=8.73, 5.62 Hz,
1H); 8.02 (s, 1H); 8.27 (s, 1H); 9.17 (s, 1H).
EXAMPLE 317
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-fluoro-3-me-
thylphenyl)urea
[0579] Amine: 4-fluoro-3-methylaniline. MS (ESI(+)) m/e 422
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16 (t,
J=7.49 Hz, 3H); 2.30 (s, 3H); 2.65 (q, J=7.49 Hz, 2H); 7.06 (t,
J=9.20 Hz, 1H); 7.25-7.35 (m, J=8.42 Hz, 3H); 7.37 (dd, J=6.86,
2.50 Hz, 1H); 7.62 (d, J=8.42 Hz, 2H); 8.28 (s, 1H); 8.71 (s, 1H);
8.90 (s, 1H).
EXAMPLE 318
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chloro-4-me-
thylphenyl)urea
[0580] Amine: 3-chloro-4-methylaniline. MS (ESI(+)) m/e 438
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.17 (t,
J=7.49 Hz, 3H); 2.27 (s, 3H); 2.65 (q, J=7.49 Hz, 2H); 7.20-7.30
(m, 2H); 7.31 (d, J=8.42 Hz, 2H); 7.63 (d, J=8.42 Hz, 2H); 7.71 (d,
J=1.87 Hz, 1H); 8.29 (s, 1H); 8.88 (s, 1H); 8.96 (s, 1H).
EXAMPLE 319
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-chloro-3-me-
thylphenyl)urea
[0581] Amine: 4-chloro-3-methylaniline. MS (ESI(+)) m/e 438
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16 (t,
J=7.49 Hz, 3H); 2.31 (s, 3H); 2.65 (q, J=7.49 Hz, 2H); 7.20-7.40
(m, 4H); 7.46 (d, J=2.50 Hz, 1H); 7.63 (d, J=8.73 Hz, 2H); 8.28 (s,
1H); 8.83 (s, 1H); 8.94 (s, 1H).
EXAMPLE 320
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-bromo-4-met-
hylphenyl)urea
[0582] Amine: 3-bromo-4-methylaniline. MS (ESI(+)) m/e 482, 484
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.17 (t,
J=7.64 Hz, 3H); 2.29 (s, 3H); 2.65 (q, J=7.59 Hz, 2H); 7.26 (d,
J=0.94 Hz, 2H); 7.31 (d, J=8.73 Hz, 2H); 7.63 (d, J=8.73 Hz, 2H);
7.88 (s, 1H); 8.29 (s, 1H); 8.87 (s, 1H); 8.96 (s, 1H).
EXAMPLE 321
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-bromo-3-met-
hylphenyl)urea
[0583] Amine: 4-bromo-3-methylaniline. MS (ESI(+)) m/e 482, 484
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16 (t,
J=7.49 Hz, 3H); 2.33 (s, 3H); 2.65 (q, J=7.70 Hz, 2H); 7.25-7.35
(m, 3H); 7.40-7.55 (m, 2H); 7.63 (d, J=8.73 Hz, 2H); 8.29 (s, 1H);
8.84 (s, 1H); 8.95 (s, 1H).
EXAMPLE 322
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-fluoro-4-me-
thoxyphenyl)urea
[0584] Amine: 3-fluoro-4-methoxyaniline. MS (ESI(+)) m/e 438
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16 (t,
J=7.49 Hz, 3H); 2.65 (q, J=7.49 Hz, 2H); 3.80 (s, 3H); 7.05-7.15
(m, J=1.87 Hz, 2H); 7.31 (d, J=8.42 Hz, 2H); 7.45-7.55 (m, 1H);
7.62 (d, J=8.73 Hz, 2H); 8.29 (s, 1H); 8.78 (s, 1H); 8.91 (s,
1H).
EXAMPLE 323
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[3-methoxy-5-(-
trifluoromethyl)phenyl]urea
[0585] Amine: 3-methoxy-5-trifluoromethylaniline. MS (ESI(+)) m/e
488 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.17
(t, J=7.49 Hz, 3H); 2.65 (q, J=7.49 Hz, 2H); 3.83 (s, 3H); 6.86 (s,
1H); 7.25-7.35 (m, 3H); 7.50 (s, 1H); 7.64 (d, J=8.42 Hz, 2H); 8.28
(s, 1H); 9.04 (s, 1H); 9.15 (s, 1H).
EXAMPLE 324
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[4-(hydroxymet-
hyl)phenyl]urea
[0586] Amine: 4-hydroxymethylaniline. MS (ESI(+)) m/e 420
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.26 (t,
J=6.86 Hz, 3H); 2.65 (q, J=7.49 Hz, 2H); 4.43 (s, 2H); 7.23 (d,
J=8.42 Hz, 2H); 7.30 (d, J=8.73 Hz, 2H); 7.42 (d, J=8.42 Hz, 2H);
7.63 (d, J=8.73 Hz, 2H); 8.27 (s, 1H); 8.73 (s, 1H); 8.90 (s,
1H).
EXAMPLE 325
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methoxy-4-m-
ethylphenyl)urea
[0587] Amine: 2-methoxy-4-methylaniline. MS (ESI(+)) m/e 434
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.17 (t,
J=7.49 Hz, 3H); 2.24 (s, 3H); 2.66 (q, J=7.49 Hz, 2H); 3.86 (s,
3H); 6.76 (m, J=7.80, 1.87 Hz, 1H); 6.91 (d, J=8.11 Hz, 1H); 7.31
(d, J=8.42 Hz, 2H); 7.63 (d, J=8.74 Hz, 2H); 8.00 (d, J=2.18 Hz,
1H); 8.23 (s, 1H); 8.29 (s, 1H); 9.52 (s, 1H).
EXAMPLE 326
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-ethoxypheny-
l)urea
[0588] Amine: 2-ethoxyaniline. MS (ESI(+)) m/e 434 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.17 (t, J=7.49 Hz,
3H); 1.43 (t, J=7.02 Hz, 3H); 2.66 (q, J=7.49 Hz, 2H); 4.16 (q,
J=7.07 Hz, 2H); 6.85-6.98 (m, 2H); 7.00-7.05 (m, 1H); 7.31 (d,
J=8.42 Hz, 2H); 7.64 (d, J=8.42 Hz, 2H); 8.12-8.17 (m, 2H); 8.28
(s, 1H); 9.61 (s, 1H).
EXAMPLE 327
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[4-(methylsulf-
anyl)phenyl]urea
[0589] Amine: 4-(methylsulfanyl)aniline. MS (ESI(+)) m/e 436
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16 (t,
J=7.33 Hz, 3H); 2.44 (s, 3H); 2.60-2.70 (m, J=7.49 Hz, 2H); 7.24
(d, J=8.73 Hz, 2H); 7.31 (d, J=8.73 Hz, 2H); 7.44 (d, J=8.73 Hz,
2H); 7.62 (d, J=8.73 Hz, 2H); 8.28 (s, 1H); 8.79 (s, 1H); 8.90 (s,
1H).
EXAMPLE 328
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[3-(methylsulf-
anyl)phenyl]urea
[0590] Amine: 3-(methylsulfanyl)aniline. MS (ESI(+)) m/e 436
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.17 (t,
J=7.49 Hz, 3H); 2.47 (s, 3H); 2.65 (q, J=7.49 Hz, 2H); 6.88 (d,
J=8.74 Hz, 1H); 7.22 (m, J=7.80 Hz, 2H); 7.31 (d, J=8.73 Hz, 2H);
7.40-7.55 (m, 1H); 7.63 (d, J=8.73 Hz, 2H); 8.28 (s, 1H); 8.81 (s,
1H); 8.92 (s, 1H).
EXAMPLE 329
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-2,3-dihydro-1,
4-benzodioxin-6-ylurea
[0591] Amine: 2,3-dihydro-1,4-benzodioxin-6-amine. MS (ESI(+)) m/e
448 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16
(t, J=7.64 Hz, 3H); 2.65 (q, J=7.49 Hz, 2H); 4.10-4.30 (m, 4H);
6.65-6.85 (m, 2H); 7.11 (d, J=2.50 Hz, 1H); 7.30 (d, J=8.73 Hz,
2H); 7.61 (d, J=8.73 Hz, 2H); 8.29 (s, 1H); 8.58 (s, 1H); 8.83 (s,
1H).
EXAMPLE 330
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-{4-[(4-methoxy-
phenyl)amino]phenyl}urea
[0592] Amine: N-(4-aminophenyl)-N-(4-methoxyphenyl)amine; MS
(ESI(+)) m/e 511 (M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6)
.delta. 1.17 (t, J=7.49 Hz, 3H); 2.65 (q, J=7.59 Hz, 2H); 3.70 (s,
3H); 6.84 (d, J=8.74 Hz, 2H); 6.91 (d, J=8.73 Hz, 2H); 6.98 (d,
J=8.74 Hz, 2H); 7.25-7.33 (m, 4H); 7.61 (d, J=8.42 Hz, 2H); 8.27
(s, 1H); 8.46 (s, 1H); 8.78 (s, 1H).
EXAMPLE 331
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(5-chloro-2,4--
dimethoxyphenyl)urea
[0593] Amine: 5-chloro-2,4-dimethoxyaniline. MS (ESI(+)) m/e 484
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16 (t,
J=7.49 Hz, 3H); 2.65 (q, J=7.49 Hz, 2H); 3.86 (s, 3H); 3.95 (s,
3H); 6.88 (s, 1H); 7.31 (d, J=8.74 Hz, 2H); 7.61 (d, J=8.42 Hz,
2H); 8.16 (s, 1H); 8.23 (s, 1H); 8.28 (s, 1H); 9.45 (s, 1H).
EXAMPLE 332
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-6-quinolinylur-
ea
[0594] Amine: 6-quinolinamine. MS (ESI(+)) m/e 441 (M+H).sup.+;
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16(t, J=7.49, 3H);
2.67 (q, J=7.49 Hz, 2H); 7.34 (d, J=8.42 Hz, 2H); 7.52 (dd, J=8.42,
4.37 Hz, 1H); 7.68 (d, J=8.42 Hz, 2H); 7.78 (dd, J=9.05, 2.50 Hz,
1H); 7.98 (d, J=9.05 Hz, 1H); 8.23 (d, J=2.18 Hz, 1H); 8.28 (s,
1H); 8.34 (d, J=8.73 Hz, 1H); 8.79 (dd, J=4.06, 1.25 Hz, 1H); 9.10
(s, 1H); 9.22 (s, 1H).
EXAMPLE 333
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-[4-(4-morpholi-
nyl)phenyl]urea
[0595] Amine: 4-(4-morpholinyl)aniline. MS (ESI(+)) m/e 475
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.17 (t,
J=7.02 Hz, 3H); 2.66 (q, J=7.59 Hz, 2H); 3.07 (m, 4H); 3.75 (m,
4H); 7.30 (d, J=8.73 Hz, 2H); 7.36 (d, J=9.05 Hz, 2H); 7.63 (d,
J=8.73 Hz, 2H); 8.10-8.14 (m, 2H); 8.32 (s, 1H); 8.60 (s, 1H); 8.89
(s, 1H).
EXAMPLE 334
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-hydroxy-4-m-
ethylphenyl)urea
[0596] Amine: 5-amino-2-methylphenol. MS (ESI(+)) m/e 420
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 1.16 (t,
J=7.49 Hz, 3H); 2.05 (s, 3H); 2.65 (q, J=7.49 Hz, 2H); 6.73 (dd,
J=7.96, 2.03 Hz, 1H); 6.88-6.95 (m, 1H); 7.08 (d, J=1.87 Hz, 1H);
7.29 (d, J=8.42 Hz, 2H); 7.61 (d, J=8.73 Hz, 2H); 8.28 (s, 1H);
8.56 (s, 1H); 8.80 (s, 1H).
EXAMPLE 335
1-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-3-phenylacetone
[0597] A mixture of Example 66A (100 mg, 0.31 mmol),
2-propynylbenzene (0.042 mL, 0.34 mmol),
Pd(PPh.sub.3).sub.2Cl.sub.2 (11 mg, 0.016 mmol), CuI (3 mg, 0.016
mmol), diethylamine (0.48 mL, 4.68 mmol), and triphenylphosphine
(16 mg, 0.062 mmol) in DMF (0.5 mL) in capped 5 mL vial was stirred
while heating to 120.degree. C. for 25 minutes in a Smith
Synthesizer microwave at 300 W. The mixture cooled using 40 psi
pressurized air, diluted with water, and extracted three times with
ethyl acetate. The combined extracts were washed with water and
brine, dried (MgSO.sub.4), filtered, and concentrated. The
concentrate was purified by silica gel chromatography with ethyl
acetate to provide 38 mg of the desired product. MS (ESI(+)) m/e
374 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.28
(s, 3H); 3.91 (s, 2H); 3.97 (s, 2H); 7.16-7.36 (m, 9H); 8.27 (s,
1H).
EXAMPLE 336
6-methyl-5-[4-(3-phenoxy-1-propynyl)phenyl]thieno[2,3-d]pyrimidin-4-amine
[0598] The desired product was prepared by substituting
(2-propynyloxy)benzene for 2-propynylbenzene in Example 335. MS
(ESI(+)) m/e 372 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 2.28 (s, 3H); 5.09 (s, 2H); 6.99 (t, J=7.29 Hz, 1H); 7.07
(d, J=7.80 Hz, 2H); 7.35 (m, 2H); 7.41 (d, J=8.14 Hz, 2H); 7.60 (d,
J=8.48 Hz, 2H); 8.27 (s, 1H).
EXAMPLE 337
N-[4-(2,4-diaminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphenyl)ur-
ea
EXAMPLE 337A
5-(4-nitrophenyl)thieno[2,3-d]pyrimidine-2,4-diamine
[0599] A suspension of Example 58B (1 g, 4.08 mmol) and
chloroformamidine hydrochloride (1.17 g, 10.2 mmol) in diglyme (40
mL) was heated to 130.degree. C. for 15 hours. The mixture was
cooled to room temperature, diluted with water, and extracted twice
with ethyl acetate. The combined extracts were washed with brine,
dried (MgSO.sub.4), filtered, and concentrated. The residue was
further concentrated under a stream of nitrogen, and purified by
silica gel chromatography with 5 to 7% methanol/dichloromethane to
provide 0.26 g of the desired product. MS (ESI(+)) m/e 288
(M+H).sup.+.
EXAMPLE 337B
5-(4-aminophenyl)thieno[2,3-d]pyrimidine-2,4-diamine
[0600] A suspension of Example 337A (0.26 g) in methanol (5 mL) was
stirred under a hydrogen atmosphere (balloon) in the presence of
10% Pd/C (100 mg) for 24 hours, and filtered through diatomaceous
earth (Celite.RTM.). The pad was washed with methanol and the
combined filtrates were concentrated and purified by silica gel
chromatography with 7% methanol/dichloromethane to provide 0.127 g
of the desired product. MS (ESI(+)) m/e 258 (M+H).sup.+.
EXAMPLE 337C
N-[4-(2,4-diaminothieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphenyl)ur-
ea
[0601] The desired product was prepared by substituting Example
337B and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 391
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.28 (s,
3H); 6.14 (s, 2H); 6.80 (m, 2H); 7.16 (t, J=7.8 Hz, 1H); 7.25 (d,
J=8.5 Hz, 1H); 7.31 (br s, 1H); 7.34 (d, J=8.5 Hz, 2H); 7.57 (d,
J=8.8 Hz, 2H); 8.64 (s, 1H); 8.82 (s, 1H).
EXAMPLE 338
N-{4-[(4-aminoisothiazolo[5,4-d]pyrimidin-3-yl)methyl]phenyl}-N'-(3-methyl-
phenyl)urea
EXAMPLE 338A
5-amino-3-(4-nitrobenzyl)-4-isothiazolecarbonitrile
[0602] The desired product was prepared by substituting
(4-nitrophenyl)acetyl chloride for 4-nitrobenzoyl chloride in
Examples 96A-E. MS (ESI(-)) m/e 259 (M-H).sup.-.
EXAMPLE 338B
N'-[4-cyano-3-(4-nitrobenzyl)-5-isothiazolyl]imidoformamide
[0603] A suspension of Example 338A (1 g, 3.8 mmol) and ammonium
sulfate (50 mg, 0.38 mmol) in triethylorthoformate (25 mL) was
stirred at reflux for 18 hours, cooled to 0.degree. C., treated
with ammonia (40 mL, 2M in propanol), stirred at room temperauture
for 4 hours, and concentrated. The residue was purified by silica
gel chromatography with 35% ethyl acetate/hexanes to provide 0.38 g
of the desired product. MS (ESI(-)) m/e 286 (M-H).sup.-.
EXAMPLE 338C
3-(4-nitrobenzyl)isothiazolo[5,4-d]pyrimidin-4-amine
[0604] A solution of Example 338B (0.37 g, 1.29 mmol) in methanol
(3 mL) was treated with LiOCH.sub.3 (1.4 mL, 1M in methanol), and
heated to 70.degree. C. for 4 hours. The reaction was cooled to
room temperature resulting in a brown precipitate which was
collected by filtration. The filter cake was washed with cold
methanol and dried to provide 0.175 g of the desired product. MS
(ESI(+)) m/e 288 (M+H).sup.+.
EXAMPLE 338D
3-(4-aminobenzyl)isothiazolo[5,4-d]pyrimidin-4-amine
[0605] The desired product was prepared by substituting Example
338C for Example 96F in Example 97. MS (ESI(+)) m/e 258
(M+H).sup.+.
EXAMPLE 338E
N-{4-[(4-aminoisothiazolo[5,4-d]pyrimidin-3-yl)methyl]phenyl}-N'-(3-methyl-
phenyl)urea
[0606] The desired product was prepared by substituting Example
338D and 3-methylphenyl isocyanate for Example 1E and phenyl
isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 391
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.27 (s,
3H); 4.50 (s, 2H); 6.77 (d, J=7.46 Hz, 1H); 6.96 (s, 1H); 7.05-7.45
(m, 6H); 8.37 (s, 1H); 8.66 (s, 1H); 8.72 (s, 1H).
EXAMPLE 339
N-{4-[(4-aminoisothiazolo[5,4-d]pyrimidin-3-yl)methyl]phenyl}-N'-[2-fluoro-
-5-(trifluoromethyl)phenyl]urea
[0607] The desired product was prepared by substituting Example
338D and 2-fluoro-5-trifluomethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e
463 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 4.51
(s, 2H); 7.10-7.60 (m, 6H); 8.00 (s, 1H); 8.37 (s, 1H); 8.76 (s,
1H); 9.03 (s, 1H).
EXAMPLE 340
N-{4-[(4-aminoisothiazolo[5,4-d]pyrimidin-3-yl)methyl]phenyl}-N'-[3-(trifl-
uoromethyl)phenyl]urea
[0608] The desired product was prepared by substituting Example
338D and 3-trifluoromethylphenyl isocyanate for Example 1E and
phenyl isocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 445
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 4.52 (s,
2H); 7.16 (d, J=8.48 Hz, 2H); 7.35-7.55 (m, 5H); 8.37 (s, 1H); 8.61
(dd, J=7.46, 2.71 Hz, 1H); 8.87 (d, J=2.71 Hz, 1H); 9.15 (s,
1H).
EXAMPLE 341
(2E)-N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-3-(3-methylp-
henyl)acrylamide
[0609] The desired product was prepared by substituting Example 78A
and (2E)-3-(3-methylphenyl)acrylic acid for aniline and Example
66B, respectively, in Example 66C. MS (ESI(+)) m/e 415 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.17 (t, J=7.46 Hz,
3H); 2.36 (s, 3H); 2.65 (q, J=7.69 Hz, 2H); 6.86 (d, J=15.60 Hz,
1H); 7.35-7.80 (m, 6H); 7.59 (d, J=15.60 Hz, 1H); 7.88 (d, J=8.48
Hz, 2H); 8.27 (s, 1H); 10.28 (s, 1H).
EXAMPLE 342
(2E)-N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]-3-[3-(triflu-
oromethyl)phenyl]acrylamide
[0610] The desired product was prepared by substituting Example 78A
and (2E)-3-[3-(trifluoromethyl)phenyl]acryloyl chloride for Example
1E and benzoyl chloride, respectively, in Example 4. MS (ESI(+))
m/e 469 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
1.17 (t, J=7.46 Hz, 3H); 2.65 (q, J=7.46 Hz, 2H); 7.00 (d, J=15.93
Hz, 1H); 7.39 (d, J=8.48 Hz, 2H); 7.60-8.05 (m, 7H); 8.27 (s, 1H);
10.48 (s, 1H).
EXAMPLE 343
N-[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]urea
[0611] A mixture of Example 78A (0.27 g, 1 mmol) and NaOCN (0.13 g,
2 mmol) in water (1.5 mL) and acetic acid (1.5 mL) was stirred
overnight at room temperature and partitioned between water and
ethyl acetate. The organic extract was washed with saturated
aqueous NaHCO.sub.3 and brine, dried (MgSO.sub.4), filtered, and
concentrated to provide 0.3 g of the desired product. MS (ESI(+))
m/e 314 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
1.15 (t, J=7.46 Hz, 3H); 2.63 (q, J=7.57 Hz, 2H); 5.94 (m, 2H);
7.24 (d, J=8.48 Hz, 2H); 7.56 (d, J=8.48 Hz, 2H); 8.25 (s, 1H);
8.75 (s, 1H).
EXAMPLE 344
3-{[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]amino}-4-[(3-meth-
ylphenyl)amino]-3-cyclobutene-1, 2-dione
EXAMPLE 344A
3-{[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]amino}-4-ethoxy-3-
-cyclobutene-1,2-dione
[0612] A mixture of Example 78A (0.135 g, 0.5 mmol) and
3,4-diethoxy-3-cyclobutene-1,2-dione (0.22 mL, 1.5 mmol) in ethanol
(5 mL) was heated at 70-80.degree. C. for 48 hours, then filtered
while still hot. The filtrate was concentrated and the resulting
residue was washed with hexanes and diethyl ether, and dried to
provide 0.11 g of the desired product. MS (ESI(+)) m/e 395
(M+H).sup.+.
EXAMPLE 344B
3-{[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]amino}-4-[(3-meth-
ylphenyl)amino]-3-cyclobutene-1, 2-dione
[0613] A mixture of Example 344A (0.027 g, 0.068 mol) and
3-methylaniline (0.073 mL, 0.68 mmol) in ethanol (2 mL) was stirred
at reflux for 48 hours and concentrated. The residue was purified
by silica gel chromatography with 5% methanol/dichloromethane to
provide 8 mg of the desired product. MS (ESI(+)) m/e 346
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.17 (t,
J=7.46 Hz, 3H); 2.32 (s, 3H); 2.66 (q, J=7.12 Hz, 2H); 6.80-7.00
(m, 2H); 7.20-7.50 (m, 4H); 7.67 (d, J=8.48 Hz, 2H); 8.28 (s, 1H);
10.11 (s, 1H); 10.30 (s, 1H).
EXAMPLE 345
3-{[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]amino}-4-[(3-chlo-
rophenyl)amino]-3-cyclobutene-1, 2-dione
[0614] The desired product was prepared by substituting
3-chloroaniline for 3-methylaniline in Example 344B. MS (ESI(+))
m/e 476 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
1.17 (t, J=7.46 Hz, 3H); 2.65 (q, J=7.57 Hz, 2H); 7.14 (d, J=7.46
Hz, 1H); 7.30-7.50 (m, 4H); 7.50-7.80 (m, 3H); 8.28 (s, 1H); 10.14
(s, 1H); 10.24 (s, 1H).
EXAMPLE 346
ethyl
{[4-(4-amino-6-ethylthieno[2,3-d]pyrimidin-5-yl)phenyl]amino}(oxo)ac-
etate
[0615] A solution of Example 78A (0.065 g, 0.25 mmol), ethyl
chloro(oxo)acetate (0.028 mL, 0.25 mmol), and pyridine (0.02 mL,
0.25 mmol) in dichloromethane (5 mL) was stirred at room
temperature overnight and partitioned between water and
dichloromethane. The organic extract was washed with brine, dried
(MgSO.sub.4), filtered, and concentrated. The concentrate was
purified by silica gel column chromatography with 5%
methanol/dichloromethane to provide 60 mg of the desired product.
MS (ESI(+)) m/e 371(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 1.15 (t, J=7.46 Hz, 3H); 1.34 (t, J=7.12 Hz, 3H); 2.64 (q,
J=7.46 Hz, 2H); 4.34 (q, J=7.12 Hz, 2H); 7.41 (d, J=8.48 Hz, 2H);
7.93 (d, J=8.82 Hz, 2H); 8.27 (s, 1H); 11.00 (s, 1H).
EXAMPLE 347
3-{4-[(5,
7-dimethyl-1,3-benzoxazol-2-yl)amino]phenyl}isothiazolo[5,4-d]py-
rimidin-4-amine
[0616] The desired product was prepared by substituting Example 97
and 2-amino-4,6-dimethylphenol for Example 1E and 2-aminophenol,
respectively in Example 3. MS (ESI(+)) m/e 389(M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. ppm 2.35 (s, 3H); 2.41 (s, 3H);
6.81 (s, 1H); 7.13 (s, 1H); 7.67 (d, J=8.48 Hz, 2H); 7.96 (d,
J=8.48 Hz, 2H); 8.47 (s, 1H); 10.96 (s, 1H).
EXAMPLE 348
3-[({[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]amino}carbonyl)amino]be-
nzoic acid
EXAMPLE 348A
methyl
3-[({[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]amino}carbonyl)a-
mino]benzoate
[0617] The desired product was prepared by substituting methyl
3-isocyanatobenzoate and Example 58D for phenyl isocyanate and
Example 1E, respectively, in Example 1F. MS(ESI(+)) m/e 420
(M+H).sup.+.
EXAMPLE 348B
3-[({[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl]amino}carbonyl)amino]be-
nzoic acid
[0618] A suspension of Example 348A (0.5 g, 1.19 mmol) in methanol
(50 mL) and THF (20 mL) was treated with 2N NaOH (3.6 mL, 7.2
mmol), stirred at room temperature for 4 hours, and heated to
reflux for 1 hour. The mixture was cooled to room temperature,
diluted with water, acidified to pH 3 with 4N HCl, and diluted with
brine resulting in the formation of a precipitate. The solid was
collected by filtration and dried to give 0.417 g of the desired
product. MS (ESI(+)) m/e 406 (M+H).sup.+; .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 7.41 (m, 3H); 7.55 (s, 1H); 7.56 (d, J=6.0
Hz, 1H); 7.66-7.71 (m, 3H); 8.14 (s, 1H); 8.47 (s, 1H); 9.30 (s,
1H); 9.32 (s, 1H).
EXAMPLE 349
N-(4-{4-amino-6-[2-(dimethylamino)ethyl]thieno[2,3-d]pyrimidin-5-yl}phenyl-
)-N'-(3,5-dimethylphenyl)urea
[0619] The desired product was prepared by substituting Example
281F and 3,5-dimethylphenylisocyanate for Example 1E and
phenylisocyanate, respectively, in Example 1F. MS (ESI(+)) m/e 461
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 2.10 (s,
6H); 2.24 (s, 6H); 2.43 (t, J=7.12 Hz, 2H); 2.74 (t, J=7.12 Hz,
2H); 6.63 (s, 1H); 7.09 (s, 2H); 7.30 (d, J=8.81 Hz, 2H); 7.62 (d,
J=8.48 Hz, 2H); 8.26 (s, 1H); 8.59 (s, 1H); 8.86 (s, 1H).
EXAMPLE 350
N-{4-[4-amino-6-(2-hydroxyethyl)thieno[2,3-d]pyrimidin-5-yl]phenyl}-2-(3-m-
ethylphenyl)acetamide
[0620] The desired product was prepared by substituting Example
104B and 3-methylphenylacetic acid for aniline and Example 66B,
respectively, in Example 66C. The crude product was purified by
silica gel chromatography with 7% methanol/dichloromethane to
provide the desired product. m.p. 142-144.degree. C.; MS (ESI(+))
m/e 419 (M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
2.31 (s, 3H); 2.74 (t, J=6.61 Hz, 2H); 3.55 (m, 2H); 3.64 (s, 2H);
4.87 (t, J=5.26 Hz, 1H); 7.07 (d, J=6.78 Hz, 1H); 7.12-7.27 (m,
3H); 7.33 (d, J=8.14 Hz, 2H); 7.77 (d, J=8.48 Hz, 2H); 8.26 (s,
1H); 10.38 (s, 1H).
EXAMPLE 351
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-hydroxyphenyl]-N'-[2-fluoro-5--
(trifluoromethyl)phenyl]urea
EXAMPLE 351A
5-[4-amino-2-(benzyloxy)phenyl]thieno[2,3-d]pyrimidin-4-amine
[0621] The desired product was prepared by substituting
2-benzyloxy-4-nitro-benzoyl chloride for 3-methoxy-4-nitrobenzoyl
chloride in Examples 165A-D. MS (ESI(+)) m/e 348.9 (M+H).sup.+.
EXAMPLE 351B
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-(benzyloxy)phenyl]-N'-[2-fluor-
o-5-(trifluoromethyl)phenyl]urea
[0622] The desired product was prepared by substituting Example
351A and 2-fluoro-5-trifluoromethylphenyl isocyanate for Example 1E
and phenyl isocyanate, respectively in Example 1F. MS (ESI(+)) m/e
554 (M+H).sup.+.
EXAMPLE 351C
N-[4-(4-aminothieno[2,3-d]pyrimidin-5-yl)-3-hydroxyphenyl]-N'-[2-fluoro-5--
(trifluoromethyl)phenyl]urea
[0623] A solution of Example 351B (99 mg, 0.18 mmol) in 30%
HBr/acetic acid (1 mL) and acetic acid (2 mL) was stirred at
70.degree. C. for 3 hours, cooled to room temperature, poured into
water, basified with 2N NaOH, adjusted to pH to 7-8 with 1N HCl,
and extracted with methanol/dichloromethane. The extract was
concentrated and the residue was purified by silica gel
chromatography with 5% methanol/dichloromethane to provide 16 mg
(19% yield) of the desired product. MS(ESI(+)) m/e 464.0
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 6.94 (dd,
J=8.5, 2.0 Hz, 1H); 7.15 (d, J=8.1 Hz, 1H); 7.31 (s, 1H); 7.38-7.43
(m, 2H, 7.48-7.55 (m, 1H); 8.30 (s, 1H); 8.64 (dd, J=7.5, 2.4 Hz,
1H); 8.91 (d, J=2.7 Hz, 1H); 9.29 (s, 1H); 9.87 (s, 1H)
[0624] It will be evident to one skilled in the art that the
present invention is not limited to the foregoing illustrative
examples, and that it can be embodied in other specific forms
without departing from the essential attributes thereof. It is
therefore desired that the examples be considered in all respects
as illustrative and not restrictive, reference being made to the
appended claims, rather than to the foregoing examples, and all
changes which come within the meaning and range of equivalency of
the claims are therefore intended to be embraced therein.
* * * * *